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Abstract 
Individuals with abdominal obesity are at higher risk for developing type 2 diabetes, 
predisposing cardiovascular events and insulin resistance.  Low glycemic index (GI) diets may 
be beneficial in the management of insulin resistance.  Insulin resistance is associated with 
increased intramyocellular lipid (IMCL) content as measured by proton nuclear magnetic 
resonance spectroscopy (1H-MRS).  The primary objective of this thesis was to determine 
whether a low GI diet can improve insulin sensitivity by reducing IMCL of skeletal muscle. One 
hundred and twenty-one male and female participants aged 30 to 70 years (mean+SD, 53+10)) 
with abdominal obesity, entered a 4 to 6 week weight-maintaining, low-fat dietary advice run-in 
phase.  Of the 121 eligible participants, 95 completed the run-in phase and were randomly 
assigned to either a low-GI (LGID, n=48) or high-GI diet (HGID, n=47) for 24 weeks.  
Participants underwent a 75g oral glucose tolerance test (OGTT) and had soleus-muscle IMCL 
measured by 1H-MRS at the beginning and end of the intervention period.  Insulin sensitivity 
was assessed by the homeostatic model assessment index (HOMA) and the insulinogenic index 
(ISI) was calculated for insulin secretion.  At the end of the run-in phase, there were significant 
reductions in serum total-, LDL-, and HDL-cholesterol (all, p<0.0001) and an increase in fasting 
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plasma glucose (p<0.05).  In 57 participants who wore a continuous glucose monitoring system 
for 24 hours during the run-in period, a total of 30% (p<0.001) of the variation in the incremental 
area under the blood glucose curve after self-selected breakfast meals was explained by GI.  
After 24 weeks, diet GI was significantly lower in the LGID than HGID group (55.5+3.1 vs 
63.9+3.1, p<0.0001).  Plasma glucose 60 minutes after the OGTT was significantly lower on the 
LGID than at baseline (p<0.05) and there was a non-significant trend towards an increase in ISI 
(p=0.07).  On the HGID, ISI increased significantly from baseline (p<0.01).  It is concluded that 
the LGID reduced 60 minute plasma glucose but did not significantly affect IMCL or insulin 
sensitivity in individuals with abdominal obesity. 
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1. Introduction 
 
 Abdominal obesity, characterized by the accumulation of visceral adipose tissue, is now 
recognized as an independent risk factor for the development of cardiovascular disease (CVD), 
type 2 diabetes, metabolic syndrome and insulin resistance (1, 2, 3, 4, 5).  Insulin resistance, 
defined as an impairment of insulin action on glucose metabolism is a complex, multi-organ 
dysfunction that is brought about by a multitude of genetic and environmental factors, such as a 
sedentary lifestyle and high fat diets leading to excess energy intake (6).  Although not fully 
understood, it has been suggested that individuals with abdominal obesity cannot store lipids 
effectively in subcutaneous fat, which in turn leads to an increased delivery of fats to organs 
other than adipose tissue such as the liver, pancreas and skeletal muscle, causing insulin 
resistance in these tissues (7, 8).   
Skeletal muscle facilitates insulin-stimulated glucose uptake and is the main contributor to 
glucose homeostasis in the body (6, 9).  Research has shown that the accumulation of 
triglyceride in muscle is correlated with insulin resistance independently of visceral fat (10).  
Muscle triglyceride content is categorized as extramyocellular lipids (EMCL, lipids stored 
between muscle fibres) and intramyocellular lipids (IMCL, lipids stored within the muscle cell) 
(11).  Muscle triglyceride content can be assessed by examination from proton nuclear magnetic 
resonance spectroscopy (1H-MRS), a non-invasive quantification of muscle fat content in human 
muscle that can identify the relative contributions of IMCL (11). Research has shown a positive 
relationship between the accumulation of IMCL content and insulin resistance when measured 
by 1H-MRS demonstrating that IMCL is an indicator of whole body insulin sensitivity (12, 13, 
14, 15). 
3 
 
Evidence supports the role of carbohydrates in influencing insulin sensitivity by improving 
insulin-stimulated glucose uptake by adipocytes when following a low glycemic index diet (16, 
17, 18).   The glycemic index (GI) was developed as a classification of the blood glucose-raising 
potential of carbohydrate containing foods (19).  The GI is defined as the incremental area under 
the blood glucose response curve (iAUC) after consumption of a 50g available-CHO portion of a 
test food expressed as a percentage of that after ingestion of 50g oral glucose (20).  Low GI 
carbohydrates are slowly digested and release glucose gradually into the blood stream and 
therefore may suppress hepatic glucose production and non-esterified fatty acid (NEFA) release 
from adipocytes, creating a more insulin-sensitive condition (21, 22).  This in turn, may reduce 
IMCL storage by promoting skeletal muscle glucose uptake (23). It still remains unclear whether 
a low GI diet can reduce IMCL stores in the muscles of individuals with abdominal obesity, a 
population at risk for developing insulin resistance and type 2 diabetes. 
The primary objective of the research outlined in this dissertation was to determine 
whether a low GI diet would reduce IMCL stores thereby improving insulin sensitivity in 
individuals with abdominal obesity.  A secondary objective of this research was to determine 
whether a low GI diet would improve insulin sensitivity and glucose tolerance in individuals 
with abdominal obesity. 
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2.  Literature Review 
 
2.1  Obesity 
 
2.1.1  Obesity Definition 
 
Obesity is a complex disease characterized by an excessive accumulation of fat in adipose 
tissue (1).  It is estimated that 23.1% (CI 21.7 to 24.6) of adult Canadians are obese (2), with 
consistent trends in different parts of the world (3).  Obesity is the result of a positive energy 
balance where food intake is greater than the body’s ability to utilize the food as energy (1).  The 
excess energy, in the form of triglycerides, is stored in adipocytes which increase in size and 
weight (hypertrophic obesity) and number (hyperplasic obesity) (4).  The excessive accumulation 
of adipose tissue leads to an undesirable weight gain to the extent that health may be adversely 
affected (1).  Health risk factors and comorbidities associated with obesity include 
cardiovascular disease (CVD) (5, 9), stroke (6, 7, 9), hypertension (5, 8), type 2 diabetes (10, 11, 
12, 13), sleep disordered breathing (14), kidney disease (15) certain cancers such as colon (16), 
ovarian (17), breast (18), and endometrial cancers (19),  gallbladder disease (20), and 
musculoskeletal conditions (21). 
The World Health Organization (WHO) developed a standard classification for obesity 
based on body mass index (BMI) (defined as weight in kilograms divided by height in metres 
squared (kg/m2) and the risks associated with each classification of BMI and mortality, including 
type 2 diabetes and cardiovascular disease are shown on Table 1-1 (1).  The WHO states that 
obesity is present when BMI is 30 or greater, however it does not differentiate between weight 
associated with fat mass and weight associated with lean body weight (muscle mass) (1).  
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Table 1-1. WHO Classification of Obesity for Adults According to BMIa  
____________________________________________________________________________ 
      BMI 
Classification   (kg/m2)    Risk of Comorbidities 
____________________________________________________________________________ 
Underweight   < 18.50    Low (but risk of other clinical 
problems increased) 
 
Normal range      18.50 – 24.99   Average 
 
Overweight:   > 25.00 
 
Preobese       25.00 – 29.99   Increased 
 
Obese class I     30.00 – 34.99   Moderate 
 
Obese class II     35.00 – 39.99   Severe 
 
Obese class III  > 40.00    Very Severe 
____________________________________________________________________________ 
a These BMI values are age-independent and the same for both sexes.  However, BMI may not 
correspond to the same degree of fatness in different populations due, in part, to differences in 
body proportions.  The table shows a simplistic relationship between BMI and the risk of 
comorbidity (disease), which can be affected by a range of factors, including the nature of the 
diet, ethnic group and activity level.  The risks associated with increasing BMI are continuous 
and graded and begin at a BMI above 25.  The interpretation of BMI gradings in relation to risk 
may differ for different populations.  Both BMI and a measure of fat distribution (waist 
circumference or waist:hip ratio (WHR)) are important in calculating the risk of obesity 
comorbidities. 
 
Two large population studies, the National Health and Nutrition Examination Surveys 
(NHANES) and the Study to Help Improve early evaluation and management of risk factors 
Leading to Diabetes (SHIELD) have shown a strong relationship between BMI and diabetes, 
hypertension and dyslipidemia (p<0.001) (23, 24).  The NHANES also showed an association 
with obesity (BMI>30) and increased mortality (111,909 excess deaths; 95% CI, 53,754 – 
170,064), and of the excess deaths associated with obesity, the majority of deaths occurred in 
individuals with a BMI of 35 or greater (82,066 deaths; 95% CI, 44,843 – 119,289) (23).   
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Other population studies have also shown that obesity was related to an increase in the 
development of cardiovascular disease.  The Framingham Heart Study (5) showed the age-
adjusted relative risk (RR), 95% CI for cardiovascular disease was increased in obese individuals 
(BMI > 30) (men: 1.46 [1.20 – 1.77]; women: 1.64 [1.37 – 1.98]).  Further, the Framingham 
Offspring Study (9) demonstrated that obesity (BMI>30) was predictive of the occurrence of first 
events in both coronary heart disease (p=0.05) and cerebrovascular disease (p=0.03). 
2.1.2 Obesity and Body Fat Distribution 
 
2.1.2.1 Abdominal Obesity 
 
Abdominal obesity, characterized by the accumulation of visceral or intra-abdominal 
adipose tissue, is now recognized as an independent risk factor for the development of 
cardiovascular disease (CVD), type 2 diabetes, and metabolic syndrome (10, 11, 13, 25, 26, 27, 
28, 30, 31, 32).  The metabolic syndrome consists of metabolic disturbances such as insulin 
resistance, dysglycemia, dyslipidemia, and hypertension (25, 26, 27).  Metabolic syndrome is 
strongly associated with abdominal obesity and is also recognized as a risk factor for developing 
CVD and type 2 diabetes (22, 25, 26, 28, 29, 31).   
 The National Cholesterol Education Program, Adult Treatment Panel III (NCEP, ATP III) 
acknowledges the WHO’s definition of obesity according to BMI but also identifies obesity 
according to body fat distribution, specifically around the abdominal area (22).  The NCEP ATP 
III states that abdominal obesity is more highly correlated with insulin resistance and metabolic 
syndrome than measures of BMI (22).  The NCEP, ATP III identifies a waist circumference of 
greater than 102 cm in men, or greater than 88 cm in women as an indicator of abdominal 
obesity (22).  
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 The NCEP, ATP III (22) defines the metabolic syndrome as having 3 out of 5 criteria on 
which clinicians can diagnose the syndrome, including a high waist circumference, high serum 
triglycerides, low high density lipoprotein cholesterol (HDL-C), high blood pressure, and high 
fasting glucose (Table 1-2).  
 
Table 1-2.  NCEP-ATP III Clinical Identification of the Metabolic Syndrome  
Risk Factor Defining Level 
Abdominal Obesity* 
 
     Men 
 
     Women  
Waist Circumference† 
 
>102 cm (40 inches) 
 
>88 cm (35 inches) 
Triglycerides >1.7 mmol/L (150 mg/dL) 
HDL Cholesterol 
      
     Men 
 
     Women 
 
 
<1.0 mmol/L (<40 mg/dL) 
 
<1.3 mmol/L (<50 mg/dL) 
 
Blood Pressure 
 
>130 / >85 mmHg 
Fasting Glucose >6.1 mmol/L (110 mg/dL) 
* Overweight and obesity are associated with insulin resistance and metabolic syndrome.  
However, the presence of abdominal obesity is more highly correlated with the metabolic risk 
factors than is elevated body mass index (BMI).  Therefore, the simple measure of waist 
circumference is recommended to identify the body weight component of the metabolic 
syndrome. 
†Some male patients can develop multiple metabolic risk factors when the waist circumference 
is only marginally increased, eg. 94-102 cm (37-39 in).  Such patients may have a strong genetic 
contribution to insulin resistance.  They should benefit from changes in life habits, similarly to 
men with categorical increases in waist circumference.   
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2.1.3 Obesity and Insulin Resistance  
 Insulin resistance, a key feature of the metabolic syndrome, is a complex, multi-organ 
dysfunction that is defined as an impairment of insulin action on glucose metabolism (33) or the 
inability of the cell to respond to the action of insulin.  Insulin sensitivity on the other hand, is 
the degree to which a rise in plasma insulin can reduce postprandial blood glucose by stimulating 
glucose uptake in the peripheral tissues (skeletal muscle and adipose tissue) and suppress its 
production in the liver (33).  
 Insulin resistance rises with increases in body weight and body fat (26, 34).  Most obese 
individuals (BMI>30) tend to have hyperinsulinemia and low insulin sensitivity (34), however it 
has been established that not all obese individuals are insulin resistant (34, 36).   Imaging studies 
assessing abdominal adipose tissue (magnetic resonance imaging (MRI) and computed 
tomography (CT)) have shown that visceral adiposity is a strong predictor of insulin resistance in 
abdominally obese men (37), premenopausal women (38), and postmenopausal women (39) 
independent of subcutaneous abdominal and non-abdominal adipose tissue.   
2.1.3.1 Mechanisms Linking Obesity and Insulin Resistance  
 Mechanisms have been proposed for the development of insulin resistance in those 
individuals with visceral adiposity.  One proposed mechanism is that a combination of a 
sedentary lifestyle, high fat diet, and excess energy intake can result in a positive energy balance 
leading to adipocyte hypertrophy and an increase in visceral adipose tissue (36, 42, 43).  This 
excess of energy intake results in an increase in circulating triglycerides (via portal circulation) 
and an increase in lipolysis, with a subsequent release of glycerol and free fatty acids (FFA) into 
circulation (40, 41).  Within the adipose tissue, insulin promotes fatty acid re-esterification into 
triglyceride and inhibits lipolysis, therefore impairment of insulin action results in excess 
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circulating FFA (33).  When the liver is exposed to elevated concentrations of FFA, it may lead 
to hyperinsulinemia (due to a decrease in insulin clearance), hyperglycemia (glucose intolerance 
due to an increase in hepatic glucose production), and dyslipidemia (low HDL-C, increased 
levels of low density lipoprotein cholesterol (LDL-C), high triglycerides, and an increase in very 
low density lipoprotein (VLDL) apolipoprotein B secretion) (40, 42).      
 A second proposed mechanism is that adipose tissue, especially visceral adiposity, is now 
recognized as an endocrine organ that secretes adipokines (cytokine-like molecules in adipose 
tissue including leptin, resistin, and adiponectin), inflammatory cytokines (such as interleukin-6 
(IL-6) and tumor necrosis factor-α (TNF-α)) and free fatty acids (FFA), which contribute to 
insulin resistance and the proinflammatory, prothrombotic, and hypertensive state (26, 40, 41, 
42).  
 A third proposed mechanism is that individuals with abdominal obesity cannot store 
circulating lipids effectively in the subcutaneous adipose tissue (35, 36, 40).  If this tissue is 
subjected to excessive amounts of lipids, there will be an increased delivery and redistribution of 
fats to organs other than adipose tissue such as the liver, pancreas, heart, and skeletal muscle (33, 
35, 36, 40, 43).  This notion has been referred to as lipotoxicity (35, 44) and suggests that 
increased lipids stored in these organs appear to inhibit insulin signaling, leading to a reduction 
in insulin-stimulated glucose uptake causing insulin resistance in these tissues (33, 35, 36, 40).  
This thesis will focus on the potential role of skeletal muscle lipid accumulation in insulin 
resistance.   
2.2  Skeletal Muscle and Insulin Resistance  
 Skeletal muscle facilitates insulin-stimulated glucose uptake and is the main contributor to 
glucose homeostasis in the body (33, 45).  In obese individuals, elevated free fatty acids (FFA) 
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and excess fat located in the muscle cell appear to reduce insulin-stimulated glucose uptake and 
suppress muscle glycogen synthesis and glycolysis (33, 46) contributing to the development of 
skeletal muscle insulin resistance (41).   
 Fat stored in the muscle cell is categorized as either extramyocellular lipid (EMCL, lipids 
stored between muscle fibres) or intramyocellular lipid (IMCL, lipids stored within the muscle 
cell) (47).  IMCL provides a readily available source of energy within the muscle exceeding that 
of glycogen stores (48, 49).  However, abnormally high IMCL content tends to reduce the 
muscles sensitivity to insulin and therefore have become a focus of interest in the development 
of insulin resistance (48, 49, 50).   
 The impact of the accumulation of muscle triglyceride and the association with insulin 
resistance has been examined in muscle biopsies.  In 1985, Falholt et al (51) first proposed the 
potential relationship between elevated muscle triglycerides and insulin resistance by reporting 
an increase in muscle triglycerides in normoglycemic, hyperinsulinemic dogs with low plasma 
triglycerides (171.4+46.6 vs 41.2+7.7µmol/g, p<0.001).  In 1988, Falhot et al (52) then 
addressed the relationship between elevated muscle triglyceride in the development of insulin 
resistance in humans with type 2 diabetes.  The diabetic patients showed an elevation of 
triglyceride in the muscle biopsies compared to the non-diabetic controls (290+52 vs 
48+6µmol/g, p<0.001)).  Further proof linking elevated muscle triglycerides with insulin 
resistance came from later research demonstrating that muscle triglycerides are increased in 
healthy, normoglycemic women, varying in adiposity (50), young, healthy, overweight Pima 
Indians (54), and type I diabetics (53).  
 Computed tomography (CT) is a non-invasive approach to assess the distribution of 
adipose and lean tissue volume and density based on muscle attenuation values (Hounsfield 
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units), with lower attenuation values indicating a greater fat content within muscle (55).  
Simoneau et al (56) were first to report that muscle with reduced attenuation on CT scans 
(indicating elevated lipids in muscle) was strongly related to obesity and insulin resistance in 
healthy women.  Later, Goodpaster et al observed a relationship between elevated muscle lipids 
(reduced muscle attenuation on CT) and insulin resistance in healthy sedentary, obese men and 
women (57) and in obese individuals with and without type 2 diabetics (58).  
2.2.1 Proton-Nuclear Magnetic Resonance (1H-NMR) Spectroscopy 
 In the determination of skeletal muscle triglycerides, both muscle biopsies and CT 
techniques are unable to differentiate between IMCL and EMCL (47). Since research has shown 
that only IMCL is related to insulin resistance (59), it is necessary to quantify the 
intramyocellular triglyceride in order to establish the metabolic role of lipids within the muscle 
cell. 
 Proton-nuclear magnetic resonance (1H-NMR) spectroscopy is a non-invasive imaging 
method that is able to distinguish between IMCL and EMCL muscle triglyceride content due to 
the different geometrical arrangement of the lipid compartments (47).  IMCL are spherical 
droplets located within the cytoplasm of muscle cells close to the mitochondria, whereas EMCL 
are elongated droplets located between the muscle fibres (47).  Chemical shift differences in 
IMCL and EMCL produce separate resonance frequencies which makes it possible to identify 
peaks in the spectral patterns that correspond to the methylene signals (CH2 resonances) of these 
two types of muscle lipids (47) (Figure 2-1 (63)).  When the muscle fibre orientation is aligned 
with the axis of the magnet tube (Magnetic Resonance Imaging (MRI)), separation of the 
spectral patterns between the IMCL and EMCL is approximately 0.2 parts per million (ppm) 
(IMCL 1.28 ppm and  EMCL 1.5 ppm on the spectrum, however there is slight variation for 
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IMCL (ppm) and EMCL (ppm) between studies) (60, 61).  Spectral intensities of IMCL and 
EMCL are referenced to either water or the methyl signal of Cr (Cr3, total creatine) (47, 60, 62).     
 
Figure 2.1.  1H-NMR Spectra of the Human Soleus Muscle 
Methylene signals of IMCL and EMCL are indicated at 1.25 ppm and 1.4 ppm respectively (63). 
   
 Generally, the soleus or tibialis anterior calf muscle are the two most common muscles 
chosen in to identify IMCL using 1H-NMR spectroscopy (Figure 2-2 (59)).  The soleus muscle is 
highly oxidative due to the large amounts of slow twitch (Type I) muscle fibres, whereas the 
tibialis anterior muscle contains more fast twitch (Type II) glycolytic fibres and contain less 
IMCL than the soleus muscle (60).  Both muscle groups have been used in 1H-NMR 
spectroscopy to determine whether IMCL is a predictor of insulin resistance (59, 63, 64, 65, 66, 
67, 68, 69). 
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Figure 2.2.  Magnetic Resonance Image of the Human Calf Muscle 
1 indicates the tibialis anterior muscle and 2 indicates the soleus muscle (59). 
 
 
2.2.1.1 Intramyocellular lipid (IMCL) and Insulin Resistance/Insulin Sensitivity 
 Studies using 1H-NMR spectroscopy in lean adults have shown a relationship between 
elevated IMCL and insulin resistance.  Jacob et al (59) found that IMCL was 57% higher in the 
tibialis anterior muscle (3.26+0.36 vs 2.08+0.3 arbitrary units, p<0.017) and 84% higher in the 
soleus muscle (11.8+1.6 vs 6.4+0.59 arbitrary units, p=0.008) in lean insulin-resistant offspring 
adults of type 2 diabetic patients compared to matched insulin-sensitive offspring of type 2 
diabetic patients.  Jacob et al (59) also found a negative relationship between insulin sensitivity 
and the IMCL of the tibialis anterior muscle (r=-0.53, p<0.01) and the soleus muscle (r=-0.35, 
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but not significant p=0.1), demonstrating that insulin resistance was correlated with IMCL.  
Perseghin et al (64) found similar results where offspring adults of type 2 diabetic parents were 
characterized with insulin resistance (p=0.04) and increased IMCL content in the soleus muscle 
(p<0.01).  Perseghin et al (64) also found that IMCL of the soleus muscle was the main predictor 
of whole body insulin sensitivity (R2=0.29, p<0.01).  Krssak et al (63) also found an inverse 
correlation between IMCL and whole-body insulin sensitivity in a group of normal weight non-
diabetic adults (r=-0.69, p=0.0017) using 1H-NMR spectroscopy of the soleus muscle.   
 Studies using 1H-NMR spectroscopy have also shown a relationship between elevated 
IMCL and insulin resistance in overweight and obese individuals.  Sinha et al (65) found both 
the IMCL and EMCL content of the soleus muscle was significantly greater in obese adolescents 
compared to the lean, control adolescents (p<0.01).  Further, the results from Sinha et al (65) 
showed an inverse correlation between IMCL and insulin sensitivity (r=-0.59, p<0.02) and that 
this relationship was independent of percent total body fat and subcutaneous abdominal fat     
(r=-0.73, p<0.01) but not of visceral fat (r=-0.54, p<0.08).  Moro et al (69) studied a group of 
sedentary obese non-diabetic and diabetic adults treated with sulfonylurea and metformin.  In 
Moro’s study (69), IMCL was inversely related to insulin sensitivity in both the soleus muscle 
(r=-0.48, p=0.02) and tibialis anterior muscle (r=-0.18, but not significant p=0.06).  Further, body 
fat was the main determinant of IMCL in the tibialis anterior muscle (r2=0.30, p=0.0054) (69).  
In contrast to these studies, Perseghin et al (66) showed no significant differences in IMCL 
content in the soleus muscle (p=0.22) or the tibialis anterior muscle (p=0.67) in moderately 
overweight vs normal weight subjects.  The lack of significance in IMCL in Perseghin’s study 
(66) may be due to the small variation and definition of overweight according to BMI 
(overweight 23.5+0.8 vs normal weight 21.2+0.6 kg/m2).  Perseghin (66) did find that insulin 
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sensitivity was inversely related to the IMCL content of the soleus muscle (R2=0.38, p<0.01) and 
the tibialis anterior muscle (R2=0.36, p<0.02). 
2.3 Effect of Diet on IMCL and Insulin Sensitivity 
2.3.1 High fat diets, IMCL and Insulin Sensitivity  
 In animal studies, high fat feeding in rats increased muscle lipids and reported links 
between the accumulation of intramyocellular lipids and insulin resistance, characterized by 
reduced insulin-stimulated skeletal muscle glucose uptake and disposal (70, 71, 72, 73).  In 
human studies using 1H-NMR spectroscopy to determine IMCL content, high fat diets have also 
been shown to increase IMCL in healthy individuals.  Studies using a lipid infusion protocol to 
increase plasma FFA (74) or circulating non-esterified fatty acids (75) found increases in IMCL 
and corresponding changes in insulin sensitivity.  Short term high fat diets of 3 days (75) and 7 
days (76) consisting of approximately 60% total energy from dietary fat found that IMCL 
increased with high fat feeding as well as a decrease in insulin sensitivity (75).  A longer 
crossover design study (25 days) consisting of a diet which was either low fat (30.8%), high fat 
(37.9%), or high in total fat (36.3%) and polyunsaturated fat (9.7%) in healthy adults with mildly 
elevated LDL-cholesterol found that IMCL was higher in the high fat diet but was not changed 
by type of dietary fat (77).  St-Onge et al (77) did not find any correlations between IMCL and 
glucose or insulin concentrations. 
2.3.2 Carbohydrate, IMCL and Insulin Sensitivity 
2.3.2.1 Carbohydrate 
 The majority of dietary carbohydrate consists of monosaccharides (glucose, fructose, 
galactose), disaccharides (sucrose, lactose, maltose), and polysaccharides (starch (amylose, 
amylopectin)), and fibre (soluble, insoluble)) (111, 112).  Ingestion of dietary carbohydrate 
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increases postprandial blood glucose.  This in turn results in the release of insulin by the 
pancreas to stimulate the uptake of glucose into the skeletal muscle and adipose tissue, as well as 
decreasing the production of glucose by the liver by reducing glycogenolysis and 
gluconeogenesis (111, 112).  Postprandial blood glucose response is dependent on the type of 
dietary carbohydrate consumed.  Foods with carbohydrate high in glucose are easily digested, 
absorbed rapidly, and have an immediate effect on postprandial blood glucose, whereas soluble 
fibre decreases the rate of glucose absorption and reduces the glycemic response (113).  
Specifically, soluble fibres high in viscosity (gel forming) slow carbohydrate absorption and 
decrease postprandial blood glucose responses (112).  Plant starch occurs mainly as amylose and 
amylopectin however amylopectin breaks down more easily and digests more rapidly (112).  
Research has shown that consumption of high-amylose carbohydrates decreases the glucose and 
insulin responses in normal individuals (112, 114).  Some starches are partially broken down and 
very slowly digested, or do not get digested at all in the human small intestine because humans 
lack the enzymes to break them down (115).  These starches are termed partially resistant starch 
and resistant starch, and reduce the glycemic responses compared to readily digestible starch 
(115).  Further, research has demonstrated the role of dietary fibre in reducing the risk for 
diseases including diabetes (116, 117) and cardiovascular disease (118).  The interest in the 
glycemic effects of carbohydrate and the mechanisms by which dietary fibre improves blood 
glucose and insulin responses led to the development of the glycemic index (GI).       
2.3.2.2 Glycemic Index 
The glycemic index (GI) was developed in 1981 by Jenkins et al (78) as a classification of 
the blood glucose-raising potential of the available carbohydrate in foods.  The GI is defined as 
the 2 hour incremental area under the blood glucose response curve (iAUC, defined as the area 
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under the curve that is above fasting values only) after consuming a 50 gram available-
carbohydrate (total carbohydrate minus fibre) portion of a test food expressed as a percentage of 
the response after consuming 50 grams of oral anhydrous glucose by the same subject (79, 80).  
The term glycemic load (GL) was also developed to account for the amount of carbohydrate in 
food and is calculated by multiplying the glycemic index of the food by the food’s available 
carbohydrate (g) (81).  Research has demonstrated that both the source and amount of 
carbohydrate in foods influence postprandial blood glucose and insulin (82, 83).  Foods 
containing carbohydrate that are classified as low GI are digested and absorbed more slowly than 
high GI foods and would therefore have a lower postprandial blood glucose and insulin response 
due to the reduced rate of glucose absorption (81).  Examples of carbohydrate foods with a low 
GI include barley, cooked pasta (al-dente), parboiled rice, beans, lentils, and oatmeal (non-
instant), whereas white bread, cooked potatoes, and breakfast cereals (low in fibre) are a few 
examples of high GI foods (84).  Since the GI is a classification of the degree to which 
carbohydrate containing foods increase blood glucose, foods containing solely protein and/or fat 
would not have a GI value (85).  Further, differences in the amounts of fat and protein in normal 
meals have been shown to have little effect on the postprandial glucose and insulin responses 
(86). 
Since its development, many studies with varying populations have shown that low GI 
diets improve fasting blood lipids (87, 88, 89, 90, 91, 92, 93, 94, 95, 96) and glycemic control 
(88, 92, 93, 94, 95, 96, 97, 98, 99), as well as decreasing the risk of developing cardiovascular 
disease (100), type 2 diabetes (101, 102, 103, 104), metabolic syndrome and insulin resistance, 
(105) and obesity (106), suggesting a possible role in the treatment and prevention of disease.  
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2.3.2.2.1 Glycemic Index and Insulin Sensitivity 
Research has demonstrated that low glycemic index carbohydrates can influence insulin 
sensitivity by improving glucose and insulin responses during the day as well as improving 
insulin-stimulated glucose uptake by adipocytes (93, 98, 99).  Frost et al (98) studied the effects 
of a 4 week low-vs-high GI diet on glucose and insulin responses in patients with coronary heart 
disease as well as the relationship between insulin-stimulated glucose uptake in adipocytes (fat 
biopsy) and insulin sensitivity (hyperinsulinemic glucose clamp technique).  A significant 
positive linear relationship was found between glucose uptake in adipocytes and the 
hyperinsulinemic glucose-clamp technique (r=0.72, p<0.02).  Subjects on the low GI diet had a 
significant decrease in insulin iAUC (p<0.03) and a significant increase in insulin-stimulated 
glucose uptake (p<0.05).  In a second study, Frost et al (99) studied the effects of a 3 week low-
vs-high GI diet on in-vivo whole-body insulin sensitivity (measured by the short insulin tolerance 
test) and in vitro adipocyte insulin sensitivity (fat biopsy) in premenopausal women with a 
parental history of coronary heart disease.  The low GI diet increased the in vitro adipocyte 
insulin sensitivity (p<0.05) and the in vivo insulin sensitivity (p<0.01).  Although these two 
studies by Frost et al (98, 99) have demonstrated that low GI diets can improve insulin 
sensitivity, they have been criticized because the ‘gold standard’ euglycaemic, hyperinsulinaemic 
clamp technique was not used.  
In a randomized, crossover study of either a low-vs-high glycemic index diet for 24 days in 
20 type 2 diabetic subjects, Jarvi et al (93) evaluated insulin sensitivity using the euglycemic-
hyperinsulinemic clamp technique.  Subjects peripheral insulin sensitivity increased significantly 
on both the low GI diet (p<0.01) and the high GI diet (p<0.05), however it was more pronounced 
on the low GI diet compared to the high GI diet (30% vs 21% change respectively).  The iAUC 
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was also 31% lower (p<0.05) for blood glucose and 27% lower (p<0.01) for plasma insulin 
following the low GI diet.   
Rizkall et al (92) also performed a randomized crossover design study of a 4 week low and 
high glycemic index diet in 12 type 2 diabetic subjects using the euglycemic-hyperinsulinemic 
clamp technique to measure insulin sensitivity.  Whole body glucose disposal was significantly 
higher following the low-vs-high GI diet (7.0+1.3 vs 4.8+0.9mg glucose/kg/min, respectively, 
p<0.001).  The iAUCs were also lower for plasma glucose after the low GI meals compared with 
the high GI meals during the 8 hour metabolic profiles at baseline (32%, p<0.05) and at 4 weeks 
following the diet (47%, p<0.05) and 23% lower for plasma insulin (p<0.05) after the low GI 
diet compared to the high GI diet during the 8 hour metabolic profile at the beginning of the two 
dietary periods. 
2.3.2.2.2 Glycemic Index and IMCL 
 Since low GI carbohydrates are slowly absorbed and release glucose gradually into the 
blood stream, they may suppress hepatic glucose production and non-esterified fatty acid 
(NEFA) release from adipocytes (107, 108).  Reducing plasma fatty acids may decrease IMCL 
storage and promote insulin-stimulated glucose transport by muscle (109) creating a more insulin 
sensitive condition.  Goff et al (110) investigated the effects of a 4 week low GI diet on insulin 
sensitivity (oral glucose tolerance test) and IMCL storage (magnetic resonance spectroscopy) in 
healthy adults.  Results showed a significant improvement in the insulin sensitivity index 
(baseline 7.8+1.1 (SEM) vs post-intervention 9.7+1.1, p<0.02) and a significant decrease in the 
insulin iAUC (baseline 30.8+4.2 vs post-intervention 23.7+3.3 mmol/min/L, p<0.01).  There 
were also significant decreases in fasting LDL cholesterol (p=0.01), plasma triglycerides 
(p=0.01), but no significant changes in NEFA concentrations (p=0.63) post-intervention.  IMCL 
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concentrations did not significantly change post-intervention, and no significant correlations 
were found between IMCL and insulin sensitivity suggesting that insulin sensitivity is 
independent of IMCL in healthy individuals.  It must be noted however, that the reduction in GI 
was only 15% for four weeks, which may not have been enough of a reduction in GI or a long 
enough intervention to affect IMCL concentrations.     
 It still remains unclear whether a low GI diet can reduce IMCL stores in the muscles of 
individuals with abdominal obesity, a population at risk for developing insulin resistance and 
type 2 diabetes.  The primary purpose of this thesis was to determine if a low GI diet would 
reduce IMCL stores thereby improving insulin sensitivity in individuals with abdominal obesity. 
2.4 Continuous Glucose Monitoring System (CGMS) 
2.4.1   Overview of the CGMS 
Both fasting and postprandial blood glucose monitoring are used for the diagnosis and 
treatment of diabetes, as well as improving glycemic control and reducing the risk of 
complications arising from diabetes (119, 120).  Self-monitoring blood glucose (SMBG) is an 
important practice for those individuals with diabetes (121), and may also help with glycemic 
control in non-diabetic individuals who are at risk for developing diabetes (e.g. obese 
individuals), however, there are limitations to this practice.  Since blood glucose is influenced by 
changing variables throughout the day (e.g. stress, physical activity, diet, rate of nutrient 
absorption) (122)), SMBG would need to be performed several times throughout the day which 
may not be practical for most individuals.  Continuous glucose monitoring systems were 
originally developed for diabetics to accurately identify blood glucose levels throughout the day 
(123).  The MiniMed Continuous Glucose Monitoring System (CGMS; MiniMed Inc., 
Northridge, CA) (Figure 2.3) was the first to develop a continuous sensor that could monitor 
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Figure 2.3. Continuous Glucose Monitoring System (MiniMed Inc, Northridge, CA)  
A: CGMS Monitor and Sensor; B: CGMS Com-Station (123) 
 
glucose profiles for 72 hours (123) and is the monitor used in this research (refer to Chapter 6). 
This model is a Holter-style sensor system consisting of the following components: a glucose 
monitor that stores the electrical signals from the glucose sensor; a sensor inserter (senserter) 
which is used to insert the sensor; a sterile, subcutaneous glucose sensor that continuously 
detects electrical signals (measured in namoamperes (nA)) every 10 seconds by the reaction of 
glucose in the interstitial fluid with glucose oxidase, and averages 30 electrical signals every 5 
minutes from the sensor for a total of 288 measurements per day; a connecting cable; and a 
communication device (Com-Station) which enables glucose data stored in the monitor to be 
downloaded to a computer to be analyzed (123).  Once the sensor is inserted, typically in the 
abdominal area, the individual must enter at least four blood glucose values obtained from a 
portable finger-stick glucose meter to calibrate the monitor (123).  Since the original 
development of the CGMS, MiniMed Inc. and other manufacturers have updated the design of 
the monitors to give the individual real-time access to their blood glucose values, as well as 
A B 
26 
 
providing alarms when blood glucose values reach hypoglycemic and hyperglycemic ranges 
(124, 125).  Research has shown that CGMS is beneficial for glycemic control in patients with 
diabetes and is an important clinical tool to help health care providers make recommendations to 
patients for reducing complications arising from diabetes (124, 126, 127, 128). 
2.4.2   CGMS and Glycemic Index 
 Research has examined the effects of glycemic index on glycemic control using the CGMS 
in type 2 diabetics (129), type 1 diabetics (130), healthy adults (131), and healthy adults at risk 
for heart disease (132).  Brynes et al (129) investigated the effects of a 7 day low GI diet (LGID) 
on glycemic profiles in free-living type 2 diabetics using the CGMS for two 24 hour periods.  
Significant reductions were found in fasting glucose (p<0.01), 24 hour area under the curve 
(AUC) for glucose (p<0.04), and overnight 8 hour AUC glucose (p<0.05), suggesting that 
glycemic control can be improved following a short term LGID (129).  Byrnes et al (131) 
performed another study in free-living healthy young adults, and used the CGMS to investigate 
changes in blood glucose profiles after following a 7 day LGID.  A significant reduction was 
found in fasting blood glucose (p<0.001), mean blood glucose over the 24 hour period 
(p=0.004), area under the 24 hour glucose curve (p=0.004), and overnight 8 hour glucose curve 
(p=0.01), suggesting that a LGID can have a significant effect on glucose profiles by improving 
hepatic insulin sensitivity and decreasing hepatic glucose output (131).  Nansel et al (130) used 
the CGMS to examine changes in glycemic profiles in type 1 diabetic youths, following a one 
day high vs low GI diet in a controlled setting, cross-over study.  Participants demonstrated 
lower daytime mean blood glucose and lower blood glucose area under the curve (p<0.001) 
following the low GI diet, suggesting that a low GI diet may reduce glucose excursions and 
improve glycemic control (130).  Philippou et al (132) studied the effects of a 12 week LGID on 
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24 hour glycemic responses using the CGMS in free-living adults at risk for developing heart 
disease.  Results showed a significantly lower 24 hour area under the curve (AUC) for glucose 
(p=0.045) and overnight AUC (p=0.006) for the LGID compared to the high GI diet but no 
significant changes in blood lipids (p>0.05) (132).  Further, Philippou et al (132) found that both 
groups significantly reduced their energy intake (p<0.05) but only the LGID group lost weight, 
concluding that a LGID in addition to weight loss may reduce cardiovascular risk  These studies 
(129, 130, 131, 132) showed that the GI can reduce fasting and postprandial blood glucose 
responses in individuals who are given specific foods to consume, however, the question about 
whether the GI can predict individual glycemic responses to self-selected meals remains unclear.  
Fabricatore et al (133) addressed this issue by examining the relationship of the GI and other 
dietary variables to glycemic responses, assessed by a CGMS, when meals were consumed in 
self-selected amounts by free-living overweight and obese type 2 diabetics.  Results showed that 
GI was positively related to CGMS AUC glucose (p=0.01), mean glucose (p=0.01), and time 
spent in a hyperglycemic range of greater than 10 mmol/L (p=0.02), and a multiple regression 
analysis showed that the dietary GI was the strongest predictor of glycemic variability 
accounting for 10% to 18% of the variance in each glycemic variable, independent of energy and 
carbohydrate intake (133).  Fabricatore et al (133) concluded that the results of their study 
support the validity of the GI and that consumption of a LGID is beneficial for controlling blood 
glucose in type 2 diabetics.  A purpose of this thesis was to determine whether GI is a significant 
determinant of individual glycemic responses elicited by self-selected breakfast meals in healthy, 
abdominally obese adults, a population at risk for diabetes.                     
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CHAPTER 3 
 
RATIONALE, HYPOTHESES, AND OBJECTIVES 
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3.  Rationale, Hypotheses, and Objectives 
 Research has shown that insulin sensitivity may in part be determined by the increased 
storage of lipids in organs other than adipose tissue such as muscle.  It has been hypothesized 
that increased lipid storage in muscle reduces sensitivity to insulin, thereby reducing insulin-
mediated glucose uptake in muscle.  This would lead to elevated insulin and glucose levels 
which in turn may lead to insulin resistance. Although research has shown a relationship 
between insulin sensitivity and IMCL, it still remains unclear whether IMCL stores are a cause 
or an effect of insulin resistance. 
 Although controversial, the role of the glycemic index (GI) in influencing insulin 
sensitivity has been documented.  It has been hypothesized that low GI diets may improve 
insulin sensitivity by suppressing non-esterified fatty acid release.  This in turn may reduce 
IMCL storage by promoting skeletal muscle glucose uptake. 
 It has been suggested that individuals with abdominal obesity have elevated levels of 
IMCL.  Documenting a positive effect of a low glycemic index diet on IMCL content and 
insulin sensitivity may have important implications in the treatment for individuals with 
abdominal obesity, as well as potentially help in the prevention of metabolic and cardiovascular 
complications in these individuals.   Further, demonstrating that a low GI diet as an 
intervention can reduce IMCL content and improve insulin sensitivity would be considered a 
major step forward in the understanding of insulin resistance. 
 This dissertation will be divided into three research chapters to address the information 
discussed above, each with their hypotheses and objectives.  All three chapters are from one 
long-term study.   The first chapter is the low-fat dietary advice run-in phase of the main study, 
the second chapter is the main study, and the third chapter is a sub-study from the run-in phase. 
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3.1 Effects of an ad-libitum low fat diet on metabolic profiles in adults with abdominal 
obesity 
 Hypothesis: 
 Following dietary advice on lowering overall fat and saturated fat intake will improve 
metabolic profiles in adults with abdominal obesity. 
 Objective: 
 The primary purpose of designing a 4 to 6 week low fat dietary advice run-in phase prior to 
the main study was to eliminate potential effects of variations in dietary fat intake which may 
influence IMCL content. 
 A secondary purpose was to determine whether dietary advice on consuming low fat foods 
will improve metabolic profiles in adults with abdominal obesity. 
 A third purpose was to determine whether there is a relationship between the glycemic 
index and metabolic profiles after following a low fat dietary advice phase for 4 to 6 weeks. 
 3.2 Effects of a eucaloric low glycemic index diet on insulin sensitivity and 
intramyocellular lipid content in adults with abdominal obesity 
 Hypothesis: 
 A low glycemic index diet will reduce intramyocellular lipid stores, thereby improving 
insulin sensitivity in adults with abdominal obesity. 
 Objective: 
 The primary objective was to determine if a 24 week low glycemic index diet will reduce 
intramyocellular lipid stores, thereby improving insulin sensitivity in individuals with 
abdominal obesity compared to a high glycemic index diet.  
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3.3 Glycemic index predicts individual glucose responses after self-selected breakfasts in 
free-living, abdominally obese adults 
 Hypothesis: 
 The glycemic index is a significant determinant of individual glycemic responses elicited 
by self-selected breakfast meals in free-living, abdominally obese adults. 
 Objective: 
 The primary objective was to determine if the glycemic index is a significant determinant 
of individual glycemic responses elicited by self-selected breakfast meals in free-living 
abdominally obese adults. 
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CHAPTER 4 
 
EFFECTS OF AN AD-LIBITUM LOW FAT DIET ON METABOLIC PROFILES IN  
 
ADULTS WITH ABDOMINAL OBESITY 
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4. Effects of an ad-libitum low fat diet on metabolic profiles in adults with abdominal 
obesity 
4.1 Introductory Statement 
 In both animal and human studies, high fat diets have been shown to increase IMCL 
storage.  In order to examine the role of the glycemic index and IMCL in the primary study, a 
weight maintaining, ad-libitum low fat dietary advice run-in phase was designed to eliminate 
potential effects of variations in fat intake on IMCL content. 
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4.2 Abstract 
Background: Individuals with abdominal obesity are at higher risk for developing 
cardiovascular disease, type 2 diabetes, and insulin resistance. High fat diets have been shown to 
increase intramyocellular lipids (IMCL) causing insulin resistance in these individuals.  Low fat 
and low glycemic index (GI) diets may be beneficial in the management of insulin resistance. 
Objectives: The primary purpose of this low fat, dietary advice study was to eliminate potential 
effects of variations in dietary fat intake which may influence IMCL content and insulin 
sensitivity in a primary study.   
Design: Ninety-five men and non-pregnant, non-lactating women with abdominal obesity, ages 
30 to 70 years (mean+SD 53.3+9.5) completed a 4-to-6 week weight maintaining, low fat dietary 
advice run-in study.  The participants completed a 3-day food diary at the start and end of the 
study.  At 4 to 6 weeks, participants underwent a 75g oral glucose test (OGTT) and soleus-
muscle IMCL, visceral adipose tissue (VAT), and subcutaneous adipose tissue (SAT) were 
measured by proton nuclear magnetic resonance spectroscopy (1H-MRS).   
Results: Participants significantly reduced their serum total-, LDL-, and HDL-cholesterol (all, 
p<0.0001), and fasting plasma glucose significantly increased (p<0.05).  The GI was positively 
correlated with the insulinogenic index and fasting insulin (both, p<0.05).  IMCL was positively 
correlated with waist circumference (p<0.01) and BMI, hip circumference, VAT, and total grams 
of dietary fat (all, p<0.05).     
Conclusions: This study demonstrated that individuals with abdominal obesity can significantly 
reduce blood lipids by following a weight maintaining, low fat diet.     
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4.3 Introduction 
 Obesity is a complex disease characterized by an abnormal deposition of fat in adipose 
tissue and is mainly the result of a positive energy balance where food intake is greater than the 
body’s ability to utilize the food as energy (1).  Individuals who have  excessive accumulation of 
adipose tissue, especially in the abdominal region, are at higher risk for developing 
cardiovascular disease (2, 9), type 2 diabetes (3, 4, 5, 6, 9) and metabolic syndrome and insulin 
resistance (7, 8).  Dietary interventions for these individuals include lowering the overall fat, 
saturated fat, and cholesterol in the diet (1).  One purpose of this study was to determine whether 
dietary advice on consuming low fat foods will improve metabolic profiles in adults with 
abdominal obesity. 
 It has been suggested that individuals with abdominal obesity cannot store lipids 
effectively in the subcutaneous adipose tissue which in turn leads to an increase in intracellular 
storage of lipids in organs other than adipose tissue such as the liver, pancreas and skeletal 
muscle causing insulin resistance in these tissues (10, 11).  In animal (12, 13, 14, 15) and human 
studies (16, 17, 18), high fat diets have been shown to increase skeletal muscle fat, specifically 
intramyocellular fat (IMCL) and decrease insulin sensitivity. The primary purpose of designing a 
low fat dietary advice run-in phase prior to the main study was to eliminate potential effects of 
variations in dietary fat intake which may influence IMCL content and insulin sensitivity. 
 Low glycemic index carbohydrate foods have also been extensively researched as a 
possible dietary intervention in the prevention of diseases.  The glycemic index (GI) was 
developed as a classification of the blood glucose-raising potential of the available carbohydrate 
in foods (19) and is defined as the incremental area under the blood glucose response curve after 
consuming a 50 gram available-carbohydrate portion of a test food expressed as a percentage of 
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the response after consuming 50 grams of oral anhydrous glucose or white bread by the same 
subject (20, 21).  Low glycemic index carbohydrate foods have been shown to improve 
metabolic profiles related to obesity, diabetes and cardiovascular disease among free-living 
individuals (22).  A third purpose of this study was to determine whether there is a relationship 
between the glycemic index and metabolic profiles after following a low fat dietary advice phase 
for 4 to 6 weeks. 
4.4 Subjects and Methods  
This study was carried out on an outpatient basis at the Hamilton General Hospital, 
Centre for Cardiovascular Obesity Research and Management, McMaster University, Faculty of 
Health Sciences.  The study protocol was approved by the Hamilton Health Sciences, McMaster 
University human research ethics board and carried out in accordance with the Declaration of 
Helsinki as revised in 2000.  All participants were given a participant information sheet and gave 
informed consent to participate in the study (Appendix 8.1).  The trial is publicly registered with 
ClinicalTrials.gov, number NCT00147264. 
4.4.1 Protocol 
This thesis chapter describes the results of a 4-to-6 week weight maintaining low-fat 
dietary advice run-in period of a randomized 2x2 factorial design clinical trial which determined 
the effects of a low GI diet and telmisartan on intramyocellular lipids (TRIM trial (Telmistartan-
Induced Reduction in Intra-Myocellular Lipids)).  An initial screening visit occurred two weeks 
prior to the study to determine whether the participant met the inclusion criteria.  The dietary 
intervention phase of the TRIM trial is discussed in Chapter 5 of this thesis.  The results of the 
telmisartan trial are not reported in this thesis. 
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4.4.2 Study Sample 
A total of 2433 participants from the general population responded through advertisement 
in local media and underwent a telephone screening process.  Of the 171 participants who were 
invited for an initial screening visit to assess eligibility, 32 participants did not meet the inclusion 
criteria and 18 refused to participate.  Of the 121 enrolled participants, 95 completed the study 
resulting in a 21% drop out rate.  Seven of the subjects dropped out because they wanted to lose 
weight, 6 left due to personal reasons, 5 participants had time commitment issues, 5 had adverse 
events and 3 dropped out for other unknown reasons.  Men and non-pregnant, non-lactating 
women aged 30 to 70 years with abdominal obesity, with or without additional features of the 
metabolic syndrome, were eligible to participate.  Abdominal obesity was defined as a waist 
circumference of >102 cm for males and >88 cm for females (Third Report of the National 
Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment 
of High Blood Cholesterol in Adults (Adult Treatment Panel III) (ATP III)) (23).  Inclusion 
criteria included abdominal obesity, ability to provide written informed consent, between 30 and 
70 years of age, and the ability and willingness to complete dietary and activity diaries and 
questionnaires.  Exclusion criteria included diabetes or use of any anti-diabetic drug, 
uncontrolled hypertension, serum triglycerides >10 mmol/L, active malignancy, chronic 
inflammatory disorders, endocrine, renal or hepatic dysfunction, use of angiotensin converting 
enzyme inhibitors or angiotensin receptor blockers in the last 3 months, use of a lipid lowering 
medication-the dose of which had not been stable for at least 3 months, body mass index of >45, 
intent to lose weight or use weight loss medications during the study, contraindications to 
magnetic resonance imaging (MRI) such as claustrophobia or metal prostheses, and any dietary 
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restrictions that would prevent the participants from following the study protocol during the 
randomization phase of the study (to be discussed in Chapter 5). 
4.4.3 Ad-Libitum Low Fat Diet 
The run-in phase consisted of dietary advice on following a standardized low fat diet as 
outlined by the American Heart Association (24) consisting of 55% energy from carbohydrate, 
30% from fat, less than 7% from saturated fat and 15% from protein.  Daily energy requirements 
were estimated according to the Lipid Research Clinic Requirement formula (25) with an 
additional 300 kcal per day added on for exercise and daily energy expenditure (Appendix 8.2).  
Diets were prescribed on an ad libitum basis.  The aim of the diet was to be weight maintaining 
and to eliminate potential effects of variations in fat intake on IMCL content.  Participants were 
given an information sheet (Appendix 8.3) to provide dietary advice on following a low fat diet.  
The participants completed three MEDFICTS dietary assessment questionnaires to assess dietary 
fat intake (Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on 
Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment 
Panel III) (ATP III)) (26) and completed a 3-day food diary at the start and end of the study to 
assess fat intake and to provide dietary advice (Appendix 8.5). Micronutrients, macronutrients, 
and GI of test foods were calculated using the Food Processor SQL Nutrition Analysis & Fitness 
software package version 9.5 (ESHA Research, Salem, OR, USA) with missing values for GI 
added using the NutriPro diet analysis program (Glycemic Index Laboratories Inc., University of 
Toronto).  The GI was expressed with the GI of glucose = 100.  Participants were instructed to 
maintain their habitual level of physical activity throughout the study.  The Baecke habitual 
physical activity questionnaire was administered at the start and end of the study to determine 
activity levels (Appendix 8.6) (27).   
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4.4.4 Anthropometric Measurements, Blood Pressure and Heart Rate 
Height (cm) was measured at the initial screening visit to the nearest 0.1 cm using a wall 
mounted stadiometer and body weight was measured at every visit to the nearest 0.1 kg on a 
digital weigh scale.  Body mass index (BMI) was calculated as body weight (kg) divided by 
height (m2).  Waist circumference (WC) was measured to the nearest 0.1 cm using the World 
Health Organization (WHO) method (mid-point between the palpated inferior border of the last 
rib and upper border of the iliac crest in a horizontal plane at the end of normal expiration) (28).  
Hip circumference (HC) was measured to the nearest 0.1 cm at the level of the major trochanter 
(usually around the largest diameter of the buttocks) (28).  Waist-to-hip ratio (WHR) was 
calculated (waist (cm) divided by hip (cm)) from the measurement of the waist and hip 
circumference. Body composition analysis (body fat percentage) was assessed by bioelectrical 
impedance analysis as per manufacturer’s instructions (BioScan 916, Maltron International Lt, 
Rayleigh, Essex, UK).  Waist and hip circumference and body fat percentage were measured at 
the start and end of the study. 
Blood pressure (BP) and heart rate (HR) were measured at every visit in the sitting 
position using an automatic blood pressure monitor (BpTRU®, VSM MedTech Ltd., Vancouver, 
BC, Canada) following five minutes of seated rest. 
4.4.5 Fasting Plasma Glucose and Lipids 
 Blood samples were collected from the antecubital vein following a 12 hour fast at the start 
of the study.  Screening blood tests included fasting glucose, total cholesterol, HDL cholesterol, 
LDL cholesterol, and triglycerides.  Plasma glucose and lipids were analyzed using standard 
enzymatic procedures and LDL cholesterol was calculated using the Friedewald formula (32). 
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4.4.6 Oral Glucose Tolerance Test 
 An oral glucose tolerance test (OGTT) was performed in the fasting participant (12 hours) 
at the end of the study.  An indwelling catheter was inserted in the forearm and three blood 
samples for glucose and insulin were taken five minutes apart (-15, -10, -5 minutes).  Participants 
then ingested (0 minutes) a 75 gram solution of dextrose and venous blood samples were 
obtained again at 30, 60, and 120 minutes for determination of plasma glucose and insulin.  
Glucose was measured by a glucose oxidase method and serum insulin was measured with an 
immunometric assay (Diagnostic Products Corporation, Los Angeles, CA).  The glucose and 
insulin data from the OGTT was used to assess insulin sensitivity (homeostatic model 
assessment index, HOMA = fasting insulin (µU/ml) x fasting glucose (mmol/L) divided by 22.5 
(29)) and insulin secretion (insulinogenic index (ISI) = ratio of change in insulin to change in 
glucose from 0 to 30 minutes (Delta I30 divided by Delta G30) (30)).  The HOMA index has been 
validated with the gold standard euglycemic hyperinsulinemic clamp technique (31).  During the 
OGTT, fasting blood samples were also collected for of total, HDL and LDL cholesterol, free 
fatty acids, and triglycerides.  LDL was calculated using the Friedewald formula (32). 
4.4.7 Magnetic Resonance Imaging 
 Intramyocellular lipid (IMCL) content of the mid-soleus muscle (predominately oxidative 
muscle fibres) was assessed by proton magnetic resonance spectroscopy (1H-MRS) at the end of 
the run-in period.  MRS was performed on a 1.5 Tesla whole body MR system (Siemens 
Symphony AG, Munich, Germany) using a body coil for radiofrequency transmission and 
surface coil to receive signals.  The 1H-MRS scans were performed at the Nuclear Medicine 
Department at the McMaster University Medical Centre.  Participants were advised to fast and 
restrict physical activity for six hours prior to the procedure.  Following screening for absence of 
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MRI contraindications, the participant was placed in the supine position and the leg was 
positioned and immobilized so that the calf was situated as close to the center of the magnet as 
possible.  The radio-frequency receive coil was fastened nearest to the region of interest to 
collect the greatest signal.  Participants remained in the supine position (feet first) within the MR 
system. Three-plane spin-echo T1-weighted MR images were performed to guide placement of 
the volume of interest for spectroscopy.  Imaging parameters were chosen for suitable separation 
of muscle, fascia, IMCL and extramyocellular lipid (EMCL) content (TR 3000 milliseconds 
(ms), TE 30 ms, 128 averages, 1,024 data points over 1000 Hz spectral width, 1 cc voxel 
volume, water signal suppressed using chemical selective saturation).  Semi-automatic shimming 
of the magnet with typical line widths of the water signal of 10 Hz was performed to optimize 
magnetic field homogeneity.  Several scout images were taken to determine the ideal position for 
the voxel location.  Volume of interest was centered over the mid-soleus muscle and vascular 
structures and gross adipose tissue deposits were excluded as much as possible.  The IMCL and 
EMCL peak was integrated at 1.28 ppm and 1.48 ppm respectively.  Since creatine content is 
stable within the same muscle across a population (50), spectral intensities were referenced to the 
methyl signal of creatine (Cr3) at 3.05 ppm serving as an internal reference. Spectra were 
processed and the resonance curves for IMCL, EMCL, and creatine were measured using jMRUI 
software v2.1 (51).  Data is presented as arbitrary units.  
 After 3-plane localizer image acquisition, breath-hold axial T1-weighted image at the level 
of mid-L4 (TR 400 ms, TE 13 ms) was acquired for the volume of visceral adipose tissue (VAT) 
and subcutaneous adipose tissue (SAT).  VAT and SAT was calculated using SliceOmatic 4.2 
medical imaging software (SliceOmatic v.4.2, Tomovision, Montreal).  VAT was defined as 
adipose tissue within the inside edge of the abdominal wall and SAT was defined as adipose 
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tissue on the outside edge of the abdominal wall.  The intra-and-inter-observer coefficients of 
variation for this method are 0.53% and 0.44% for SAT and 1.46% and 2.42% for VAT 
respectively. 
4.4.8 Statistical Analysis 
 Statistical analyses were performed using SPSS 10.1 for Windows (SPSS Inc., Chicago, 
IL, USA).  Pearson product moment correlation coefficient and Student’s t-tests were used to 
determine correlations and differences of means between IMCL, GI, macronutrient composition 
of the diet, anthropometric data, blood glucose, blood insulin and blood lipid parameters.  
Statistical significance was set at p<0.05.  All data are presented as means +SD unless otherwise 
indicated.     
4.5 Results 
4.5.1 Subject Characteristics 
 Entering the 4 to 6 week study, the majority of the study population were female (73%) 
and Caucasian (89%), with a mean age of 52 (+10) and the majority of the women were 
menopausal (92%).  According to the NCEP-ATP III definition for metabolic syndrome (1), all 
participants had abdominal obesity (100%) (Waist Circumference (WC) >102 cm (males), >88 
cm (females), 56% elevated triglycerides (>1.7mmol/L), 27% high blood pressure (>130/85), 
23% low HDL cholesterol (<1.0mmol/L (males), <1.3mmol/L (females)) and 9% impaired 
fasting glucose (>6.1mmol/L).  The clinical characteristics of the study population had changed 
very little by the end of the study (within 3%), however due to drop out rate, 6% more 
participants had impaired fasting glucose, 10% lower HDL cholesterol, and 23% fewer women 
were menopausal (Table 4.1). 
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Table 4.1. Clinical Characteristics of the Study Population at Screening, Start and End of Study 
 
 
Variable 
Screening 
 
N = 171 
Start 
 
N = 121 
End 
 
N = 95 
 
Age 52 [+10] 52 [ +10] 53 [+9] 
Male 47 (27) 33 (27) 28 (29) 
Female 124 (73) 88 (73) 67 (71) 
Menopause 115 (93) 81 (92) 62 (69) 
Caucasian 152 (89) 108 (89) 86 (91) 
Smoker 60 (35) 41 (34) 34 (36) 
Calcium Channel Blocker medication 9 (6) 7 (6) 8 (9) 
Beta Blocker medication 12 (7) 8 (7) 5 (6) 
Anti-hypertensive medications (excluding ARB) 31 (18) 20 (17) 15 (16) 
Diuretics 10 (6) 6 (5) 5 (5) 
Aspirin 17(10) 12 (10) 8 (8) 
Lipid Lowering Drugs 27 (16) 19 (16) 16 (17) 
Abdominal Obesity 171 (100) 121 (100) 95 (100) 
Triglycerides > 1.7 mmol/L 85 (50) 68 (56) 51 (54) 
Blood Pressure > 130/85 mmHg 53 (31) 33 (27) 23 (24) 
Fasting Glucose  6.1- 6.9 mmol/L 16 (9) 11 (9) 14 (15) 
HDL-C < 1.0 mmol/L (M), < 1.3 mmol/L (F) 40 (23) 28 (23) 31 (33) 
 
Numbers in round ( ) brackets represent percentage of the study population. Numbers in square 
 
brackets [ ] represent + SD of the mean.  M indicates males, F indicates females.  ARB  
 
designates angiotensin receptor blockers. C stands for cholesterol. 
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4.5.2 Anthropometric Measurements, Blood Pressure and Heart Rate 
 At the start-and-end of the study, the participant’s mean BMI was 34.7+6.1 and 34.4+5.7 
respectively, demonstrating that participants were classified as obese (BMI>30) during the study. 
BMI, WC, HC, WHR, % body fat, systolic BP, diastolic BP and HR did not significantly change 
(p>0.05) (Table 4.2).   
 
Table 4.2.  Anthropometric Characteristics, Blood Pressure and Heart Rate at Baseline and End 
of Study   
 
 
Variable 
Start 
 
N = 121 
End 
 
N = 95 
 
 
p value 
 
BMI (kg/m2) 34.7+6.1 34.4+5.7 0.34 
Waist Circumference (cm)  111.0+14.5 110.5+12.6 0.69 
Hip Circumference (cm)  121.4+12.4 121.1+11.6 0.43 
Waist to Hip Ratio  0.92+0.09 0.91+0.08 0.44 
% body fat  42.2+9.2 41.4+9.9 0.10 
Systolic Blood Pressure (mmHg) 122.4+14.0 121.1+12.2 0.11 
Diastolic Blood Pressure (mmHg) 78.5+7.9 77.7+7.7 0.32 
Heart Rate (beats/minute) 75.4+12.8 72.9+11.2 0.07 
Data are means +SD 
 
4.5.3 Fasting Plasma Glucose and Lipids 
After following dietary advice for a low fat, weight maintaining diet, fasting total serum 
cholesterol, LDL cholesterol, and HDL cholesterol all significantly decreased (p<0.0001), while 
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fasting plasma glucose significantly increased (p<0.05) (Table 4.3).   There was a trend towards 
a decrease in fasting triglycerides but it was not significant (p>0.05) (Table 4.3).   
 
Table 4.3.  Fasting Plasma Glucose and Lipids and Significance of Changes over the Dietary 
Period 
  
Variable 
Start 
N = 121 
End 
N = 95 
%  
Change 
 
p-value 
Total Cholesterol (mmol/L) 5.6+1.2 5.1+1.0 -8.9 0.000 ** 
LDL Cholesterol (mmol/L) 3.3+1.0 3.0+0.9 -9.1 0.000 ** 
HDL Cholesterol (mmol/L) 1.4+0.4 1.3+0.3 -7.1 0.000 ** 
Triglycerides (mmol/L) 2.1+1.3 2.0+1.3 -4.8 0.186 
Fasting Plasma Glucose (mmol/L) 5.4+0.6 5.5+0.8 +1.9 0.036 * 
 
Data are means +SD, *p<0.05, ** p<0.0001  
 
 
4.5.4 Dietary Intake and Physical Activity  
There was a significant decrease in the percentage of energy (kilocalories (kcal)) from 
total fat (p<0.0001) and saturated fat (p<0.01) and the MEDFICTS dietary assessment 
questionnaire of fat intake (p<0.00001) (Table 4.4).  The percentage of energy (kcal) from 
carbohydrate and protein, as well as grams of fibre intake significantly increased (p<0.01) (Table 
4.4). No significant differences were seen in energy intake (total kilocalories), GI, alcohol, or 
physical activity level (p>0.05) (Table 4.4).   
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Table 4.4.  Dietary Intake and Physical Activity at the Start and End of the Study 
Variable Start (N = 121) End (N = 95) p value 
Energy intake (kcal) 2077.4+625.1 2020.5+584.8 0.465 
Total Fat (g) 79.1+32.8 70.7+32.8 0.025 * 
Total Fat (% kcal) 33.0+7.1 29.6+7.5 0.0000 **** 
Saturated Fat (g) 27.2+22.9 21.5+9.7 0.017 * 
Saturated Fat (% kcal) 10.7+3.0 9.5+3.4 0.005** 
Total Carbohydrate (g) 253.0+80.6 260.1+88.5 0.305 
Total Carbohydrate (% kcal) 48.4+8.4 51.0+8.5 0.003** 
Fibre (g) 20.7+9.8 23.8+11.3 0.008 ** 
Protein (g) 88.7+30.5 91.2+29.8 0.453 
Protein (%) 17.0+3.4 18.0+3.4 0.010 ** 
Alcohol (%) 3.6+18.7 1.2+3.2 0.020* 
Glycemic Index (%) 59.7+4.2 59.8+3.7 0.931 
MEDFICTS score 64.4+25.8 46+18.6 0.0000**** 
Baecke Activity 
 
2.4+0.6 2.5+0.5 0.417 
 
Data are means +SD, *p<0.05, **p<0.01, ***p<0.0001, ****p<0.00001  
 
% kcal;percentage of total energy, Baecke Activity;Baecke activity questionnaire  
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4.5.5 Oral Glucose Tolerance Test 
4.5.5.1 Insulin and Glucose 
Upon completion of the study, there was a significant positive correlation with the 
insulinogenic index (ISI) and percentage body fat and the MEDFICTS dietary fat questionnaire 
(both, p<0.05), and a negative correlation between ISI and activity level (both, p<0.05).  HOMA 
was positively correlated with BMI, WC, and visceral adipose tissue (VAT) (all, p<0.0001), HC 
and percentage of body fat (both, p<0.001), percentage of energy from dietary fat and grams of 
saturated fat (both, p<0.05), and negatively correlated with HDL cholesterol (p<0.01). 
Fasting insulin was positively correlated with BMI, VAT, WC and HC (all, p<0.001), 
percentage of body fat (p<0.01), and grams of saturated fat, percentage of energy from dietary 
fat, and GI (all, p<0.05), and negatively correlated with HDL cholesterol and activity level (both, 
p<0.05).  Thirty minute insulin was positively correlated with the MEDFICTS dietary fat 
questionnaire (p<0.01), and BMI, VAT, percentage of body fat, and percentage of energy from 
dietary fat and saturated fat (all, p<0.05), and negatively correlated with activity level, dietary 
fibre (g) and percentage of energy from carbohydrate (all, p<0.05). 
Fasting glucose was positively correlated with VAT (p<0.05).  Thirty minute glucose was 
positively correlated with VAT (p<0.05) and percentage of energy from saturated fat and total fat 
(both, p<0.01), and negatively correlated with dietary fibre (g) and percentage of energy from 
carbohydrate (both, p<0.05).  Sixty minute glucose was positively correlated with VAT and WC 
(both, p<0.01) and negatively correlated with HDL cholesterol (p<0.001).  Glucose at 120 
minutes was positively correlated with free fatty acids (FFA) (p<0.05) and negatively correlated 
with carbohydrate (g) (p<0.05).  Refer to Table 4.5 for insulin and glucose correlations. 
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Table 4.5. Correlation Grid for Insulin and Glucose        
 GI 
% 
MED- 
FICTS 
Total 
Fat % 
Total 
Fat (g) 
Sat 
Fat % 
Sat 
Fat (g) 
Fibre 
(g) 
CHO  
% 
CHO 
(g) 
ISI 0.22 0.26* 0.10 0.13 0.09 0.17 0.02 -0.07 0.10 
HOMA 0.19 0.14 0.23* 0.21 0.19 0.22* 0.02 -0.07 0.10 
FastIns 0.21* 0.16 0.22* 0.21 0.19 0.23* -0.15 -0.14 -0.01 
30mIns 0.18 0.31** 0.25* 0.13 0.25* 0.22 -0.27* -0.23* -0.12 
30mPG 0.05 0.16 0.32** 0.16 0.31** 0.19 -0.25* -0.25 -0.15 
120mPG -0.07 -0.08 -0.02 -0.15 0.03 -0.15 -0.05 0.04 -0.21* 
 
 IMCL  VAT Baecke %BF BMI WC HC HDL FFA 
ISI -0.02 0.02 -0.23* 0.23* 0.16 0.06 0.15 0.01 -0.18 
HOMA 0.12 0.53$ -0.18 0.38# 0.51$ 0.42$ 0.40# -0.30** -0.17 
FastIns 0.10 0.56$ -0.21* 0.35** 0.52$ 0.43$ 0.40$ -0.29* -0.18 
30mIns -0.01 0.30* -0.25* 0.26* 0.28* 0.21 0.19 -0.05 -0.12 
FPG 0.11 0.26* 0.06 0.13 0.14 0.19 0.08 -0.16 -0.14 
30mPG 0.09 0.23* 0.09 0.02 0.06 0.19 0.00 -0.17 -0.02 
60mPG 0.15 0.33** 0.05 0.05 0.08 0.27** 0.08 -0.35# 0.17 
120mPG -0.01 0.16 -0.01 0.21 0.11 0.08 0.08 -0.14 0.26* 
The data in the table represent correlation r values.  *p<0.05, **p<0.01, #p<0.001, $p<0.0001, 
GI;glycemic index, %;percentage of total energy, sat fat;saturated fat, CHO;carbohydrate, IMCL: 
intramyocellular lipids (arbitrary units (AU)), VAT;visceral adipose tissue (AU), Baecke; Baecke activity 
questionnaire, %BF;percentage body fat, BMI;body mass index, WC;waist circumference (cm), HC;hip 
circumference (cm), HDL;high density lipoprotein cholesterol (mmol/L), FFA;free fatty acids (µmol/L), 
ISI;insulinogenic index, HOMA;homeostasis model assessment, FastIns;fasting insulin, 30mIns;30 
minute insulin, FPG;fasting plasma glucose, 30mPG;30 minute plasma glucose, 60mPG;60 minute 
plasma glucose, 120mPG;120 minute plasma glucose: plasma glucose was measured in mmol/L, plasma 
insulin was measured in pmol/L): insulin, glucose, FFA, HDL cholesterol were obtained during the oral 
glucose tolerance test 
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4.5.5.2 Blood lipids 
At the end of the run-in period, fasting total cholesterol was negatively correlated with 
dietary carbohydrate (p<0.05).  LDL cholesterol was positively correlated with percentage of 
energy from total fat and negatively correlated with percentage of energy from carbohydrate 
(both p<0.05).  Triglycerides were positively correlated with VAT (p<0.01).  Free fatty acids 
were positively correlated with percentage of body fat (p<0.01) and 120 minute plasma glucose 
(p<0.05) and negatively correlated with WHR, dietary carbohydrate (g) and protein (g) (all, 
p<0.05).  HDL cholesterol was negatively correlated with WHR (p<0.0001), WC (p<0.001), 
fasting insulin, 60 minute plasma glucose, VAT, HOMA, and dietary carbohydrate and protein 
(g) (all, p<0.01), and fibre (p<0.05).  Refer to Table 4.6 for blood lipid correlations.    
 4.5.6 Intramyocellular Lipids (IMCL), Subcutaneous Adipose Tissue (SAT), Visceral 
Adipose Tissue (VAT) 
 At the end of the run-in period, IMCL was positively correlated with VAT (r=0.27, 
p<0.05).  IMCL was also positively correlated with WC (p<0.01), BMI, and HC (both, p<0.05), 
and grams of dietary carbohydrate, fat and protein (all, p<0.05) (Table 4.7).  IMCL was not 
significantly correlated with HOMA, ISI, or any insulin, glucose or lipid measurements obtained 
during the OGTT (p>0.05) (Table 4.5, 4.6).  Subcutaneous adipose tissue (SAT) was positively 
correlated with BMI, WC and HC (all, p<0.0001) and percentage of body fat (p<0.001) (Table 
4.7).  VAT was positively correlated with BMI, WHR, WC, fasting plasma insulin and HOMA 
(all, p<0.0001), HC (p<0.001), triglycerides and 60 minute plasma glucose (both, p<0.01), 
IMCL, 30 minute plasma insulin, MEDFICTS dietary fat questionnaire, fasting and 30 minute 
plasma glucose, and grams of dietary protein and fat (all, p<0.05) (Tables 4.5, 4.6, 4.7).  VAT 
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was negatively correlated with HDL cholesterol (p<0.01) and activity level (p<0.05) (Tables 4.6, 
4.7).  The GI was positively correlated with VAT however it was not significant (p=0.06).   
 
Table 4.6. Correlation Grid for Serum Lipids 
 CHO % CHO (g) Total Fat % Protein (g) Fibre (g) IMCL 
Total-C -0.25* -0.21* 0.20 -0.01 -0.15 -0.17 
LDL-C -0.26* -0.14 0.23* 0.07 -0.10 -0.11 
HDL-C -0.09 -0.29** 0.23 -0.32** -0.26* -0.20 
FFA 0.04 -0.23* -0.03 -0.22* -0.18 -0.10 
TG 0.01 -0.00 -0.04 0.13 0.07 -0.00 
 VAT WC WHR %BF FastIns HOMA 60mPG 120mPG 
HDL-C -0.32** -0.33# -0.44$ 0.07 -0.29** -0.30** -0.35** -0.14 
FFA -0.11 -0.02 -0.23* 0.30** -0.18 -0.17 0.17 0.26* 
TG 0.31** 0.04 0.11 0.13 0.13 0.14 0.15 0.11 
The data in the table represent correlation r values.  *p<0.05, **p<0.01, #p<0.001, $p<0.0001,  
%;percentage of total energy, CHO;carbohydrate, IMCL;intramyocellular lipids (arbitrary units 
(AU)), VAT;visceral adipose tissue (AU), %BF;percentage body fat, WC;waist circumference 
(cm), Total-C;total cholesterol (mmol/L), HDL;high density lipoprotein cholesterol (mmol/L), 
LDL-C;low density lipoprotein cholesterol (mmol/L), FFA;free fatty acids (µmol/L), 
TG;triglycerides (mmol/L), HOMA;homeostasis model assessment index, FastIns;fasting plasma 
insulin (pmol/L), 60mPG;60 minute plasma glucose (mmol/L), 120mPG;120 minute plasma 
glucose (mmol/L): FFA, insulin, glucose and cholesterol were obtained during the oral glucose 
tolerance test 
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Table 4.7. Correlation Grid for IMCL, SAT, VAT  
 BMI WC HC %BF WHR Baecke 
IMCL 0.22* 0.31** 0.23* 0.04 0.21 -0.04 
SAT 0.68$ 0.54$ 0.81$ 0.41# -0.12 -0.21 
VAT 0.48$ 0.65$ 0.37# 0.13 0.50$ -0.25* 
 
 MEDFICTS Protein (g) Total Fat (g) CHO (g)  
IMCL 0.05 0.24* 0.22* 0.28*  
VAT 0.23* 0.25* 0.25* 0.05  
The data in the table represent correlation r values.  *p<0.05, **p<0.01, #p<0.001, $p<0.0001, 
IMCL;intramyocellular lipid (arbitrary units (AU)), SAT;subcutaneous adipose tissue (AU), 
VAT;visceral adipose tissue (AU), BMI;body mass index, WC;waist circumference (cm), 
HC;hip circumference (cm), %BF;percentage body fat, WHR;waist to hip ratio, Baecke;Baecke 
activity questionnaire, CHO;carbohydrate.  
 
4.6 Discussion and Conclusions 
This study demonstrated that individuals with abdominal obesity can significantly reduce 
blood lipids by following dietary advice on consuming an ad-libitum low fat diet without any 
strict dietary protocol to follow and without losing weight or increasing physical activity. At the 
start-and-end of the study, the participant’s mean BMI was 34.7+6.1 and 34.4+5.7 respectively, 
demonstrating that participants were classified as obese (BMI>30) during the study. Total energy 
(kcal) intake, activity level, BMI, WC, hip circumference, WHR, and percentage body fat did not 
significantly change (p>0.05) indicating that participants followed a weight maintaining diet.  
There was a significant decrease in the percentage of total dietary fat (p<0.0001) and saturated 
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fat (p<0.01) and the MEDFICTS score (dietary assessment questionnaire of fat intake) 
(p<0.00001) demonstrating that the participant’s lowered their fat intake during the study.   
The recommended NCEP-ATP III dietary interventions for obese individuals, specifically 
to prevent coronary heart disease, include weight loss, physical activity and lowering the overall 
fat, saturated fat, and cholesterol in the diet, with the primary goal of lowering LDL cholesterol 
(1).  This study provided dietary advice for following the NCEP-ATP III dietary 
recommendations for lowering the overall fat and saturated fat.  Participants reduced the 
saturated fat and total fat in their diet while increasing the carbohydrate and protein in the diet.  
The significant reductions (p<0.0001) in total cholesterol (-8.9% change) and LDL cholesterol   
(-9.1% change) are consistent with other studies showing a reduction in serum lipids when 
following a low fat diet (33, 37).  A meta-analysis by Clarke et al (33) reported that replacing 
saturated fat with complex carbohydrate can decrease total serum cholesterol by 0.52 (SE+0.03) 
mmol/L and LDL cholesterol by 0.36 (SE+0.05) mmol/L.  Other studies have shown an increase 
in triglycerides and a decrease in HDL cholesterol when replacing saturated fat with 
carbohydrate (34, 35), however, when fibre is increased along with carbohydrate intake, the 
negative effects  are reduced (35, 36).  In this study, there were no significant changes in 
triglycerides after following an ad-libitum low fat diet, however, HDL cholesterol decreased 
significantly (p<0.0001) even though fibre intake increased throughout the study.  An 
explanation for the reduction in HDL cholesterol is that all serum lipids will be reduced when 
restricting fat intake in the diet.  Reductions in HDL cholesterol have been previously reported 
when following a low fat diet (37) which prompted the NCEP-ATP III to include physical 
activity and weight reduction along with following a low fat diet to reduce cardiovascular disease 
risk (1).  The focus of this study was to eliminate potential effects of variations in dietary fat 
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intake which may influence IMCL content and not to lower serum lipids, therefore physical 
activity and weight loss were not part of the protocol in this study.  This study did demonstrate 
that a weight maintaining, low fat, ad-libitum diet for 4 to 6 weeks can significantly reduce 
serum lipids in obese individuals.  Thus, a weight-maintaining, low fat diet may reduce an 
individuals’ risk for developing cardiovascular disease if followed for a longer duration. 
In animal (12, 13, 14, 15) and human studies (16, 17, 18), high fat diets have been shown 
to increase IMCL and decrease insulin sensitivity.  In this study, IMCL was positively correlated 
with total dietary fat (p<0.05), which is consistent with studies showing a relationship with 
dietary fat and IMCL however there were no significant correlations between IMCL and insulin 
sensitivity.  A possible explanation for not finding correlations with IMCL and insulin sensitivity 
in this study is participants were given dietary advice regarding food choices for following a low 
fat diet whereas other studies provided controlled high fat feedings and diets.  Further, studies 
demonstrating a relationship between insulin resistance and IMCL used the euglycemic 
hyperinsulinemic clamp method (16, 17, 45).  The current study did not find a correlation 
between insulin resistance and IMCL possibly due to using the HOMA index to estimate insulin 
sensitivity.  The results of the current study are in agreement with previous studies using HOMA 
that did not find a relationship between IMCL and insulin sensitivity (46, 47).  Although HOMA 
has been validated with the euglycemic hyperinsulinemic clamp technique (31), it is more a 
measure of hepatic insulin resistance rather than an indicator of muscle insulin sensitivity.  It 
may be possible that the relationship between insulin resistance and IMCL may not be found 
when using HOMA and a more accurate technique may have identified this relationship in the 
current study.  Further, no relationship was found between IMCL and two hour plasma glucose 
(120mPG) after OGTT which is an indicator of muscle insulin sensitivity.  The lack of 
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relationship between IMCL and two hour plasma glucose may be due to the fact that the study 
population was abdominally obese but otherwise healthy individuals with fasting and 120 minute 
glucose and insulin within recommended ranges. The current results are consistent with other 
studies that found no correlation between IMCL and insulin sensitivity in healthy, overweight 
individuals (46, 48, 49).  Further, a limitation of this run-in phase was that IMCL content was 
measured only at the end of the study, therefore conclusions cannot be made on whether changes 
occurred in IMCL and if there was any effect on insulin sensitivity after reducing fat in the diet.  
On the other hand, IMCL was positively correlated with VAT (p<0.05) and VAT was positively 
correlated with the OGTT fasting insulin (p<0.00001) and glucose (p<0.05), 30 minute insulin 
and glucose (p<0.05), 60 minute glucose (p<0.01) and HOMA (p<0.0001).  Findings are 
consistent with a study by Koska et al (38) who found a positive correlation with fasting plasma 
insulin and VAT (p<0.01) but no correlation with IMCL and insulin action on glucose uptake 
and production in obese individuals.  The results of this study showed that IMCL and VAT were 
correlated with fat intake however VAT may independently have an effect on insulin sensitivity.    
 A third purpose of this study was to determine whether there was a relationship between 
the glycemic index and metabolic profiles after following a low fat dietary advice phase for 4 to 
6 weeks.  Although participants were not given dietary advice on following a low GI diet, there 
was a significant positive relationship between glycemic index (GI) and fasting insulin (p<0.05).  
Wolever et al (41, 42) have previously shown that individual foods with different GI’s as well as 
mixed meals varying in GI affect postprandial plasma insulin and glucose differently.  Although 
this study did not find a correlation between GI and plasma glucose, research has shown a 
relationship between mean plasma insulin and glucose response areas under the curve with foods 
varying in GI (41).  Findings from this study are consistent with previous research demonstrating 
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that insulin is positively correlated with the GI, indicating that lower GI foods can be less 
demanding on the pancreas for insulin production (43, 44).  Since abdominally obese individuals 
are susceptible to developing insulin resistance, following a diet with lower GI foods may have 
metabolic benefits such as improving insulin sensitivity and should be evaluated further. 
 In conclusion, this study has shown that a weight maintaining, low-fat, ad-libitum diet can 
reduce total serum cholesterol and LDL serum cholesterol in abdominally obese individuals, a 
population at risk for coronary heart disease, diabetes, and metabolic syndrome.  These findings 
may help to explain the importance of a low fat diet, especially for those individuals who do not 
wish to reduce body weight or increase activity level.  The participants in this study obtained 
dietary advice on following a low fat diet for a short period of time.  To confirm the present 
findings, research is needed to determine whether individuals can follow dietary advice on 
following a low fat diet for a longer duration.  Further, participants in this study did not receive 
dietary advice on following a low GI diet.  Future research is needed to determine the long-term 
effects of a non-prescribed, ad-libitum, low fat, low GI diet on metabolic profiles in free-living 
individuals with abdominal obesity.   
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CHAPTER 5 
EFFECTS OF A EUCALORIC LOW GLYCEMIC INDEX DIET ON INSULIN 
SENSITIVITY AND INTRAMYOCELLULAR LIPIDS IN ADULTS WITH 
ABDOMINAL OBESITY 
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5. Effects of a eucaloric low glycemic index diet on insulin sensitivity and intramyocellular 
lipids in adults with abdominal obesity 
5.1 Introductory Statement 
Research has shown that insulin sensitivity is negatively correlated with intramyocellular 
lipid (IMCL) content. It has been suggested that low glycemic index diets may improve insulin 
sensitivity by suppressing non-esterified fatty acid release, which in turn may promote glucose 
uptake and possibly lower IMCL content. This study was conducted to determine whether a long 
term eucaloric low glycemic index diet can improve insulin sensitivity by reducing IMCL 
content of skeletal muscle in abdominally obese individuals.   
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5.2 Abstract 
Background: Abdominal obesity is associated with insulin resistance and increased IMCL 
content of skeletal muscle.  Low-glycemic-index (GI) diets may improve insulin sensitivity in 
insulin resistant subjects but their effect on IMCL is unknown.   
Objective: The purpose of this study was to determine the effect a low-GI diet (LGID) on 
insulin sensitivity and IMCL content in weight-stable abdominally obese adults.   
Design: Ninety-five men and non-pregnant, non-lactating women aged 53+10 years with 
abdominal obesity were randomized to a 24-week intervention of either a weight-maintaining 
low glycemic index diet (LGID, n=48) or control high-GI diet (HGID, n=47). 1H-MRS of the 
soleus muscle and an oral glucose tolerance test were performed at the beginning and end of the 
study to determine IMCL content and insulin sensitivity. 
Results: On the LGID there were significant decreases from baseline in diet GI (p<0.0001), 
intakes of total and saturated fat (p<0.001), and 60 minute postprandial glucose (p<0.05), while 
intakes of carbohydrate and fibre increased (p<.0001).  On the HGID there were significant 
increases in diet GI (p<0.001), intakes of carbohydrate (p<0.001), total kcal intake (p<0.01), 
insulinogenic index (p<0.01) and BMI (p<0.05), and a significant decrease in systolic blood 
pressure (p<0.05).  There were no significant changes in IMCL or other metabolic measures for 
either group. 
Conclusions: A LGID reduced the OGTT 60 minute plasma glucose but did not significantly 
affect IMCL or insulin sensitivity in individuals with abdominal obesity.  
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5.3 Introduction 
Obesity is a complex disease characterized by an abnormal deposition of fat in adipose 
tissue and is mainly the result of a positive energy balance where food intake is greater than the 
body’s ability to utilize the food as energy (1).  The excessive accumulation of adipose tissue 
leads to an undesirable weight gain to the extent that health may be adversely affected (1). 
Obesity, in particular abdominal obesity, has been shown to be a risk factor for developing 
cardiovascular disease (2, 12), type 2 diabetes (3, 4, 5, 6, 12) and metabolic syndrome (7, 8).  
Insulin resistance, a key feature of metabolic syndrome, is higher in individuals with overall 
adiposity (9) and central abdominal obesity (10, 11).  Although the mechanism of insulin 
resistance is not fully understood, it has been suggested that individuals with abdominal obesity 
cannot store lipids effectively in the subcutaneous adipose tissue which in turn leads to an 
increase in storage of lipids in the visceral area and in organs other than adipose tissue such as 
the liver, pancreas and skeletal muscle causing insulin resistance in these tissues (13, 14).  
Research has shown that muscle fat is increased in individuals with insulin resistance (15) and 
that insulin sensitivity is negatively correlated with intramyocellular lipid (IMCL) content as 
assessed by examination from proton nuclear magnetic resonance spectroscopy (1H-MRS), a 
non-invasive quantification of IMCL content in human muscle that can identify the relative 
contributions of IMCL and whole body insulin sensitivity (16).  
Evidence supports the role of carbohydrates in influencing insulin sensitivity by 
improving insulin-stimulated glucose uptake by adipocytes when following a low glycemic 
index diet (17).  The glycemic index (GI) was developed as a classification of the blood glucose-
raising potential of the available carbohydrate in foods (43) and is defined as the incremental 
area under the blood glucose response curve after consuming a 50 gram available-carbohydrate 
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portion of a test food expressed as a percentage of the response after consuming 50 grams of oral 
anhydrous glucose by the same subject (44, 45). Low glycemic index (GI) carbohydrates are 
slowly digested and release glucose gradually into the blood stream and therefore may suppress 
plasma concentrations of fatty acids (18, 19).  The suppression of plasma fatty acids may 
improve insulin sensitivity by promoting insulin-stimulated glucose uptake by skeletal muscle 
and possibly reduce IMCL storage (19).  A four week intervention study examining the effects of 
a reduction in dietary GI on IMCL in healthy individuals showed improvements in insulin 
sensitivity but no changes in IMCL storage levels (20).  It still remains unclear whether a low GI 
diet can improve IMCL stores in muscles of individuals who are at risk for developing insulin 
resistance or type 2 diabetes. 
The primary purpose of this 24 week intervention study was to determine whether a low 
GI diet would reduce IMCL stores thereby improving insulin sensitivity in individuals with 
abdominal obesity. 
5.4 Subjects and Methods 
This study was carried out on an outpatient basis at the Hamilton General Hospital, 
Centre for Cardiovascular Obesity Research and Management, McMaster University, Faculty of 
Health Sciences.  The study protocol was approved by the Hamilton Health Sciences, McMaster 
University human research ethics board and carried out in accordance with the Declaration of 
Helsinki as revised in 2000.  All participants were given a participant information sheet and gave 
informed consent to participate in the study (Appendix 8.1).  The trial is publicly registered with 
ClinicalTrials.gov, number NCT00147264. 
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5.4.1 Protocol 
This thesis chapter consists of a 24 week low GI diet which is the randomization phase of a 
parallel, 2x2 factorial design clinical trial that studied the effects of a low GI diet and telmisartan, 
an angiotensin receptor blocker, on intramyocellular lipids (TRIM trial (Telmisartan-Induced 
Reduction in Intra-Myocellular Lipids)).    
5.4.2 Study Sample 
 A total of 2433 individuals from the general population responded through advertisement 
in local media and underwent a telephone screening process.  Of the 171 people who were 
invited for an initial screening visit to assess eligibility, 32 did not meet the inclusion criteria and 
18 refused to participate. Of the 121 enrolled participants, 95 completed the run-in phase of the 
study resulting in a 21% drop out rate.  Of the 95 men, and non-pregnant, non-lactating women 
aged 30 to 70 years with abdominal obesity, with or without additional features of the metabolic 
syndrome, who were eligible to participate in the randomization study, 48 participants were 
randomized to the low GI diet (LGID) and 47 participants were randomized to the control, high 
GI diet (HGID) (Figure 5.1).  For the primary outcome (1H-MRS), 12 participants in the LGID 
and 10 participants in the HGID had poor quality MRI scans and were excluded in the data 
analysis (Figure 5.1).  Abdominal obesity was defined as a waist circumference of >102 cm for 
males and >88 cm for females (NCEP, ATP III) (21).  Inclusion criteria included abdominal 
obesity, ability to provide written informed consent, age between 30 and 70 years, and the ability 
and willingness to complete dietary and activity diaries and questionnaires.  Exclusion criteria 
included diabetes or use of any anti-diabetic drug, uncontrolled hypertension, serum triglycerides 
>10 mmol/L, active malignancy, chronic inflammatory disorders, endocrine, renal or hepatic 
dysfunction, use of angiotensin converting enzyme inhibitors or angiotensin receptor blockers in 
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the last 3 months, use of a lipid lowering medication-the dose of which had not been stable for at 
least 3 months, body mass index of >45, intent to lose weight or use weight loss medications 
during the study, contraindications to magnetic resonance imaging (MRI) such as claustrophobia 
or metal prostheses, and any dietary restrictions that would prevent the participants from 
following the study protocol. 
5.4.3. Dietary Intervention 
Participants were randomly assigned to either a low glycemic index diet (LGID, n=48) or 
a control, high glycemic index diet (HGID, n=47) for 24 weeks by using an automated 
randomization system.  The aim of both diets was to be weight maintaining consisting of 55% of 
energy from carbohydrate, 30% from fat, 15% from protein and 7% or less from saturated fats as 
outlined by the American Heart Association (22).  Forty percent of the total carbohydrate 
consisted of either low glycemic index (GI) foods or high GI foods.  Participants were provided 
with low GI and high GI test foods on a monthly basis (Appendix 8.7) and were asked to keep 
daily dietary records of the number of test foods they consumed each day (Appendix 8.7).  The 
number of test foods to be eaten each day was calculated based on the participant’s daily 
estimated energy requirements according to the Lipid Research Clinic Requirement formula (23) 
with an additional 300 kilocalories (kcal) per day added on for exercise and daily energy 
expenditure (Appendix 8.2).  One serving of test food contained approximately 15 grams of 
available carbohydrate.  Participants were asked to consume two servings of test foods with the 
first meal of each day, with the remainder of the test foods to be consumed throughout the day.  
Weekly compliance of test foods was calculated as the number of test foods consumed divided 
by the number of test foods required multiplied by 100.    
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Figure 5.1. Participant Recruitment Flow Chart 
Participants Screened 
N = 2433 
N = 2261, Excluded 
N = 860, Not meeting inclusion 
criteria  
N = 1313, Refused to participate  
N = 89, Other reasons (desired 
weight loss, no birth control, 
diabetes, medications) 
 Patients Consented to Participate in Run-In Dietary Phase 
N = 171 
Excluded, N = 50 
N = 32, Did not meet inclusion 
criteria 
N = 18, Refused to participate     
N = 0, Other reasons 
Participants Enrolled in Run-In Dietary Phase 
N = 121 
Withdrawals during Run-In Dietary Phase, 
N = 26 
 
Main Reasons for Exclusion: 
N = 7, desired weight loss 
N = 6, personal reasons 
N = 5, time commitment 
N = 5, adverse events 
N = 3, unknown reasons 
 
Participants Enrolled in Randomization Phase 
N = 95 
Low Glycemic Index Diet 
N = 48 
Lost to Follow Up N= 0 
High Glycemic Index Diet 
N = 47 
Lost to Follow Up N = 0 
Primary Analysis (1H-MRS) N = 40 
Excluded from analysis due to technical reasons  
(poor quality MRI scans)  N = 8 
Primary Analysis (1H-MRS) N = 40 
Excluded from analysis due to technical 
reasons (poor quality MRI scans) N = 7 
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Participants met seven times during the study for dietary advice, the collection and 
dispensing of daily food records, analysis of diet compliance, dispensing of test foods, and 
completing the MEDFICTS dietary assessment questionnaire (NCEP, ATP III) (Appendix 8.4) 
(21).  The 3-day food diaries were analyzed at baseline, and weeks 4, 12, and 24 (Appendix 8.5).  
Micronutrients, macronutrients, and the GI of foods were calculated using the Food Processor 
SQL Nutrition Analysis & Fitness software package version 9.5 (ESHA Research, Salem, OR, 
USA) with missing values for GI added using the NutriPro diet analysis program (Glycemic 
Index Laboratories Inc., University of Toronto).  The GI was expressed with the GI of 
glucose=100.  Participants were instructed to maintain their habitual level of physical activity 
throughout the study.  The Baecke habitual physical activity questionnaire was administered at 
the start-and-end of the study to determine activity levels (Appendix 8.6) (24).   
5.4.4 Anthropometric Measurements, Blood Pressure and Heart Rate 
Height (cm) was measured at the initial screening visit to the nearest 0.1 cm using a wall 
mounted stadiometer and body weight was measured at every visit to the nearest 0.1 kg on a 
digital weigh scale.  Body mass index (BMI) was calculated as body weight (kg) divided by 
height (m2).  Waist circumference (WC) was measured to the nearest 0.1 cm using the World 
Health Organization (WHO) method (mid-point between the palpated inferior border of the last 
rib and upper border of the iliac crest in a horizontal plane at the end of normal expiration) (25).  
Hip circumference (HC) was measured to the nearest 0.1 cm at the level of the major trochanter 
(usually around the largest diameter of the buttocks) (25).  Waist-to-hip ratio (WHR) was 
calculated (waist (cm) divided by hip (cm)) from the measurement of the waist and hip 
circumference. Body composition analysis (percentage of body fat) was assessed by bioelectrical 
impedance analysis as per manufacturer’s instructions (BioScan 916, Maltron International Lt, 
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Rayleigh, Essex, UK).  Waist and hip circumference and body fat percentage were measured at 
the start, middle and end of the study. 
Blood pressure (BP) (mmHg) and heart rate (HR) (beats per minute) were measured at 
every visit in the sitting position using an automatic blood pressure monitor (BpTRU®, VSM 
MedTech Ltd., Vancouver, BC, Canada) following five minutes of seated rest. 
5.4.5 Oral Glucose Tolerance Test 
 An oral glucose tolerance test (OGTT) was performed in the fasting participant (12 hours) 
at the start, middle and end of the study.  An indwelling catheter was inserted in the forearm and 
three fasting blood samples for glucose and insulin were taken five minutes apart (-15, -10, -5 
minutes).  Participants then ingested (0 minutes) a 75 gram solution of dextrose and venous 
blood samples were obtained again at 30, 60, and 120 minutes for determination of plasma 
glucose and insulin.  Glucose was measured by a glucose oxidase method and serum insulin was 
measured with an immunometric assay (Diagnostic Products Corporation, Los Angeles, CA).  
The glucose and insulin data from the OGTT was used to assess insulin sensitivity (homeostatic 
model assessment index, HOMA = fasting insulin (µU/ml) x fasting glucose (mmol/L) divided 
by 22.5 (26)) and insulin secretion (insulinogenic index (ISI) = ratio of change in insulin to 
change in glucose from 0 to 30 minutes (Delta I30 divided by Delta G30) (27)).  The HOMA 
index has been validated with the gold standard euglycemic hyperinsulinemic clamp technique 
(28).  During the OGTT, fasting blood samples were also collected for serum total, HDL and 
LDL cholesterol, free fatty acids, and triglycerides.  LDL was calculated using the Friedewald 
formula (29). 
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5.4.6 Magnetic Resonance Imaging 
Intramyocellular lipid (IMCL) content of the mid-soleus muscle (predominately oxidative 
muscle fibres) was assessed by proton magnetic resonance spectroscopy (1H-MRS) at the end of 
the run-in period.  MRS was performed on a 1.5 Tesla whole body MR system (Siemens 
Symphony AG, Munich, Germany) using a body coil for radiofrequency transmission and 
surface coil to receive signals.  The 1H-MRS scans were performed at the Nuclear Medicine 
Department at the McMaster University Medical Centre.  Participants were advised to fast and 
restrict physical activity for six hours prior to the procedure.  Following screening for absence of 
MRI contraindications, the participant was placed in the supine position and the leg was 
positioned and immobilized so that the calf was situated as close to the center of the magnet as 
possible.  The radio-frequency receive coil was fastened nearest to the region of interest to 
collect the greatest signal.  Participants remained in the supine position (feet first) within the MR 
system. Three-plane spin-echo T1-weighted MR images were performed to guide placement of 
the volume of interest for spectroscopy.  Imaging parameters were chosen for suitable separation 
of muscle, fascia, IMCL and extramyocellular lipid (EMCL) content (TR 3000 milliseconds 
(ms), TE 30 ms, 128 averages, 1,024 data points over 1000 Hz spectral width, 1 cc voxel 
volume, water signal suppressed using chemical selective saturation).  Semi-automatic shimming 
of the magnet with typical line widths of the water signal of 10 Hz was performed to optimize 
magnetic field homogeneity.  Several scout images were taken to determine the ideal position for 
the voxel location.  Volume of interest was centered over the mid-soleus muscle and vascular 
structures and gross adipose tissue deposits were excluded as much as possible.  The IMCL and 
EMCL peak was integrated at 1.28 ppm and 1.48 ppm respectively.  Since creatine content is 
stable within the same muscle across a population (50), spectral intensities were referenced to the 
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methyl signal of creatine (Cr3) at 3.05 ppm serving as an internal reference. Spectra were 
processed and the resonance curves for IMCL, EMCL, and creatine were measured using jMRUI 
software v2.1 (51).  Data is presented as arbitrary units (AU).  
 After 3-plane localizer image acquisition, breath-hold axial T1-weighted image at the level 
of mid-L4 (TR 400 ms, TE 13 ms) was acquired for the volume of visceral adipose tissue (VAT) 
and subcutaneous adipose tissue (SAT).  VAT and SAT was calculated using SliceOmatic 4.2 
medical imaging software (SliceOmatic v.4.2, Tomovision, Montreal).  VAT was defined as 
adipose tissue within the inside edge of the abdominal wall and SAT was defined as adipose 
tissue on the outside edge of the abdominal wall.  The intra-and-inter-observer coefficients of 
variation for this method are 0.53% and 0.44% for SAT and 1.46% and 2.42% for VAT 
respectively. 
5.4.7 Statistical Analysis 
 The statistical analyses were performed using SPSS 10.1 for Windows (SPSS Inc., 
Chicago, IL, USA).  The primary analysis was an ANOVA of change in IMCL content in the 
soleus muscle by treatment group covarying out baseline IMCL measurement, age, sex, change 
in body weight, and body mass index.  Pearson product moment correlation coefficient and 
Student’s t-tests were used to determine correlations and differences of means between IMCL, 
GI, macronutrient composition of the diet, anthropometric data, blood glucose, blood insulin and 
blood lipid parameters.  Statistical significance was set at p<0.05.  All data are presented as 
means + standard deviation (SD) unless otherwise indicated.     
 Assuming a two-sided alpha of 0.05 and a standard deviation of 5, the study sample was 
powered at 90% to detect a minimum difference in change in IMCL content between treatment 
groups of 3.7 (Arbitrary Units (AU)), based on a t-test with 40 participants per group.  
94 
 
Additional participants were randomized to account for an anticipated drop-out rate of 30%.  The 
study sample was also powered at 90% to detect average changes between the start and end of 
the 24 week study for insulin sensitivity of 0.96, free fatty acids of 26.6 µmol/L, triglycerides of 
0.49 mmol/L, total cholesterol of 0.62 mmol/L, and LDL cholesterol of 0.56 mmol/L. 
5.5 Results 
5.5.1 Subject Characteristics 
Entering the study, participants in the LGID and HGID group had abdominal obesity 
(100%) and  were similar in age (LGID 53.1+9.2 vs HGID 53.5+9.9) and sex (female, LGID 
71% vs HGID 70%).  The majority of the participants were Caucasian (LGID 88% vs HGID 
94%) and the women were menopausal (LGID 97% vs HGID 91%).  Clinical characteristics of 
the study population at baseline and end-of-study are listed in Table 5.1.   
5.5.2 Anthropometric Measurements 
BMI significantly increased from the start-to-end of the study in the HGID group 
(34.8+6.1 vs 35.0+6.2, p<0.05), but did not significantly change in the LGID group (34.0+5.2 vs 
33.9+5.4, p>0.05).  All participants in both groups maintained abdominal obesity throughout the 
study for both the LGID group (start 109.5+14.0 vs end 110.0+14.4cm) and the HGID group 
(start  111.6+11.1 vs end 112.0+12.1cm) but was not significant from start-to-end of study or 
between groups (p>0.05).  WC, HC, WHR, and percentage body fat did not significantly change 
in either group, nor where there any significant differences between groups for any of the 
variables after controlling for baseline (p>0.05).  The participants’ anthropometric characteristics 
at baseline and end of study are shown in Table 5.2. 
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Table 5.1. Clinical Characteristics of the Study Population at Baseline and End of Study 
 
 
Variable 
LGID  
Baseline 
N = 48 
LGID 
End  
N = 48 
HGID 
Baseline 
 N = 47 
HGID  
End  
N = 47 
Age 53.1 [+9.2]  53.5 [+9.9]  
Male 14 (29.2)  14 (29.8)   
Female 34 (70.8)  33 (70.2)  
Menopause 33 (97.1)  30 (90.9)  
Caucasian 42 (87.5)  44 (93.6)  
Smoker 18 (37.5)  16 (34.0)  
Calcium Channel Blocker medication 4 (9.1) 2 (4.7) 4 (8.9) 3 (6.7) 
Anti-hypertensive medications  10 (20.8) 9 (19.6) 5 (10.6) 4 (8.5) 
Diuretics 3 (6.3) 2 (4.3) 2 (4.3) 2 (4.3) 
Aspirin 3 (6.3) 5 (11.4) 5 (10.6) 4 (8.9) 
Lipid Lowering Drugs 9 (18.8) 10 (20.8) 7 (14.9) 7 (14.9) 
Abdominal Obesity 48 (100) 48 (100) 47 (100) 47 (100) 
Triglycerides > 1.7 mmol/L 25 (52.1) 26 (60.5) 26 (55.3) 20 (45.5) 
Blood Pressure > 130/85 mmHg 13 (27.1) 11 (22.9) 10 (21.3) 8 (17.0) 
Fasting Glucose  6.1- 6.9 mmol/L 7 (14.9) 8 (18.6) 7 (14.9) 7 (14.9) 
HDL Cholesterol  
<1.0 mmol/L (M),<1.3 mmol/L (F) 
15 (31.3) 20 (41.7) 16 (34.0) 21 (44.7) 
Numbers in round brackets ( ) represent percentage of the study population. Numbers in square 
brackets [ ] represent +SD of the mean.  M indicates males, F indicates females. 
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Table 5.2. Anthropometric and Body Composition Characteristics at Baseline and End of Study 
 
 
Variable 
LGID 
Baseline 
N = 48 
LGID 
End 
N = 48 
 
 
P value 
HGID 
Baseline 
N = 47 
HGID  
End 
N = 47 
 
 
p value 
BMI (kg/m2) 34.0+5.2 33.9+5.4 0.93 34.8+6.13 35.0+6.2 0.02* 
WC (cm)  109.5+14.0 110.0+14.4 0.83 111.6+11.1 112.0+12.1 0.33 
HC (cm)  120.2+10.7 119.4+11.7 0.61 122.1+12.6 121.9+11.4 0.68 
WHR  0.91+0.08 0.92+0.07 0.37 0.92+0.07 0.92+0.07 0.62 
% BF  41.2+10.9 41.4+7.3 0.99 41.7+9.0 41.9+8.8 0.41 
Data are means + SD, *p < 0.05; BMI, body mass index; WC, waist circumference; HC, hip 
circumference; WHR, waist-to-hip ratio; % BF, percentage body fat  
 
 
5.5.3 Blood Pressure and Heart Rate 
Systolic BP significantly decreased in the HGID group (start 122+14 vs end 
117+15mmHg, p<0.05) but not in the LGID group (start 117+11 vs end 116+16mmHg, p>0.05), 
nor were there any significant differences between groups after controlling for baseline (p>0.05).  
Diastolic BP and HR did not significantly change in either group or between groups (p>0.05).   
5.5.4 Dietary Intake and Physical Activity 
5.5.4.1 Activity Level  
Activity level, as assessed by the Baecke questionnaire, did not significantly change during 
the randomization phase for either the LGID (p>0.05) (Table 5.3) or HGID (p>0.05) (Table 5.4) 
and was not significantly different between groups (p>0.05) (Table 5.5). 
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5.5.4.2 Compliance 
Self-reported data from the test food diaries indicated an average compliance for the 
consumption of test foods on the LGID was 87.7%+19.7 (range 30% to 138%) and 91.6%+15.9 
(range 36% to 116%) on the HGID.  Diet compliance was not significantly different between 
groups (p>0.05).  There was a significant positive relationship between average compliance and 
average GI for the HGID (r=0.47, p=0.001) and a non-significant negative relationship between 
average compliance and average GI for the LGID (r=-0.27, p=0.07) (Figure 5.2).   
 
 
 
 
 
Figure 5.2. Test Food Compliance and Glycemic Index 
Average compliance (%) of test foods from weekly test food diaries and mean GI for the high 
glycemic index diet, HGID □ (N = 47) and the low glycemic index diet, LGID ◆ (N = 48).  
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There was a significant negative correlation between average compliance of test foods and 
end of study IMCL for the LGID (r=-0.36, p=0.02) (Figure 5.3).  No correlation was found 
between average compliance of test foods and end of study IMCL for the HGID (r=0.05, p=0.73) 
(Figure 5.3). 
 
 
 
Figure 5.3. Test Food Compliance and IMCL 
Average compliance (%) of test foods from weekly test food diaries (duration of study) and 
intramyocellular lipid content (IMCL) (end of study) for the high glycemic index diet,         
HGID □ (N = 40) and the low glycemic index diet, LGID ◆ (N = 40).  
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 There was a significant negative correlation between average test food compliance for 
participants who were 70% or greater in compliance and change in IMCL from baseline to end of 
study for the LGID (r=-0.44, p<0.007).  For the HGID, there was a significant positive 
correlation between average test food compliance (70% or greater) and change in IMCL from 
baseline to end of study (r=0.35, p<0.04) (Figure 5.4) 
 
 
 
 
. 
Figure 5.4. Test Food Compliance of 70% or greater and Change in IMCL  
Average compliance (%) of test foods from weekly test food diaries for participants who were 
70% or greater in compliance (duration of the study) and the change in intramyocellular lipid 
content (IMCL) from baseline to end of study for the low glycemic index diet, LGID ◆           
(N = 36), and the HGID □ (N = 37). 
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5.5.4.3 Dietary Intake 
 The 3-day average GI and macronutrient data from the self-reported food diaries at 
baseline and end-of-study for the LGID and HGID are listed in Table 5.3 and Table 5.4 
respectively and comparisons between groups after controlling for baseline are listed in Table 
5.5.   
The participant’s achieved a significant reduction in the GI on the LGID (59.6+4.0 baseline 
vs 55.4+2.7 end, p=0.0000) and a significant increase in the GI on the HGID (60.0+3.4 baseline 
vs end 63.9+3.5, p=0.0000).  There was also a significant difference in the GI between groups 
after controlling for baseline (LGID 55.5+3.1 vs HGID 63.9+3.1, p<0.0001).  The average GI 
analyzed from the three-3 day food diaries on the LGID was 54.6+2.6 and 64.3+3.1 on the HGID 
and was significantly different between groups (p<0.0000).  The GI was not correlated with any 
anthropometric measurements, fasting blood lipids, or blood glucose and insulin measurements 
obtained from the OGTT (p>0.05). 
Energy intake (kilocalories (kcal)) significantly increased on the HGID (1980+626 vs 
2212+524kcal, p<0.05) but did not change on the LGID (2061+544 vs 2070+423kcal, p>0.05).  
There were no significant differences in means between groups for energy intake after 
controlling for baseline (HGID 2212+400 vs LGID 2065+400kcal, p>0.05). 
Total carbohydrate intake significantly increased on both the LGID (baseline 261+92 vs 
end 316+75g, p<0.0001) and the HGID (baseline 259+86 vs end 304+69g, p<0.01), but was not 
significant between groups after controlling for baseline (LGID 316+62 vs 303+62g, p>0.05).  
When expressed as a percentage of energy, carbohydrate significantly increased on the LGID 
(LGID baseline 50+9 vs end 57+8% p<0.0001) but not on the HGID (baseline 52+8 vs end 
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54+8%, p>0.05), and was significantly different between groups after controlling for baseline 
(LGID 57+7 vs HGID 54+7%, p<0.05).   
Total dietary fibre intake significantly increased on the LGID (baseline 23+11 vs end 
42+14g, p<0.0000) but not on the HGID (baseline 25+12 vs end 24+7g, p>0.05), and was 
significantly different between groups after controlling for baseline (LGID 43+10 vs HGID 
23+10g p<0.0001). 
Total fat intake significantly decreased on the LGID (baseline 75+39 vs end 58+18g, 
p<0.05) but not on the HGID (baseline 66+31 vs end 70+30g, p>0.05) and was significantly 
different between groups after controlling for baseline (LGID 58+23 vs HGID 70+23g, p<0.05).  
When expressed as a percentage of energy, total fat intake significantly decreased on the LGID 
(baseline 30+9 vs end 24+6, p<0.001) but not on the HGID (baseline 29+6 vs end 27+7, p>0.05) 
and was significantly different between groups after controlling for baseline (LGID 24+6 vs 
HGID 27+6, p<0.05).    
Saturated fat intake significantly decreased on the LGID (baseline 23+11 vs end 17+6g, 
p<0.01) but not on the HGID (baseline 20+9 vs end 21+11g, p>0.05), and was significantly 
different between groups after controlling for baseline (LGID 17+9 vs HGID 21+9g, p<0.05).  
When expressed as a percentage of energy, saturated fat intake significantly decreased on the 
LGID (baseline 10+4. vs end 7+3%, p<0.001) and decreased on the HGID but it was not 
significant (baseline 9+2 vs end 8+3%, p>0.05). 
Protein intake expressed as grams or  percentage of energy and alcohol intake as a 
percentage of energy did not significantly change in either group or between groups after 
controlling for baseline (p>0.05). 
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Table 5.3.  Dietary Intake and Physical Activity at Baseline and End-of-Study for the LGID 
 
 
Variable 
Low GI 
Baseline 
N = 48 
Low GI 
End 
N = 48 
 
 
p value 
GI (%) 59.6+4.0 55.4+2.7 <0.0000 
Energy (kcal) 2061+544 2070+423   0.253 
CHO (g) 261.3+92.0 316.1+74.7 <0.0001 
CHO (% energy) 49.7+9.4 57.3+7.6 <0.0001 
Fibre (g) 22.9+11.0 42.0+13.9  <0.0000 
Protein (g) 93.0+22.1 92.8+23.6    0.384 
Protein (% energy) 18.0+3.4 17.1+3.1    0.121 
Fat (g) 75.0+39.0 58.1+18.0  <0.05 
Fat (% energy) 30.3+8.8 24.0+6.3  <0.001 
Saturated Fat (g) 22.7+10.8 16.8+6.0  <0.01 
Saturated Fat (% energy) 10.0+4.2 7.1+2.5 < 0.001 
Alcohol (% energy) 1.6+4.0 1.3+2.6    0.756 
MEDFICTS score 47.2+19.0 44.5+16.3    0.551 
Activity Level (Baecke) 2.4+0.5 2.4+0.8    0.700 
 
Data are means + SD; GI, glycemic index; CHO, carbohydrate 
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Table 5.4.  Dietary Intake and Physical Activity at Baseline and End-of-Study for the HGID 
 
 
Variable 
HGID 
Baseline 
N = 47 
HGID 
End 
N = 47 
 
 
p value 
GI (%) 60.0+3.4 63.9+3.5 <0.0000 
Energy (kcal) 1980+626 2212+524 <0.05 
CHO (g) 258.9+85.9 303.7+69.3 <0.01 
CHO (% energy) 52.3+7.5 54.2+7.6   0.105 
Fibre (g) 24.6+11.7 23.8+7.0   0.553 
Protein (g) 89.5+36.1 99.3+27.7   0.076 
Protein (% energy) 18.0+3.5 17.7+3.1   0.202 
Fat (g) 66.4+30.5 69.9+29.6   0.494 
Fat (% energy) 28.9+6.0 27.2+6.8   0.208 
Saturated Fat (g) 20.3+8.5 21.0+11.3   0.575 
Saturated Fat (% energy) 9.0+2.2 8.2+2.9   0.141 
Alcohol (% energy) 0.9+2.0 1.6+4.3   0.169 
MEDFICTS score 44.7+18.2 44.3+14.4   0.970 
Activity Level (Baecke) 2.6+0.5 2.4+0.8   0.118 
 
Data are means + SD; GI, glycemic index; CHO, carbohydrate 
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Table 5.5. Dietary Intake and Physical Activity for the LGID vs the HGID after Controlling for 
Baseline  
 
Variable 
LGID 
N = 48 
HGID 
N = 47 
 
p value 
Glycemic Index (%) 55.5+3.1 63.9+3.1 <0.0001 
Energy (kcal) 2064.7+400.1 2211.8+400.1   0.107 
Carbohydrate (g) 316.1+62.0 303.1+62.0   0.353 
Carbohydrate (% energy) 57.5+7.1 54.0+7.1 <0.05  
Fibre (g) 42.6+10.2 23.3+10.2 <0.0001 
Protein (g) 93.3+22.1 98.9+22.1   0.267 
Protein (% energy) 17.2+2.9 17.6+2.9   0.524 
Fat (g) 57.8+23.0 70.2+23.0 <0.05 
Fat (% energy) 23.9+6.4 27.3+6.4 <0.05 
Saturated Fat (g) 16.7+8.7 21.2+8.7 <0.05 
Saturated Fat (% energy) 7.1+2.6 8.3+2.6   0.058 
Alcohol (% energy) 1.0+2.9 1.8+2.9   0.262 
MEDFICTS score 44.3+14.6 44.6+14.6   0.920 
Activity Level (Baecke) 2.4+0.7 2.4+0.7   0.620 
 
Data are means + SD; data are differences in means controlling for baseline 
 
 
 
 
105 
 
5.5.5 Oral Glucose Tolerance Test 
5.5.5.1 Insulin and Glucose 
HOMA index, fasting insulin, and insulin at 30, 60, and 120 minutes during the OGTT, 
did not significantly change in either group or between groups after controlling for baseline 
(p>0.05) (Figure 5.4, Table 5.6).  The insulinogenic index (ISI) significantly increased in the 
HGID group (baseline 15.2+9.7 vs end 19.2+15.0, p<0.01) and there was a non-significant trend 
towards an increase in ISI in the LGID group (baseline 16.2+10.9 vs end 19.5+15.9, p=0.07) 
(Table 5.6).  The incremental area under the curve for insulin (iiAUC) significantly decreased in 
the HGID (baseline 7047.0+4661.8 vs end 6718.2+4322.6, p<0.05) and a non-significant 
decrease in the iiAUC in the LGID (baseline 6858.9+5500.1 vs end 6622.6+5658.2, p>0.05) 
(Table 5.6).  There was also a significant positive correlation between baseline and end-of-study 
iiAUC for the LGID (r=0.77, p<0.0001) and the HGID (r=0.89, p<0.0001) but the slope of the 
regression lines were not significantly different between groups (p>0.05) (Figure 5.5).  
During the OGTT, 60 minute plasma glucose significantly decreased in the LGID 
(baseline 10.7+2.2 vs end 10.2+2.1, p<0.05), but not in the HGID (baseline 10.7+2.9 vs end 
10.4+3.2, p>0.05) and fasting, 30 minute and 120 minute plasma glucose did not significantly 
change in either group (p>0.05) (Figure 5.4, Table 5.6).  There was a significant positive 
correlation between baseline and end-of-study 120 minute plasma glucose for the LGID (r=0.62, 
p<0.0001) and the HGID (r=0.81, p<0.0001) and the regression slopes significantly differed 
between the LGID and the HGID (p=0.04) (Figure 5.6).  The incremental area under the curve 
for glucose (igAUC) significantly decreased in the HGID (baseline 461.6+171.2 vs end 
423.8+185.3, p<0.05) and decreased in the LGID but was not significant (baseline 440.3+153.6 
vs end 399.9+138.1, p>0.05) (Figure 5.4, Table 5.6).  There was a significant positive correlation 
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between baseline and end-of-study igAUC for the LGID (r=0.56, p<0.001) and the HGID 
(r=0.80, p<0.0001), and the slopes of the regression lines were significantly lower on the LGID 
compared to the HGID (p=0.04) (Figure 5.5).   
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Figure 5.4. Mean Glucose and Insulin Values at Baseline (• ) and End-of-Study (ο) for the 
HGID and LGID, obtained during the OGTT.  Plasma glucose at 60 minutes significantly 
decreased in the LGID group (*p<0.05).   
* 
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Table 5.6. Fasting Plasma Glucose and Insulin at Baseline and End of Study 
 
 
Variable 
LGID 
Baseline 
N = 48 
LGID 
End 
N = 48 
 
p  
value 
HGID  
Baseline 
N = 47 
HGID  
End 
N = 47 
 
p 
value 
HOMA 3.6+2.4 3.7+2.3 0.72 3.6+4.8 3.7+2.5 0.94 
ISI 16.2+10.9 19.5+15.9 0.07 15.2+9.7 19.2+15.0 0.00** 
Glucose       
Fasting   5.6+0.7 5.6+0.6 0.52 5.5+0.8 5.6+0.7 0.17 
30 min   9.6+1.8 9.8+1.6 0.93 9.5+2.2 9.4+1.9 0.29 
60 min   10.7+2.2 10.2+2.1 0.03* 10.7+2.9 10.4+3.2 0.07 
120 min  8.3+2.7 8.2+0.172 0.17 8.8+2.8 8.6+2.6 0.89 
igAUC 440.3+153.6 399.9+138.1 0.10 461.6+171.2 423.8+185.3 0.05* 
Insulin       
Fasting   13.9+8.9 14.3+8.6 0.66 13.7+12.5 14.6+9.5 0.58 
30 min  75.1+47.4 82.5+51.6 0.33 71.2+53.3 78.1+58.7 0.25 
60 min  109.2+56.0 106.7+57.0 0.83 92.8+59.7 81.3+48.1 0.78 
120 min  108.9+58.1 102.6+66.0 0.84 103.9+92.6 84.5+59.3 0.31 
iiAUC 6858.9 
+5500.1 
6622.6 
+5658.2 
0.50 7047.0 
+4661.8 
6718.2 
+4322.6 
0.02* 
Data are means + SD; ISI, insulinogenic index; plasma glucose is measured in mmol/L; plasma 
insulin is measured in pmol/L; igAUC, incremental area under the curve for plasma glucose 
obtained during the OGTT; iiAUC, incremental area under the curve for plasma insulin obtained 
during the OGTT; *p < 0.05, **p < 0.01 
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Figure 5.5. Relationship between Baseline and End-of-Study Incremental Area under the Plasma 
Glucose Curve (Glucose AUC) and Incremental Area under the Plasma Insulin Curve (Insulin 
AUC) Obtained During the OGTT for the HGID (•) and LGID (ο).  For glucose AUC, 
correlations were statistically significant for both HGID (r=0.795, p<0.0001) and LGID 
(r=0.562, p<0.001), and the difference in the regression slopes was significantly different 
(p=0.04).  For insulin AUC, correlations were statistically significant for both HGID (r=0.886, 
p<0.0001) and LGID (r=0.769, p<0.0001), but there was no significant difference in the 
regression slopes between the two groups (p>0.05). 
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Figure 5.6. Relationship between Baseline and End-of-Study 120 minute Plasma Glucose 
obtained during the OGTT for the HGID (•) and LGID (ο).  Correlations were statistically 
significant for both HGID (r=0.81, p<0.0001) and LGID (r=0.62, p<0.0001) and the differences 
in slopes between the two groups was significant (p=0.04).  
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5.5.5.2 Blood Lipids 
There were no significant changes in fasting total serum cholesterol, LDL cholesterol, 
HDL cholesterol, triglycerides or free fatty acids in either group, nor were there any significant 
differences between groups after controlling for baseline (p > 0.05).  The participants’ fasting 
serum lipids at baseline and end of study are shown in Table 5.7. 
 
Table 5.7. Fasting Serum Lipids at Baseline and End of Study 
 
 
Variable 
LGID 
Baseline 
N = 48 
LGID 
End 
N = 48 
 
p  
value 
HGID 
Baseline 
N = 47 
HGID 
End 
N = 47 
 
p  
Value 
Total C (mmol/L) 5.3+1.1 5.2+1.1 0.31 4.9+0.9 4.9+0.8 0.78 
LDL (mmol/L) 3.1+0.9 3.0+0.9 0.16 2.8+0.8 2.8+0.7 0.58 
HDL (mmol/L) 1.3+0.4 1.3+0.4 0.28 1.2+0.3 1.2+0.4 0.24 
TG (mmol/L) 1.9+0.8 2.1+0.9 0.15 2.2+1.7 2.1+1.4 0.63 
FFA (µmol/L) 594.2 
+231.9 
600.9 
+228.2 
0.73 635.4 
+235.6 
566.3 
+208.0 
0.07 
Data are means + SD; C, cholesterol; TG, triglycerides: FFA, free fatty acids  
 
5.5.6. Intramyocellular Lipids (IMCL), Subcutaneous Adipose Tissue (SAT), Visceral 
Adipose Tissue (VAT) 
There were no significant changes in IMCL, in either group during the dietary intervention 
or between groups after controlling for baseline. There were no significant changes in either 
group during the dietary intervention or between groups for SAT or VAT after controlling for 
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baseline (p>0.05).  The participants IMCL, VAT and SAT at baseline and end of study are 
shown in Table 5.8. 
  Post dietary intervention, there were significant positive correlations with IMCL and BMI 
(r=0.21, p<0.5), WC (r=0.33, p<0.01), WHR (r=0.37, p<0.001), VAT (r=0.34, p<0.01), HOMA 
(r=0.23, p<0.05), fasting plasma insulin (r=0.26, p < 0.05), diastolic BP (r=0.29, p<0.01), 
percentage of energy from saturated fat (r=0.23, p<0.05) and total fat intake (g) (r=29, p<0.05).  
IMCL was not significantly correlated with GI (p>0.05).   
 
 
Table 5.8. IMCL, VAT and SAT at Baseline and End of Study 
 
 
Variable 
LGID 
Baseline 
N = 40 
LGID 
End 
N = 40 
 
p 
value 
HGID 
Baseline 
N = 40 
HGID 
End 
N = 40 
 
p 
value 
IMCL:Cr   6.1+1.3   6.1+1.2   0.52 5.7+1.2  5.9+1.6  0.42 
 
 
 
Variable 
 
LGID 
Baseline 
N = 48 
 
LGID 
End 
N = 48 
 
 
p 
value 
 
HGID 
Baseline 
N = 47 
 
HGID 
End 
N = 47 
 
 
p 
value 
VAT  211.4+73.6 226.7+86.5 0.16 195.8+63.4 201.9+75.0 0.53 
SAT  365.0+125.4 373.7+125.4 0.24 405.0+148.9 388.0+148.5 0.82 
Data are means + SD; muscle triglycerides are expressed as intramyocellular lipid:total creatine 
ratio (IMCL/Cr) (Arbitrary Units (AU)); VAT, visceral adipose tissue (AU); SAT, subcutaneous 
adipose tissue (AU).   
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5.6 Discussion and Conclusions 
Individuals who are obese or have abdominal obesity tend to consume excess kcal and/or 
fat, which results in an accumulation of fat in organs other than adipose tissue such as muscle 
causing insulin resistance in these tissues (13, 14).  Research has demonstrated that dietary fat 
intake is associated with IMCL content (30, 31).  This study found significant positive 
correlations with IMCL and total dietary fat (g) and percentage of energy from saturated fat 
(p<0.05) which supports the role of IMCL being a storage site for fat when dietary fat is 
increased.  Further, IMCL was positively correlated with the HOMA index at end of study 
(r=0.23, p<0.05) supporting the research demonstrating the positive relationship between IMCL 
and insulin resistance (15, 16). 
Insulin resistance is higher in individuals with abdominal obesity (10,11) and puts them at 
risk for developing type 2 diabetes, coronary heart disease, and metabolic syndrome (2, 3, 4, 5, 6, 
7, 8,12). de Koning et al (32) studied various ethnic groups in 5 different countries who were at 
risk of developing type 2 diabetes and found that an increase in BMI, WC and WHR all had 
positive associations with type 2 diabetes.  This study showed significant positive correlations 
with IMCL and BMI (p<0.05), WC (p<0.01) and WHR (p<0.001) which supports the beneficial 
effects of reducing IMCL in a population at risk for developing type 2 diabetes.  This study also 
found positive linear correlations with GI and BMI, WC, and WHR but they were not significant 
post intervention (r=0.21, p=0.06; r=0.20, p=0.07; r=0.17, p=0.13 respectively).  Liese et al (33) 
found similar results and suggested that the lack of relationship between GI and adiposity in their 
study may have been due to an average GI of 58.0+4.0 which is similar to high GI diets in other 
studies (18).  In contrast to these findings, Ma et al (34) found the GI was independently and 
positively associated with BMI (p=0.01), and the mean GI was also 58.0+3.9.  This study had a 
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slightly lower average GI of 55.4+2.7 for the LGID post-intervention. The difference in results 
may be due to the difference in ranges for BMI. Ma et al (34) collected data on individuals with a 
BMI varying from 18.5 to >30, whereas this study only looked at abdominally obese individuals 
(BMI 34.4+5.7).  
 This study investigated whether a 24 week low glycemic index diet can improve insulin 
sensitivity by reducing IMCL content of skeletal muscle in weight stable abdominally obese 
individuals. Despite a significant reduction in GI on the LGID (59.6+4.0 baseline vs end 
55.4+2.7, p=0.0000) and a significant increase in the GI on the HGID (60.0+3 baseline vs end 
63.9+3.5, p=0.0000), as well as a significant difference in the GI between groups after 
controlling for baseline (LGID 55.5+3.1 vs HGID 63.9+3.1, p<0.0001), neither IMCL or insulin 
resistance (HOMA) significantly changed on the LGID (p>0.05).  There was a trend towards an 
improvement in insulin secretion (insulinogenic index (ISI)) on the LGID but it was not 
significant (p=0.07), however the HGID did significantly improve ISI (p<0.01).  The significant 
improvement in ISI in the HGID is not consistent with other research, especially since the HGID 
group significantly increased BMI (p<0.05) due to a significant increase in total daily energy 
intake (p<0.05). Research generally favours weight loss for improvements in insulin sensitivity 
without reductions in IMCL.  Larson-Meyer et al (35) examined the effect of weight loss and 
exercise on IMCL and insulin sensitivity and found no reductions in IMCL but improvements in 
insulin sensitivity in all intervention groups (25% kcal restriction, 12.5% kcal reduction and 
12.5% increase in energy expenditure, kcal restriction until a 15% reduction in body weight 
followed by weight maintenance) (p<0.05), however there was no significant improvements in 
insulin sensitivity between groups.   
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This study does not support the hypothesis that a weight maintaining LGID will improve 
insulin sensitivity by reducing IMCL content of skeletal muscle in abdominally obese 
individuals.  The lack of relationship may be due to the minimal change of -6.9% in GI for the 
LGID.  Goff et al (20) also investigated the effects of a 4 week low GI diet on IMCL and also 
found no changes in storage levels of IMCL which may have been attributed to only a 15% 
change in GI.  Goff et al (20) did find significant changes in insulin sensitivity following the low 
GI diet suggesting that insulin sensitivity may be independent of IMCL storage.   
Another possible explanation for the lack of relationship between GI and IMCL could be 
due to diet compliance.  A limitation of the present study was the inability to control compliance 
of the self-selected low or high GI test foods that the participants were required to consume each 
day.  Participants were free-living and choose a specific number of test foods from a list based on 
their estimated energy intake and recorded the food choices on a daily food diary.  The 
compliance was calculated from self-reported data on the food diaries at the monthly visit.  A 
criticism of the low GI diet is that it is too complicated and difficult to follow (42).  This study 
does not support this criticism since average diet compliance for the LGID was high 
(87.7+19.7%), however it is evident that not all individuals are willing to make changes to their 
diet since compliance for the LGID ranged from 30% to 138%.  Similar results were found for 
the HGID; average diet compliance was 91.6+15.9% and ranged from 36% to 116%.  These 
results demonstrate that it is difficult to follow any type of diet if individuals are not motivated to 
make changes to their usual dietary habits.  Further, results showed a relationship between 
average GI and average diet compliance for both the LGID and HGID.  As diet compliance 
increased on the LGID, the GI decreased (p=0.07), and as diet compliance increased on the 
HGID, the GI increased (p<0.05).  For example, the lowest compliance of 30% on the LGID 
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resulted in an average GI of 59 which is similar to the average GI of 59.5 for the participant who 
was 36% compliant on the HGID.  For the participants who were highest in compliance (LGID 
138% and HGID 116%), there was a greater difference in the GI of the diets (LGID 50.7 vs 
HGID 63.3), which further demonstrates the importance of diet compliance.  Results also 
showed a significant (p<0.05) negative correlation between average diet compliance and IMCL 
for the LGID, indicating that as diet compliance increases, IMCL decreases on the LGID.  In 
considering future long term studies, the compliance issue may need to be addressed to find 
significant differences in outcome variables.   
It is well documented that individuals with abdominal obesity are at risk for developing 
diabetes (36), cardiovascular disease (36) and metabolic syndrome (7, 8).  One characteristic of 
metabolic syndrome is fasting blood glucose of >6.1 mmol/L (1).  Fasting blood glucose values 
of 6.1 to 6.9 is termed impaired fasting glucose (IFG) (37), or commonly called “prediabetes”, 
which is also a risk factor for developing diabetes and cardiovascular disease (38).  Maintaining 
and/or improving glycemic control is therefore an important goal for abdominally obese 
individuals, a population at risk for developing type 2 diabetes and cardiovascular disease.  
Although only 14.6% of the participants entering this study had a fasting blood glucose of >6.1 
mmol/L, the LGID did show significant improvements in 60 minute blood glucose obtained from 
the OGTT (p<0.05) indicating that the responses to the different diets varied significantly post 
intervention.  Further, the slope of the regression line was significantly lower for the LGID 
compared to the HGID for 120 minute glucose obtained from the OGTT (p = 0.04).  This 
suggests that the LGID lowers 120 minute glucose in abdominally obese individuals if their 
blood glucose is high to begin with. 
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 Interventional studies examining the effects of dietary GI on serum lipids tend to favour 
the role of the GI in improving triglycerides, LDL cholesterol and HDL cholesterol (39, 40, 41).  
In the present study, despite the significant reductions in GI (p<0.0001), percentage of kcal from 
total fat (p<0.001) and saturated fat in the diet (p<0.001), there were no significant changes in 
fasting blood lipids post-intervention.  A possible explanation may be that the participants 
reduced their fasting blood lipids to normal levels after completion of the 4-to-6 week low fat 
dietary advice run-in phase prior to entering this primary study.  Participants in the run-in phase 
did significantly decrease fasting serum total cholesterol, LDL cholesterol and triglycerides 
(p<0.0001) due to a significant reduction in total dietary fat (p < 0.0001) and saturated fat 
(p<0.01).   
In conclusion, results from this study did not show improvements in insulin sensitivity or 
reduce IMCL content of skeletal muscle in weight-stable abdominally obese individuals after 
following a 24 week low glycemic index diet.  Further research on the GI and IMCL is needed to 
determine whether these findings would occur in different populations such as those with 
impaired glucose tolerance or type 2 diabetes since these individuals would likely have insulin 
resistance.    
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CHAPTER 6 
GLYCEMIC INDEX PREDICTS INDIVIDUAL GLUCOSE RESPONSES AFTER SELF-
SELECTED BREAKFASTS IN FREE-LIVING, ABDOMINALLY OBESE ADULTS 
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Glycemic Index Predicts Individual Glucose Responses after Self-Selected Breakfasts in 
Free-Living, Abdominally Obese Adults 
6.1 Introductory Statement 
Research has shown that the glycemic index (GI) predicts the postprandial glucose 
responses elicited by mixed meals in various populations.  The degree to which an individual’s 
glycemic response to a meal is determined by the GI and other components of the meal remains 
unclear, especially when meals are not consumed in a controlled setting.  This study was 
conducted to determine whether GI is a significant determinant of individual glycemic responses 
elicited by self-selected breakfast meals in abdominally obese adults.    
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6.2 Abstract 
Background: Research has shown that the glycemic index (GI) predicts the postprandial glucose 
responses elicited by mixed meals in various populations.  The degree to which an individual’s 
glycemic response to a meal is determined by the GI and other components of the meal remains 
unclear, especially when meals are not consumed in a controlled setting. 
Objective: The purpose of this study was to test whether the GI of self-selected breakfast meals 
was a determinant of the individual glycemic responses in free-living adults with abdominal 
obesity. 
Design: Free-living non-diabetic adults (n=57) aged 53.9±9.8 with a BMI of 33.9±5.3 and waist-
circumference (WC) 109±11cm underwent a 75g oral glucose tolerance test (OGTT) and, on a 
separate day, wore a continuous glucose monitoring system (CGMS) for 24h during which time 
they recorded all foods consumed.  The protein, fat, available-carbohydrate (avCHO), and GI of 
the breakfast meals were calculated from the food records and the incremental areas under the 
glycemic response curves (iAUC) for 2h after breakfast (iAUCbreakfast) were calculated from 
CGMS data.  Values for iAUCbreakfast, avCHO, fat, fibre, and BMI were normalized by log-
transformation. The ability of participant characteristics and breakfast composition to predict 
individual iAUCbreakfast  response was determined using a step-wise multiple linear regression 
analysis. 
Results: A total of 56% of the variation in iAUCbreakfast was explained by GI (30%, p<0.001), 
iAUC after the OGTT (11%, p<0.001), avCHO (11%, p<0.001), and waist circumference (3%, 
p<0.05).  The effects fat, protein, dietary fibre, age, sex, and BMI were not significant (p>0.05).    
Conclusions: In free-living abdominally obese adults, GI is a significant determinant of 
individual glycemic responses elicited by self-selected breakfast meals.  
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6.3 Introduction 
 The glycemic index (GI) was developed in 1981 as a classification of the blood 
glucose-raising potential of carbohydrate containing foods (1) and is defined as the incremental 
area under the blood glucose response curve after consuming a 50 gram available-carbohydrate 
portion of a test food expressed as a percentage of the response after consuming 50 grams of oral 
anhydrous glucose by the same subject (2, 3).  Research has demonstrated that low-GI diets 
improve glycemic control in diabetes (4, 5) and may decrease the risk of developing type 2 
diabetes (6).  Despite this evidence, there is controversy about the relevance of GI for free-living 
individuals because of concerns that it is difficult to choose low-GI foods, that GI values are 
imprecise, and that the GI does not predict the glycemic responses of individuals consuming 
normal mixed meals due to the high day-to-day variation of glycemic responses and the 
confounding effects of fat and protein (7, 8, 9, 10, 11).  Previous studies showed that GI predicts 
the postprandial glucose responses elicited by mixed meals in groups of normal individuals (12, 
13), adults with type 2 diabetes (14), and youths with type 1 diabetes (15).  These studies 
examined the mean glycemic responses of groups of participants under controlled conditions.   
The question about whether the GI can predict individual glycemic responses to self-selected 
meals remains unclear.  Variation in glycemic responses arises from at least four major sources: 
diurnal variation (time of day), meal-related factors, participant-related factors (between-
individual variation), and unexplained day-to-day variation (within individuals) (16).  The 
purpose of this study was to determine whether GI is a significant determinant of individual 
glycemic responses elicited by self-selected breakfast meals in abdominally obese adults.    
Only breakfast meals were included to remove the confounding effects of diurnal variation.  
Abdominally obese adults were studied because they represent a population at risk for 
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developing type 2 diabetes and may benefit from dietary approaches to reducing risk for 
diabetes. 
6.4 Subjects and Methods 
This study was carried out on an outpatient basis at the Hamilton General Hospital, 
Centre for Cardiovascular Obesity Research and Management, McMaster University, Faculty of 
Health Sciences.  The study protocol was approved by the Hamilton Health Sciences, McMaster 
University human research ethics board.  All participants were given a participant information 
sheet and gave informed consent to participate in the study (Appendix 8.1).  The trial is publicly 
registered with ClinicalTrials.gov, number NCT00147264. 
6.4.1 Protocol 
This thesis chapter consists of results of an analysis of data collected at the end of the run-
in period of a randomized 2x2 factorial design clinical trial which studied the effects of a low GI 
diet and telmisartan on intramyocellular lipids (TRIM trial (Telmisartan-Induced Reduction in 
Intra-Myocellular Lipids).   
6.4.2 Study Sample 
A total of 2433 participants from the general population responded through advertisement 
in local media and underwent a telephone screening process.  Of the 171 participants who were 
invited for an initial screening visit to assess eligibility, 121 participants met inclusion criteria 
(refer to chapter 6 of this thesis) and were recruited for the main study.  Participants were males 
and non-pregnant, non-lactating females aged 30-70yrs with abdominal obesity and a fasting 
plasma glucose <7.0 mmol/L.  Abdominal obesity was defined as a waist circumference of >102 
cm for males and >88 cm for females (17).  Ninety-three of the 121 participants agreed to CGMS 
monitoring and of these, 57 met inclusion criteria for this study which included: food intake 
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including a breakfast meal, recorded for at least one day of the CGMS monitoring; valid and 
complete CGMS data on the day food intake was recorded; the time between breakfast and the 
next food intake being at least two hours; and a complete and valid OGTT.  Reasons for 
exclusion were: 11 participants did not meet CGMS criteria, 9 did not record a food diary, 7 had 
an incomplete OGTT, one person did not eat breakfast, and 8 dropped out after the CGMS was 
inserted.     
6.4.3 Ad-Libitum Low Fat Diet 
After recruitment, the study participants underwent a 6 week dietary advice run in period 
during which time they followed a standardized low fat diet as outlined by the American Heart 
Association (19) consisting of 55% energy from carbohydrate, 30% from fat, less than 7% from 
saturated fat and 15% from protein.  Daily energy requirements were estimated according to the 
Lipid Research Clinic Requirement formula (18) with an additional 300 kcal per day added on 
for exercise and daily energy expenditure (Appendix 8.2).  Diets were prescribed on an ad-
libitum basis.  The aim of the diet was to be weight maintaining and to eliminate potential effects 
of variations in fat intake on IMCL content.  Participants met with a nutrition counselor three 
times during the run in period and were given an information sheet (Appendix 8.3) to provide 
dietary advice on following a low fat diet.  The participants completed three MEDFICTS dietary 
assessment questionnaires to assess dietary fat (17) and the Baecke habitual physical activity 
questionnaire was administered at the start-and-end of the study to determine activity levels 
(Appendix 8.6) (20).  Participants were instructed to maintain their habitual level of physical 
activity throughout the study.        
At the end of the run in period, participants completed a 3-day food diary (Appendix 8.5) 
starting on the second day of the CGMS monitoring.  The composition of the breakfast meal 
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during one of the two days that included the CGMS monitoring was used for the purposes of this 
study. A valid breakfast meal was defined as: first food intake before noon of greater than 99 
kcal, recorded for at least one day of the CGMS monitoring; and, the time between breakfast and 
the next food intake being at least two hours (because GI is a measure of glycemic response over 
two hours).  If valid data existed for more than one breakfast meal, one meal per participant was 
chosen at random for analysis. 
Macronutrients and GI of test foods were calculated using the Food Processor SQL 
Nutrition Analysis & Fitness software package version 9.5 (ESHA Research, Salem, OR, USA) 
for GI and macronutrient composition as a measure of the participant’s habitual dietary intake. 
The GI values for the foods were expressed with the GI of glucose = 100 and derived from 
published tables by using locally tested values where possible, as previously described by 
Wolever et al (13).  The GI of the breakfast meal was calculated as the sum of, for all foods in 
the breakfast meal, the amount of available carbohydrate (avCHO) in the portion of food 
consumed (gf) multiplied by (the GI of that food (GIf) divided by the amount of avCHO in the 
breakfast meal) (gb)), (gf x GIf/gb) (13). 
6.4.4 Continuous Glucose Monitoring System 
 One to two weeks before the end of the run in period, participants underwent 24 hour 
continuous glucose monitoring for three days using a Medtronic MiniMed CGMS monitor 
(Medtronic-MiniMed, Northridge, CA, USA).  The CGMS monitor included a disposable 
glucose indwelling sensor with an external electrical connector that was inserted using a sensor 
inserter applicator into the subcutaneous tissue of the abdominal wall to measure interstitial fluid, 
a glucose monitor that recorded a mean of 30 signals from the sensor every 5 minutes for a total 
of 288 readings for a 24 hour period, and a communication device (Com-Station) enabling data 
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stored in the monitor to be downloaded into a computer (21).  The participants were instructed 
on the use of the CGMS and a blood glucose meter (AscensiaTM ContourTM, Bayer HealthCare 
LLC, Mishawaka, IN, USA) to enter four blood glucose values per day to calibrate the CGMS 
monitor.  A valid and complete CGMS data on the day food intake was recorded was defined as 
288 sensor readings, at least three meter readings entered by the participant in the blood glucose 
meter, and no sensor errors detected.  The start of breakfast for the CGMS data analysis was 
determined by examining the CGMS glucose values near the time the participant indicated that 
breakfast was consumed to find when blood glucose started to increase, defined as when the 
second of two successive glucose readings differed by > 0.2 mmol/L from the first.  Fasting 
blood glucose was taken to be the mean of the four values (0, 5, 10, and 15 minutes) before the 
first increase in blood glucose.  The glycemic response was measured for 120 minutes (24 
readings) after the start of breakfast (iAUCbreakfast).    
6.4.5 Oral Glucose Tolerance Test 
 At the end of the run in period, participants underwent a 75 gram oral glucose tolerance 
test (OGTT) after a 12 hour fast.  An indwelling catheter was inserted in the forearm and venous 
blood samples were obtained for plasma glucose at 15, 10, and 5 minutes prior to ingestion of the 
glucose load (75 gram solution of dextrose) and then again at 30, 60, and 120 minutes after 
starting the glucose drink.  Fasting plasma glucose was taken to be the mean of the three readings 
following the fast.  Glucose was measured by a glucose oxidase method and serum insulin was 
measured with an immunometric assay (Diagnostic Products Corporation, Los Angeles, CA).  A 
complete and valid OGTT was defined as obtaining blood samples at 0, 30, 60 and 120 minutes 
(iAUCOGTT). 
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6.4.6 Anthropometric Measurements 
 Height (cm) was measured at the initial screening visit to the nearest 0.1 cm using a wall 
mounted stadiometer and body weight was measured at every visit to the nearest 0.1 kg on a 
digital weigh scale.  Body mass index (BMI) was calculated as body weight (kg) divided by 
height (m2).  Waist circumference (WC) was measured to the nearest 0.1 cm at the beginning at 
end of the run in period, using the World Health Organization (WHO) method (mid-point 
between the palpated inferior border of the last rib and upper border of the iliac crest in a 
horizontal plane at the end of normal expiration) (22).   
6.4.7 Statistical Analysis 
 All data are presented as means +SD unless otherwise indicated.  Calculations for 
iAUCbreakfast and iAUCOGTT, ignoring area beneath the baseline were determined as previously 
described (23).  The values for iAUCbreakfast were divided into tertiles, and the mean values for 
iAUCOGTT, protein, fat, avCHO, dietary fibre, and GI for participants within the iAUCbreakfast 
tertiles were compared by ANOVA.  The independent contributions of iAUCOGTT, BMI, WC, 
protein, fat, avCHO, dietary fibre, and GI to predicting iAUCbreakfast was determined by step-wise 
multiple linear regression (Lotus 123, Lotus Development) using the step-up procedure (24), 
with age and sex included in all models (because some anthropometric and breakfast intake 
variables were significantly related to age and sex).  The variable with the most significant 
correlation with iAUCbreakfast was added to the model first, all remaining variables were then 
tested, and the most significant added sequentially to the model until no further significant 
reduction in the residual variation was obtained.  Prior to regression analysis, non-normally 
distributed variables based on D’Agostino’s test (iAUCbreakfast, avCHO, BMI, fat, and fibre) were 
normalized by log-transformation.  Statistical significance was taken to be 2-tailed p<0.05, with 
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comparisons between individual means adjusted for multiple comparisons using Tukey’s 
method. 
6.5 Results 
6.5.1 Subject Characteristics 
 Entering the study, participants mean age was 53.9+9.8 years and 68% were female.  All 
participants had abdominal obesity (109+11cm) (17) with a BMI of 33.9+5.3 (22).  Age, BMI, 
and WC were significantly correlated with total dietary fat (g) (r=0.28, p<0.05; r=0.27, p<0.05; 
r=0.27, p<0.05, respectively).  WC was also correlated with BMI (r=0.68, p<0.001) and avCHO 
(g) (r=0.37, p<0.01).  Clinical characteristics of the study population are listed in Table 6.1.   
 
Table 6.1. Clinical Characteristics of the Study Population Divided by Tertile of iAUCbreakfast. 
 
Variable 
All Participants 
N = 57 
Tertile 1 
N = 19 
Tertile 2 
N = 19 
Tertile 3 
N = 19 
Sex (M:F), N 18:39 6:13 6:13 6:13 
Age (years) 53.9±9.8  (37-69) 54.8±8.9 52.4±11.8 54.3±9.8 
BMI (kg/m²) 33.9±5.3  (27-39) 32.3±2.9 36.1±5.8 33.1±6.1 
Waist circumference (cm) 109±11  (93-122) 108±8 113±13 106±11 
Data are means + SD; brackets ( ) are range; M, Males; F, Females 
 
6.5.2 OGTT, CGMS and Dietary Intake 
 The OGTT showed 36 participants with normal fasting glucose (<5.6 mmol/L) of whom 19 
had normal plasma glucose two hours after 75 grams oral glucose (2hPCG) (<7.8 mmol/L), 16 
had impaired glucose tolerance (IGT) (2hPCG >7.8 to <11.1 mmol/L), and one had diabetes 
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(2hPCG >11.1 mmol/L); 20 participants had impaired fasting glucose (IFG) (fasting glucose of 
>5.6 to <7.0 mmol/L) of whom 8 had normal 2hPCG, 6 had IGT, and 6 had a diabetic 2hPCG; 
one individual had diabetic values for both fasting and 2hPCG.  Participants with diabetes based 
on the OGTT had higher iAUCOGTT (405+41 vs 232+74 mmol/L x min/L) and iAUCbreakfast 
(204+92 vs 114+83 mmol x min/L) compared to the participants without diabetes.  The GI and 
avCHO intake at breakfast did not significantly differ between the participants with and without 
diabetes (p>0.05) (GI, 64+10 vs 60+9g; avCHO, 60+21 vs 68+40g, respectively). 
 Mean fasting glucose before breakfast was similar across the tertiles of iAUCbreakfast (Table 
6.2).  Participants in the highest tertile of iAUCbreakfast had significantly higher glycemic 
responses after breakfast (Figure 6.1), higher fasting glucose before the OGTT, and a higher 
iAUCOGTT than those in the lowest tertile of iAUCbreakfast (p<0.05) (Table 6.2).  Despite large 
ranges of intakes of avCHO, fat, protein, and fibre, only GI significantly differed between the 
highest and lowest tertiles of iAUCbreakfast (p<0.05) (Table 6.2). 
iAUCbreakfast was significantly correlated with GI (r=0.55, p<0.001), avCHO (r=0.35, 
p<0.01), OGTT 2hPCG (r=0.40, p<0.01), and iAUCOGTT (r=0.38, p<0.01).  Neither iAUCOGTT 
nor iAUCbreakfast were significantly related to age, sex, BMI, WC, protein, fat, or fibre, and no 
significant relationship was found between GI and avCHO (p>0.05).   
When considered individually, the variable that explained most of the variation in 
iAUCbreakfast was GI (r2=0.30) followed by 2hPCG (r2=0.16), iAUCOGTT (r2=0.14), and avCHO 
(r2=0.12).  Multiple regression analysis showed that, whereas age and sex were not significantly 
related to iAUCbreakfast, GI, avCHO and  iAUCOGTT  had significant independent effects that 
together explained 56% of the variation in iAUCbreakfast (GI, standardized β = 0.47+0.09, 
p<0.001; avCHO, standardized β = 0.43+0.11, p<0.001; iAUCOGTT, standardized β = 0.36+0.09, 
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p<0.001).  WC, BMI, protein, fat, and fibre had no significant effects when added to the model 
(p>0.05). 
 When the 8 participants with diabetes by OGTT or fasting glucose were excluded, the 
results of the multiple regression analysis were similar to those for the total population, with age 
(standardized β = -0.15+0.11, p=0.17), sex (standardized β = 0.16+0.14, p=0.24), GI 
(standardized β = 0.51+0.11, p<0.001), avCHO (standardized β = 0.45+0.13, p<0.001), and 
iAUCOGTT (standardized β = 0.28+0.12, p<0.05) explaining 51% of the variation in iAUCbreakfast. 
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Figure 6.1. iAUCbreakfast for 57 free-living, abdominally obese adults by tertile of iAUCbreakfast.  
Values are means±SEM, n = 19 per tertile group.  Tertile 1 (), Tertile 2 (), Tertile 3 ().  
iAUCbreakfast, incremental area under the glycemic response curve for 2 hours after breakfast. 
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Table 6.2. CGMS, OGTT and Breakfast Meal Composition of Abdominally Obese Adults  
Divided by Tertile of iAUCbreakfast. 
 
Variable 
All Participants 
N = 57 
Tertile 1 
N = 19 
Tertile 2 
N = 19 
Tertile 3 
N = 19 
iAUCbreakfast (mmol×min/L) 127+89  
(16-456) 
52.9+16.5a 
(16-81) 
104.6+15.6b 
(84-132) 
222.5+91.6c 
(133-456) 
iAUCOGTT (mmol×min/L) 256+93 (65-478) 214+85a 264+77ab 292+102b 
Breakfast fasting glucose (mmol/L) 6.0+1.0 (3.2-8.9) 5.9+1.0 5.8+1.1 6.2+1.0 
OGTT fasting glucose (mmol/L) 5.5+0.6 (4.4-7.6) 5.3+0.5a 5.5+0.8ab 5.7+0.6b 
OGTT FG status (N:IFG:D) 36:20:1 15:4:0 12:6:1 9:10:0 
OGTT 2hPCG status (N:IFG:D) 27:22:8 13:6:0 8:9:2 6:7:6 
Composition of Breakfast Meal     
Energy (kcal) 400+187  
(124-1136) 
350+112 403+156 447+259 
Protein (g) 17+8 (3-43) 16+7 17+8 16+10 
Fat (g) 7+5 (1-28) 8+5 7+7 8+4 
Available carbohydrate (g)  67+38 (16-222) 55+24 67+28 79+53 
Glycemic Index (%) 60+9 (37-85) 54+8a  62+8b  65+8b  
Data are means + SD; brackets ( ) are range; means in a row with superscripts without a common 
letterab differ, p<0.05. iAUCbreakfast, incremental area under the glycemic response curve for 2 
hours after breakfast; iAUCOGTT, incremental area under the glycemic response curve for 2 hours 
after 75 grams oral glucose; OGTT, oral glucose tolerance test; N, normal; IGT, impaired 
glucose tolerance; D, diabetic; IFG, impaired fasting glucose; FG, fasting glucose; 2hPCG, 
plasma glucose 2 hours after 75 grams oral glucose.   
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6.6 Discussion and Conclusions 
 The results showed that in free-living participants with nondiabetic fasting glucose on 
recruitment, a high WC, and a wide range of nutrient intakes, the GI of self-selected breakfast 
meals varied over a considerable range and was a highly significant determinant of individual 
glycemic responses.  The 2.3-fold variation in meal GI (37-85) was a more important 
determinant of iAUCbreakfast than the 13.8-fold variation in recorded avCHO intake (16-222 g).  
The variation in recorded protein (3-43 g), fat (1-28 g), and fibre (0-56 g) intakes had a 
negligible effect.   
 The present results are consistent with those of previous studies (13, 25) showing that GI 
was a significant determinant of the glycemic response elicited by mixed breakfast meals 
containing variable amounts of energy, avCHO, protein, fat, and fibre.  In the present study 
however, avCHO and GI together explained approximately 40% of the variation in iAUC 
compared to approximately 90% in previous studies.  There are two main reasons for this; one is 
because each value of iAUC used in the regression analysis was the response of a single 
individual on one occasion as opposed to the mean value for 8 to 12 individuals in previous 
studies.  The second reason is that in earlier studies, between-individual variation was reduced to 
zero by having every participant test all of the test meals.  In this study, every participant ate a 
different test meal therefore the variation in iAUCbreakfast includes between-individual variation.  
Further, this study used iAUCOGTT to control for between-individual variation, but iAUCOGTT is 
an imprecise estimate of each person’s true response because of within-individual variation. 
 Upon enrollment, all participants met the eligibility criterion of a nondiabetic fasting 
glucose of <7.0 mmol/L, however, during the OGTT, 8 participants had 2hPCG values in the 
diabetic range of >11.1 mmol/L and one of these participants had a fasting glucose in the 
138 
 
diabetic range of 7.6 mmol/L.  The differences in classification based on 2hPCG compared to 
fasting glucose were not unexpected because raised 2hPCG tends to occur earlier in the natural 
history of type 2 diabetes than raised fasting glucose (26).  Further, studies have shown that 
when individuals not known to have diabetes are screened with an OGTT, 30-40% of those with 
a 2hPCG in the diabetic range have nondiabetic fasting glucose (27, 28, 29).  Day-to-day 
variations in fasting glucose, occurring presumably due to variations in recent diet, activity, 
sleep, stress, and illness, may account for differences in classification of diabetes on repeated 
testing.  In this study, participants who had diabetic 2hPCG were not excluded from the primary 
analysis because they met inclusion criteria of a normal fasting glucose on screening.  Although 
the results with respect to the ability of GI to predict glycemic responses were not changed by 
excluding participants with diabetic 2hPCG, the effect of iAUCOGTT was reduced because of the 
reduced range of iAUCOGTT values after excluding those with diabetic 2hPCG values. 
 The results of this study showed that variation in the protein and fat content of self-selected 
breakfast meals had a negligible effect on the glycemic responses they elicited. It is generally 
considered that protein and fat reduce glycemic responses by delaying gastric emptying and 
increasing insulin secretion (8, 30).  The interquartile ranges (25th to 75th percentiles) for our 
participants’ protein and fat intakes were 10-20g and 3-10g respectively, and the 10th and 90th 
percentiles were 8-27g and 2-13g, which was within the range used in previous studies 
examining whether adding 10-20g protein or 5-15g fat to avCHO reduces glycemic responses 
(31, 32, 33, 34, 35).  The results of these previous studies however are inconsistent; the effect of 
10-20 g protein varies from 0 (31, 32) to modest (15% to 40%) (33, 34), to large (40% to 50%) 
(35), and the effect of 5-15 g fat varied across a similar range (33, 34, 36, 37, 38, 39).  The 
results of this study do not challenge the concept that adding fat and protein to avCHO reduces 
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glycemic responses but rather challenge the ability to extrapolate the results of this experimental 
design to normal mixed meals.  The experimental model of adding protein or fat to a fixed 
amount of avCHO does not reflect normal eating patterns in which meals vary in the amounts of 
all the nutrients they contain.  To maintain energy balance, meals high in protein or fat would be 
low in avCHO which would have more influence on the glycemic response.  For example, 
adding 15g fat to 50g avCHO from bread would reduce the glycemic response by approximately 
20% (38), however, to make a meal isocaloric, the amount of avCHO would have to be reduced 
to 16g, which would reduce the glycemic response by approximately 55% (40). 
 A perceived barrier to the clinical use of GI is a concern that it limits food choice (41), 
however many commonly eaten foods have a low GI.  In this study, 28% of self-selected 
breakfast meals had a low GI (i.e.<55), thus the barrier may not be that the GI limits food choice 
because they are uncommon but rather because it is difficult to know which specific foods have a 
low GI.  This difficulty arises because most foods are not labeled with their GI value, and the GI 
values of foods reported in the International GI Tables (42) vary considerably.  For example, 
there are 100 GI values for various types of rice (42), which 34% are low GI (<56) and 33% are 
high GI (>69).  The present results do not address this issue directly, although they show it is 
possible to select GI values for the foods recorded on a food record that predict the glycemic 
response elicited by a mixed meal.  It has been suggested that the variation in GI values for 
similar foods is due to imprecise method of measuring GI (10), however when performed 
correctly, the GI method is precise enough to distinguish between low GI and high GI foods with 
95% certainty (43).  This suggests that the variation of GI values for similar foods arises either 
from use of incorrect methods or from real differences among foods due to differences in starch 
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structure (44, 45, 46) related to genetic variety (47, 48), food processing, cooking, storage, and 
serving methods (49, 50, 51).  
 A limitation of this study was that only the glycemic response elicited by breakfast was 
considered, therefore the present results cannot necessarily be extrapolated to other meals of the 
day.  The glycemic response after lunch and dinner depends on many factors other than the 
composition of the meal.  These include the composition of the previous meal, the time interval 
between meals, and the time of day (52, 53, 54, 55, 56, 57, 58).  Another limitation of this study 
is that only 57 of the 121 participants (47%) from the primary study were included.  This number 
is small in relation to the number of variables available for inclusion into the multiple regression 
model, thus the results need to be interpreted with caution.  In addition, the participants in this 
study were all abdominally obese.  The relative importance of the variables studied here in 
determining glycemic responses may vary in different populations. 
In conclusion, GI was a significant determinant of individual glycemic responses elicited 
by self-selected breakfast meals in free-living, abdominally obese adults.     
  
141 
 
6.7 References 
1. Jenkins DJA, Wolever TMS, Taylor RH, Barker HM, Fielden H, Baldwin JM, Bowling AC, 
Newman HC, Jenkins AL, Goff DV.  Glycemic index of foods: a physiological basis for 
carbohydrate exchange. American Journal of Clinical Nutrition 1981;34:362-366. 
2. Wolever TM, Jenkins DJ, Jenkins AL, Josse RG.  The glycemic index: methodology and 
clinical implications.  American Journal of Clinical Nutrition 1991;54:846-854.  
3. Wolever TM.  Effect of blood sampling schedule and method of calculating the area under 
the curve on validity and precision of glycaemic index values.  British Journal of Nutrition 
2004;91:295-300. 
4. Brand-Miller J, Hayne S, Petocz P. Colagiuri S.  Low-glycemic index diets in the 
management of diabetes. Diabetes Care 2003;26:2261-2267. 
5. Jenkins DJA, Kendall CWC, McKeown-Eyssen G, Josse RG, Silverberg J, Booth GL, 
Vidgen E, Josse AR, Nguyen TH, Corrigan S, Banach MS, Ares S, Mitchell S, Emam A, 
Augustin LSA, Parker TL, Leiter LA.  Effect of a low-glycemic index or a high-cereal fiber 
diet on type 2 diabetes.  Journal of the American Medical Association 2008;300:2742-2753. 
6. Barclay AW, Petocz P, McMillan-Price J et al. (2008) Glycemic load and chronic disease 
risk-a meta-analysis of observational studies. American Journal of  Clinical Nutrition 
2008;87:627-637. 
7. Williams SM, Venn BJ, Perry T et al. (2008) Another approach to estimating the reliability 
of glycaemic index. British Journal of Nutrition 100, 364-372. 
8. Pi-Suyer FX.  Glycemic index and disease. American Journal of  Clinical Nutrition 
2002;76:290S-2908S. 
142 
 
9. Franz MJ. The Glycemic Index: Not the most effective nutrition therapy intervention.  
Diabetes Care 2003;26:2466-2468. 
10. DeVries JW. (2007) The glycemic index: the analytical perspective. Cereal Foods World 
2007;52:45-49. 
11. Vega-López S, Ausman LM, Griffith JL et al. (2007) Interindividual variability and intra-
individual reproducibility of glycemic index values for commercial white bread. Diabetes 
Care 2007;30:1412-1417. 
12. Brynes AE, Adamson J, Dornhorst A, Frost GS.  The beneficial effect of a diet with low 
glycaemic index on 24 h glucose profiles in healthy young people as assessed by continuous 
glucose monitoring. British Journal of Nutrition 2005;93:179-182. 
13. Wolever TMS, Yang M, Yi Zeng X, Atkinson F, Brand-Miller JC.  Food glycemic index, as 
given in Glycemic Index tables, is a significant determinant of glycemic responses elicited by 
composite breakfast meals. American Journal of Clinical Nutrition 2006;83:1306-1312. 
14. Brynes AE, Lee JL, Brighton RE, Leeds AR, Dornhorst A, Frost GS.  A low glycemic diet 
significantly improves the 24-h blood glucose profile in people with type 2 diabetes, as 
assessed using the continuous glucose MiniMed monitor. Diabetes Care 2003;26:548-549. 
15. Nansel TR, Gellar L & McGill A. Effect of varying glycemic index meals on blood glucose 
control assessed with continuous glucose monitoring in youth with type 1 diabetes on basal-
bolus insulin regimens. Diabetes Care 2008;31:695-697. 
16. Franc S, Dardari D, Peschard C, Riveline JP, Biedzinski M, Boucherie B, Petit C, Requeda 
E, Mistretta F, Varroud-Vial M, Charpentier G.  Can postprandial blood glucose excursion be 
predicted in type 2 diabetes?  Diabetes Care 2010;33:1913-1918. 
143 
 
17. National Cholesterol Education Program National Heart, Lung, and Blood Institute.  Third 
Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, 
Evaluation and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III) 
Executive Summary, National Institutes of Health.  NIH Publication No. 01-3670, May 2001. 
18. The lipid research clinics population studies data book.  Volume 2.  The prevalence study-
nutrient intake.  Washington, D.C. Government Printing Office, National Institutes of Health.  
NIH Publication No. 82-2014, September 1982. 
19. Krauss RM, Eckel RH, Howard B, Appel LJ, Daniels SR, Deckelbaum RJ, Erdman JW, 
Kris-Etherton P, Goldberg IJ, Kotchen TA, Lichtenstein AH, Mitch WE, Mullis R, Robinson 
K, Wylie-Rosett J, St.Jeor S, Suttie J, Tribble DL Bazzarre TL.  AHA dietary guidelines: 
revision 2000: a statement for healthcare professionals from the nutrition committee of the 
American Heart Association.   Circulation 2000;102:2284-2299. 
20. Baecke JAH, Burema J, Frijters, JER.  A short questionnaire for the measurement of habitual 
physical activity in epidemiological studies.  American Journal of Clinical Nutrition 
1982;36:936-942. 
21. Mastrototaro JJ.  The MiniMed Continuous Glucose Monitoring System.  Diabetes 
Technology and Therapeutics 2000;2:S13-S18. 
22. World Health Organization.  Physical Status: the use and interpretation of anthropometry.  
Report of a WHO Expert Committee.  Technical Report Series No 854, Annex 2.  
1995;854:1-452. 
23. Wolever TM, Jenkins DF, Jenkins AL, Josse RG.  The glycemic index: methodology and 
clinical implications.  American Journal of Clinical Nutrition 1991;54:846-854. 
144 
 
24. Snedecor GW, Cochran WG.  Statistical methods. 7th edition. Ames (IA): Iowa State 
University Press; 1980. 
25. Wolever TMS, Bolognesi C.  Prediction of glucose and insulin responses of normal subjects 
after consuming mixed meals varying in energy, protein, fat, carbohydrate and glycemic 
index.  Journal of Nutrition 1996;126:2807-2812. 
26. DeFronzo RA.  The triumvirate: β-cell, muscle, liver.  A collusion responsible for NIDDM.  
Diabetes 1988;37:667-687. 
27. Shaw JE, Zimmet PZ, de Courten M, Dowse GK, Ghitson P, Gareeboo H, Hemraj F, Fareed 
D, Tuomilehto J, Alberti KGMM.  Impaired fasting glucose or impaired glucose tolerance: 
what be predicts future diabetes in Mauitius?  Diabetes Care 1999;22:399-402. 
28. Kousta E, Lawrence NJ, Penn A, Millauer BA, Robinson S, Dornhorst A, de Swiet M, Steer 
PJ, Grenfeli A, Mather HM, Johnston DG, McCarthy MI.  Implications of new diagnostic 
criteria for abnormal glucose homeostasis in women with previous gestational diabetes.  
Diabetes Care 1999;22:933-937. 
29. Wolever TMS, Mehling C.  Screening for diabetes and impaired glucose tolerance (IGT): 
lack of sensitivity of fasting plasma glucose.  Canadian Journal of Diabetes Care 
1999;23:23-28. 
30. Hollenbeck CB, Coulston AM.  The clinical utility of the glycemic index and its application 
to mixed meals.  Canadian Journal of Physiology and Pharmacology 1991;69:100-107. 
31. Westphal SA, Gannon MC, Nuttall FQ.  Metabolic response to glucose ingested with various 
amounts of protein.  American Journal of Clinical Nutrition 1990;52:267-272. 
32. Liljeberg Elmstahl H, Bjorck I.  Milk as a supplement to mixed meals may elevate 
postprandial insulinaemia.  European Journal of Clinical Nutrition 2001;55:994-999. 
145 
 
33. Moghaddam E, Vogt JA, Wolever TMS.  The effects of fat and protein on glycemic 
responses in non-diabetic humans vary with waist circumference, fasting plasma insulin and 
dietary fiber intake.  Journal of Nutrition 2006;136:2506-2511. 
34. Lan-Pidhainy X, Wolever TMS.  The hypoglycemic effect of fat and protein is not attenuated 
by insulin resistance.  American Journal of Clinical Nutrition 2010;91:98-105. 
35. Spiller GA, Jensen CD, Pattison TS, Chuck CS, Whittam JH, Scala J.  Effect of protein dose 
on serum glucose and insulin response to sugars.  American Journal of Clinical Nutrition 
1987;46:474-480. 
36. Simpson RW, McDonald J, Wahlqvist ML, Atley L, Outch K.  Macronutrients have different 
metabolic effects in nondiabetics and diabetics.  American Journal of Clinical 
Nutrition1985;42:449-453. 
37. Murphy MC, Isherwood SG, Sethi S, Gould BJ, Wright JW, Knapper JA, Williams CM.  
Postprandial lipid and hormone responses to meals of varying fat contents: modulatory role 
of lipoprotein lipase? European Journal of Clinical Nutrition 1995;578-588. 
38. Owen B, Wolever TMS.  Effect of fat on glycaemic responses in normal subjects: a dose-
response study.  Nutrition Research 2003;23:1341-1347. 
39. Normand S, Khalfallah Y, Louche-Pelissier C, Pachiaudi C, Antoine J, Blanc S, Desage M, 
Riou J, Laville M.  Influence of dietary fat on postprandial glucose metabolism (exogenous 
and endogenous) using intrinsically 13C-enriched durum wheat.  British Journal of Nutrition 
2001;86:3-11. 
40. Wolever TMS, Gibbs AL, Spolar M, Hitchner EV, Heimowitz C.  Equivalent glycemic load 
(EGL): a method for quantifying the glycemic responses elicited by low carbohydrate foods.  
Nutrition and Metabolism 2006;3:33. 
146 
 
41. Brekke HK, Sunesson A, Axelsen M, Lenner RA.  Attitudes and barriers to dietary advice 
aimed at reducing risk of type 2 diabetes in first-degree relatives of patients with type 2 
diabetes.  Journal of  Human Nutrition and Dietetics 2004;17:513-521. 
42.  Atkinson FS, Foster-Powell K, Brand-Miller J.  International tables of glycemic index and 
glycemic load values: 2008.  Diabetes Care 2008;31:2281-2283. 
43. Wolever TMS, Brand-Miller JC, Abernethy J, Astrup A, Atkinson F, Axelsen M, Bjorck I, 
Brighenti F, Brown R, Brynes A, Casiraghi MC, Cazaubiel M, Dahlqvist L, Delport e, 
Denyer GS, Erba D, Frost G, Granfeldt Y, Hampton S, Hart VA, Hatonen KA, Henry CJ, 
Hertzler S, Hull S, Jerling J, Johnston KL, Lightowler H, Mann N, Morgan L, Panlasigui LN, 
Pelkman C, Perry T, Pfeiffer AFH, Pieters m, Ramdath DD, Ramsingh RT, Robert SD, 
Robinson C, Sarkkinen E, Scazzina F, Sison DCD, Sloth B, Staniforth J, Tapola N, Valsta 
LM, Verkooijen I, Weickert MO, Weseler AR, Wilkie P, Zhang J.  Measuring the glycemic 
index of foods: interlaboratory study.  American Journal of Clinical Nutrition 
2008;87(suppl):247S-257S. 
44. Granfeldt Y, Drews A, Bjorck I.  Arepas made from high amylose corn flour produce 
favorably low glucose and insulin responses in healthy humans.  Journal of Nutrition 
1995;125:459-465. 
45. Hoebler C, Karinthi A, Chiron H, Champ M, Barry JL.  Bioavailability of starch in bread rich 
in amylose; metabolic responses in healthy subjects and starch structure.  European Journal 
of Clinical Nutrition 1999;53:360-366. 
46. Zhang G, Hamaker BR.  Slowly digestible starch: concept, mechanism, and proposed 
extended glycemic index.  Critical Reviews in Food Science and Nutrition 2009;49:852-867. 
147 
 
47.  Tian Z, Qian Q, Liu , Yan M, Liu X, Yan C, Liu G, Gao Z, Tang S, Zeng D, Wang Y, Yu J, 
Gu M, Li J.  Allelic diversities in rice starch biosynthesis lead to a diverse array of rice eating 
and cooking qualities.  Proceedings of the National Academy of Science 2009;106:21760-
21765. 
48. Gray D, Abdel-Aal E-SM, Seetharaman K, Kakuda Y.  Differences in carbohydrate 
composition and digestion in vitro of selected barley cultivars as influenced by pearling and 
cooking.  Cereal Chemistry Journal 2009;86:669-678. 
49. Granfeldt Y, Hagander B, Bjorck I.  Metabolic responses to starch in oat and wheat products.  
On the importance of food structure, incomplete gelatinization or presence of viscous dietary 
fibre.  European Journal of Clinical Nutrition 1995;49:189-199. 
50. Akerberg A, Liljeberg H, Bjorck I.  Effects of amylose/amylopectin ratio and baking 
conditions on resistant starch formation and glycaemic indices. Journal of Cereal Science 
1998;28:71-80. 
51. Fernandes G, Velangi A, Wolever TMS.  Glycemic index of potatoes commonly consumed 
in North America. Journal of the American Dietetic Association 2005;105:557-562. 
52. Jenkins DJA, Wolever TMS, Taylor RH, Griffiths C, Krzeminska K, Lawrie JA, Bennett 
CM, Goff DV, Sarson DL, Bloom SR.  Slow release carbohydrate improves second meal 
tolerance.  American Journal of Clinical Nutrition 1982;35:1339-1346. 
53. Collier GR, Wolever TMS, Jenkins DJA.  Concurrent ingestion of fat and reduction in starch 
content impairs carbohydrate tolerance to subsequent meals.  American Journal of Clinical 
Nutrition 1987;45:963-969. 
148 
 
54. Nestler JE, Barlascini CO, Clore JN, Blackard WG.  Absorption characteristic of breakfast 
determines insulin sensitivity and carbohydrate tolerance for lunch.  Diabetes Care 
1988;11:755-760. 
55. Wolever TMS, Bentum-Williams A, Jenkins DJA.  Physiologic modulation of plasma FFA 
concentrations by diet: metabolic implications in non-diabetic subjects. Diabetes Care 
1995;18:962-970. 
56. Liljeberg HGM, Akerberg AKE, Bjorck IME.  Effect of the glycemic index and content of 
indigestible carbohydrates of cereal-based breakfast meals on glucose tolerance at lunch in 
healthy subjects. American Journal of Clinical Nutrition 1999;647-655. 
57. Malherbe C, de Gasparo M, de Hertogh R, Hoet JJ.  Circadian variations of blood sugar and 
plasma insulin levels in man. Diabetologia 1969;5:397-404. 
58. Service FJ, Hall LD, Westland RE, O’Brien PC, Go VLW, Haymond MW, Rizza RA.  
Effects of size, time of day and sequence of meal ingestion on carbohydrate tolerance in 
normal subjects.  Diabetologia 1983;25:316-321. 
  
149 
 
 
 
 
 
 
 
 
 
CHAPTER 7 
GENERAL DISCUSSION AND CONCLUSIONS 
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7.1 General Discussion 
 Obesity has been on the rise in recent years and is now considered to be a worldwide 
epidemic (1).  Abdominal obesity, characterized by the accumulation of visceral fat, is now 
recognized as an independent risk factor for cardiovascular disease and type 2 diabetes (2).  
Abdominally obese individuals also have elevated stores of fat in skeletal muscle, specifically 
intramyocellular lipids (IMCL), which appear to reduce insulin-stimulated glucose uptake and 
cause insulin resistance (3, 4).  Strategies for reducing risk factors for diseases in these 
individuals include improving insulin sensitivity (5).   
 Studies examining the role of dietary fat and insulin sensitivity found that IMCL increased 
with high-fat feeding and insulin sensitivity decreased (6, 7).  The primary purpose of the first 
study (run-in phase) in this thesis was to eliminate potential effects of variations in dietary fat 
intake which may influence IMCL content in the main study.  Participants in the run-in phase 
significantly decreased dietary total fat (p<0.0001) and saturated fat (p<0.01) from advice on 
following a low-fat diet and there was a significant relationship between IMCL and dietary fat 
(p<0.05) but not with insulin sensitivity.  A limitation of the run-in study was that IMCL content 
was measured only at the end of the study, therefore conclusions cannot be made on whether 
changes occurred in IMCL and if there was any effect on insulin sensitivity after reducing fat in 
the diet.  On the other hand, it was also hypothesized that following dietary advice on lowering 
overall fat and saturated fat intake would improve metabolic profiles in adults with abdominal 
obesity.  The blood cholesterol data supported this hypothesis with an approximate 9% decrease 
in total and LDL cholesterol.  This is an important finding given that participants followed a 
short-term (4 to 6 weeks), ad-libitum, weight-maintaining, low-fat dietary advice study.  Since 
abdominally obese individuals are at risk for developing cardiovascular disease due to elevated 
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blood lipids, following a long-term low fat diet would not only help prevent cardiovascular risk, 
but may also reduce the need for blood lipid lowering medication.   
 The role of the glycemic index (GI) in improving insulin sensitivity as well as reductions 
in IMCL improving insulin resistance has been documented.  However, it is uncertain whether 
increased IMCL storage is a cause or consequence of insulin resistance.  In the second study of 
this thesis, the data did not support the hypothesis that a low glycemic index (GI) diet would 
reduce IMCL stores, thereby improving insulin sensitivity in adults with abdominal obesity.  The 
lack of significant findings may be due to the minimal change of -6.9% in GI for the low GI diet,  
as well as other issues associated with dietary studies such as accuracy in recording of 3-day 
food diaries and weekly test food record diaries, and diet compliance.  This study demonstrated 
that the change in diet GI did not reduce fasting glucose but did reduce 60 minute postprandial 
glucose and only reduced 120 minute postprandial glucose in individuals who already had high 
glucose.  Therefore the lack of effect on IMCL may be that the reduction in glucose was not 
large enough or that it takes longer than 24 weeks to see an effect.  A limitation of this study was 
that the insulinogenic index and HOMA index was used to measure insulin sensitivity, whereas 
the euglycemic hyperinsulinemic clamp technique is considered the reference standard to 
measure insulin mediated glucose disposal and insulin sensitivity (8).  Although the HOMA 
index has been validated with the euglycemic hyperinsulinemic clamp technique (9), employing 
the euglycemic hyperinsulinemic clamp technique in a long-term study may provide further 
information on the role of the GI and IMCL in improving insulin sensitivity.   
Research has demonstrated that the GI predicts postprandial glucose responses elicited by 
mixed meals (10, 11, 12, 13) in participants under controlled conditions.   The question about 
whether the GI can predict individual glycemic responses to self-selected meals remains unclear.  
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To address this issue, a continuous glucose monitoring system (CGMS) was used to assess 
glycemic responses of a breakfast meal in the third study.  It was hypothesized that the GI would 
be a significant determinant of individual glycemic responses when individuals self-selected 
their breakfast meals.  The hypothesis was supported with the GI being the greatest determinant 
of individual glycemic responses to a breakfast meal containing carbohydrate, fat and protein. 
The results of our study in abdominally obese adults were in agreement with Fabricatore et al 
(14) who also addressed this issue in overweight and obese, type 2 diabetics.  These results 
support the validity of the GI and that following a low GI diet can be beneficial in controlling 
blood glucose in obese individuals with or without diabetes.   
7.2 Future Directions 
 Both this study and research by Goff et al (15) have not shown changes in IMCL with a 
low GI diet due to the minimal change in GI.  Future long term studies are needed with a greater 
change in GI to determine whether dietary GI will reduce IMCL thereby improving insulin 
sensitivity.  Future studies could also include different populations, especially individuals with 
insulin resistance or type 2 diabetes, since they would generally have elevated IMCL at baseline.   
7.3 Conclusions 
 The main hypothesis of this study was a low glycemic index (GI) diet will reduce 
intramyocellular lipid (IMCL) stores, thereby improving insulin sensitivity in weight-stable 
adults with abdominal obesity.  The data presented in this dissertation do not support this 
hypothesis. However, IMCL was positively correlated with the HOMA index concluding that 
there is a positive relationship between IMCL and insulin resistance.  It was also concluded that 
a low GI diet improves 60 minute postprandial glucose and lowers 120 minute postprandial 
glucose in abdominally obese individuals with high blood glucose.  
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 The hypothesis for the run-in phase of the main study was following dietary advice on 
lowering overall fat and saturated fat intake will improve metabolic profiles in adults with 
abdominal obesity.  The data presented in this dissertation support this hypothesis with respect 
to total cholesterol and LDL cholesterol. It was concluded that a low fat, weight maintaining 
diet significantly reduces total cholesterol and LDL cholesterol. 
The third hypothesis was the glycemic index (GI) is a significant determinant of individual 
glycemic responses elicited by self-selected breakfast meals in free-living, abdominally obese 
adults.  The data presented in this dissertation support this hypothesis.  It was also concluded that 
GI is a more important determinant of glycemic response than available carbohydrate intake. 
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PARTICIPANT INFORMATION SHEET 
 
Title of Study:  A randomized, 2X2 factorial design study to evaluate the effects of 
telmisartan versus placebo, and of a low-glycemic index diet versus a low-fat diet, in 
reducing intra-myocellular lipid content in people with the metabolic syndrome (TRIM 
Study).   
 
Investigator:       Dr. A. M. Sharma 
                           Professor of Medicine 
                           Center for Cardiovascular Obesity Research and Management  
                           McMaster University, Faculty of Health Sciences.               
 
Sponsor:             Canadian Institutes of Health Research (CIHR) 
                            Boehringer Ingelheim Canada Ltd. /Ltee. 
                            5180 South Service Road  
                            Burlington, Ontario  
                            L7L 5H4 
 
 
INTRODUCTION 
 
You are being invited to participate in a research study conducted by Dr. Arya M. 
Sharma, because you may have signs of the “metabolic” syndrome”, which is 
characterized by the presence of abdominal obesity, high blood pressure, glucose, 
and/or lipid (fat) abnormalities. 
 
In order to decide whether you want to be a part of this research study, you should 
understand what is involved and the potential risks and benefits.  This form gives 
detailed information about the research study, which will be discussed with you.  Once 
you understand the study, you will be asked to sign this form if you wish to participate.  
Please take your time to make your decision.  Feel free to discuss it with your friends 
and family, or your family physician. 
 
McMaster University and the investigator Dr. Arya M. Sharma are under contract with 
the Sponsors of this study and are receiving compensation to cover the costs of 
conducting the study.  Dr. Sharma has previously conducted research funded by 
Boehringer Ingelheim, and has received honoraria from this company both as a 
consultant and as a speaker on topics related to the use of telmisartan (Micardis®) at 
scientific meetings sponsored by Boehringer Ingelheim. 
 
WHY IS THIS RESEARCH BEING DONE? 
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One out of two adults in Canada are currently overweight and therefore at increased 
risk for a number of medical conditions including diabetes, heart attacks and stroke.  
This increased risk is often due to the presence of the so-called “metabolic syndrome”, 
which is characterized by the presence of high blood pressure, blood glucose and/or 
lipid (fat) abnormalities.  This research is being done to better understand the factors 
underlying the metabolic syndrome and to determine whether this syndrome can be 
improved by treatment with a drug (telmisartan- Micardis®) and/or a “low-glycemic” diet. 
 
 
WHAT IS THE PURPOSE OF THIS STUDY? 
 
People with the metabolic syndrome are at increased risk for diabetes and heart 
disease because they do not respond well to insulin.  This condition is called insulin 
resistance.  Insulin is a hormone that allows sugar to enter muscle cells.  People with 
the metabolic syndrome may be insulin resistant because they have increased muscle 
fat, i.e. they store large amounts of fat in their muscle cells. Many factors like diet, 
exercise, fat tissue, liver function, and genetics can affect muscle fat. 
 
Some drugs can also influence muscle fat.  Telmisartan belongs to a class of drugs 
called “angiotensin receptor blockers” commonly used for the treatment of high blood 
pressure.  Laboratory experiments have shown that these drugs may also affect the 
growth of fat cells and may therefore influence the storage of fat in other organs like 
muscle or liver.  These drugs may also reduce insulin resistance.  This could be of 
benefit to people with the metabolic syndrome.  One aim of this study is therefore to 
examine the effect of telmisartan on muscle fat, insulin sensitivity and fat tissue in 
people with this syndrome. 
 
Dietary factors can also influence muscle fat and how the human body responds to 
insulin.  Reducing the amount of easily digested carbohydrates in the diet (a “low-
glycemic” diet) can improve how the body responds to insulin and may have positive 
effects on blood sugar and fat levels.  The mechanism of this effect is not known.  
Therefore, a second purpose of this study is to examine whether a low-glycemic diet will 
also affect muscle fat. 
 
The effect of telmisartan and a low-glycemic diet on muscle fat will be tested in about 
100 people with the metabolic syndrome.  A research ethics board that ensures that 
research studies do not violate an individual’s rights has reviewed and approved this 
study protocol. 
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WHO CAN PARTICIPATE IN THIS STUDY? 
 
You may be eligible to participate in this study if you have at least three features of the 
metabolic syndrome.  These include increased waist circumference, elevated blood 
glucose, abnormal blood fats, and/or elevated blood pressure.  You must also be willing 
to follow the dietary and treatment protocol required by the study and to complete the 
various visits and investigations required by the protocol.  As a number of medications 
can interfere with the study, you cannot take part in this study if you are currently on 
certain medications that can affect your blood pressure or blood sugar levels. 
Because one of the main tests involved in the study will be performed by magnetic 
resonance spectroscopy (MRS), you cannot participate in this study if you have any 
contraindications to this technique, e.g. claustrophobia (fear of closed spaces), metallic 
body parts, pacemakers, clipped blood vessels, or metallic fragments in your eye. 
 
HOW LONG WILL THE STUDY LAST 
 
The study will last about 32 weeks and requires at least 16 visits.  In addition there will 
be 6-8 visits for special examinations during the course of the study.   The total time for 
your participation in this study is estimated to be around 40 – 50 hours. 
 
HOW WILL I BE ASSIGNED TO A TREATMENT GROUP IN THIS STUDY? 
 
The participants in the study will be assigned at random, that is, by a method of chance 
(like a flip of a coin), to one of four groups.  You will have a 1 in 4 chance of being in 
one of the following groups: 
 
1) Telmisartan and low-glycemic diet. 
2) Placebo and low-glycemic diet. 
3) Telmisartan and control diet. 
4) Placebo and control diet. 
 
In this study you have a 50% chance of receiving telmisartan and a 50% chance of 
receiving the placebo.  A placebo is an inactive substance, like a sugar pill.  The study 
medication will be taken once per day in the morning, with or without food, for the 
duration of the study. Neither you nor your study doctor will know which group you will 
be in.  In an emergency, the randomization code can be broken.   You will also have a 
50% chance or being in the group that receives the low-glycemic diet or the control diet.  
The control diet consists of a low-fat diet, as recommended by the American Heart 
Association for the treatment of individuals with high blood fat levels.  Assignment to 
either diet is open, so both you and your doctor will know whether you are on the low-
glycemic or control diet.  Despite being on telmisartan, placebo, or either diet, it is 
possible that your metabolic syndrome may not improve or may worsen.  Your condition 
will be carefully monitored.  If it does worsen, the study doctor will determine whether 
additional treatment is necessary and whether it is safe or unsafe for you to continue in 
the trial. 
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WHAT TYPE OF A DIET WILL I NEED TO FOLLOW IF I TAKE PART IN THE STUDY? 
 
If you participate in this study, at visit 2 you will be asked to follow a low fat diet.  This 
diet is recommended by the American Heart Association for people with high blood fat 
levels.  In addition to the low fat diet, at Visit 6 you will be assigned to either the low-
glycemic diet or control diet, by chance (like flipping a coin).  If you are assigned to the 
low-glycemic diet you will be asked to eat a certain amount of carbohydrates that are 
less easily digested (e.g. whole wheat bread, whole wheat pasta, and legumes).  If you 
are assigned to the control diet, you will be asked to eat a certain amount of 
carbohydrates that are easily digested (e.g. white bread, rice, baked potato).  Some key 
foods, which will make it easier for you to follow these diets, will be provided to you in 
the study.  You will also be given instructions on how to choose other specific foods that 
you need to eat. 
 
At most visits the nutrition counsellor will meet with you to review your dietary habits, 
give advice, and have you complete a MedFICTS questionnaire.  The MedFICTS 
questionnaire is a diet assessment tool that is used to assess your Calorie and fat 
intake.  Along with the key foods you will be given a daily food record to keep track of 
their use and you will be asked to complete and return them prior to visits 7, 9, 10, 11, 
12 and 14.  These key food records will be reviewed at these visits.  You will also 
periodically be given a 3-day food diary to complete and return before future visits.  In 
these diaries, you will be asked to record your dietary intake and physical activity habits.  
These diaries will be explained to you and you will be asked to return them before visits 
2, 6, 7, 10 and 14.  The diaries will be reviewed at these visits. 
Potential Risks: There are no harmful effects with either diet. 
Potential Benefits: You will receive dietary counselling and learn how to keep accurate 
records of your food intake and activity habits.  You will not be expected to lose weight 
on either diet.  However, reducing your fat intake may result in some weight loss (3 to 5 
pounds) in some individuals. 
 
WHAT WILL MY RESPONSIBILITIES BE IF I TAKE PART IN THE STUDY? 
 
If you participate in this study, you will be asked to come to a screening visit (first 
visit) after fasting for 12 hours (no alcohol for 24 hours).  Fasting is when you do not 
have anything to eat or drink except water.  If you do not fast before visits that require a 
fast, you will have to return at another time when you have fasted. At the screening visit 
you will: a) be asked about previous medical problems, your current health and your 
medications; b) have a brief examination including your weight, height, blood pressure, 
heart rate, waist/hip circumference; c) have an electrocardiogram (a simple test that 
measures the electrical activity of the heart and that can identify damage to the heart 
muscle); d) have a bioelectrical impedance analysis (a simple test that estimates body 
water content by passing a low-voltage current through the body); e) You will also have 
blood drawn (3 tablespoons) to check your blood sugar levels, kidney and liver function, 
and blood count and fat levels; f) supply a random urine sample to check kidney 
function; and g) You will also be given a 3-day food diary to complete and return before 
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the next visit.  If you are a woman who is able to become pregnant the urine sample will 
also be used to do a pregnancy test and you will be asked about your contraceptive 
methods or childbearing potential. This visit should take between 2 and 3 hours. 
 
At the second visit you will be seen by a physician or a nurse who will review the 
screening blood test results, ECG, and your medication. Your weight, blood pressure, 
and heart rate will be measured. The physician or nurse will determine whether you can 
be enrolled in the study. If you meet the initial eligibility criteria, you will be given the 
“run-in” study medication and be asked to take the first dose in the office. You will be 
instructed on how to take your medication. You will also meet with the nutrition 
counsellor to review your three-day food diary, and you will also complete a MedFICTS 
questionnaire and be instructed on starting and maintaining the run-in diet.  This visit 
should take between 1 and 2 hours. 
 
One week after the second visit, the nutrition counsellor will telephone you to assess 
your compliance with the study diet and provide dietary advice. 
 
The third visit you will have your weight, blood pressure and heart rate monitored. The 
study nurse will review your compliance with the run-in medication, your medication, 
monitor adverse events, and you will be given run-in medication. You will then meet with 
the nutrition counsellor to complete a MedFICTS questionnaire, assess your compliance 
with the diet, and be provided with dietary advice including any dietary adjustments or 
changes that may be required.  This visit should take 1-2 hours.  
 
At the fourth visit the study nurse will review your compliance with the run-in 
medication, your medication, monitor adverse events, measure weight, blood pressure, 
and heart rate. You will then meet with the nutrition counsellor to complete a MedFICTS 
questionnaire, assess your compliance with the diet, and be provided with dietary 
advice including any dietary adjustments or changes that may be required (similar to 
third visit). You will be given a 3-day food diary to complete and bring back with you at 
the sixth visit.  This visit should take around 1-2 hours. 
 
The fifth visit includes a series of baseline tests that will be completed before you are 
assigned to a treatment group. These tests will be scheduled over a 2 week period and 
will not be completed on the same day. In order to minimize your number of visits, some 
of these tests may be scheduled with Visit 4 and/or visit 6. Due to scheduling 
availability, you will not have these tests in any particular order. The baseline tests 
include: magnetic resonance spectroscopy (MRS), HOMA/OGTT/biomarkers/lipid profile 
(fasting), bioelectrical impedance analysis (BIA), fat biopsy (fasting), muscle biopsy (4 
hour fast), Doppler ultrasound of the brachial artery in forearm (fasting), 
echocardiography, continuous subcutaneous glucose monitoring, and Actical physical 
activity monitor. With the OGTT you will have blood drawn (9 tablespoons) and your 
weight, blood pressure and heart rate will be measured. This visit will take a total of 
about  9-10 hours (not consecutive hours). 
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At the randomization (sixth) visit you will bring a completed 3-day food diary (given to 
you at visit 4). The study nurse will review your compliance with the run-in medication, 
monitor adverse events, review your medication, check biopsy and puncture sites and 
review your eligibility for the study. You will then meet with the nutrition counsellor who 
will assess your dietary compliance. If you are determined to be compliant with the run-
in medication and the run-in diet you will be randomized to one of four study groups. 
Your weight, blood pressure, heart rate, and waist/hip circumference will be measured. 
You will be asked to provide a random urine sample that will be stored until analysis 
(kidney function test). If you are a pre-menopausal woman, a pregnancy test will be 
performed on the urine sample. If you are on low-dose aspirin, an additional sample of 
your urine will be stored for until analysis. You will be given the study medication and 
will be asked to take the first dose at this visit. You will then meet with the nutrition 
counsellor to complete the MedFICTS questionnaire, get dietary instructions, and be 
given test foods. The nutrition counsellor will instruct you on how to maintain the weekly 
test-food records. You will also be given a 3-day food diary to complete and return at 
the seventh visit.   This visit should take around 1-2 hours. 
 
At the seventh visit, you will come in with a completed weekly test-food record and 3-
day food diary. The study nurse will review compliance with the study medication, 
monitor adverse events, review your medications, measure your weight, blood pressure 
and heart rate. At this visit, your dose of study medication (telmisartan or placebo as per 
assigned study arm) will be increased from 80mg to 160mg (up-titrated). You will be 
given the study medication and then asked to take the first uptitrated dose at this visit. 
You will also meet with the nutrition counsellor to complete the MedFICTS 
questionnaire, assess your compliance with the diet, be provided with dietary advice 
including any dietary adjustments or changes that may be required, and be given test 
foods. You will be given weekly test food records for you to complete and return at the 
ninth visit.  This visit should take around 1-2 hours. 
 
At the eighth visit the study nurse will review compliance with the study medication, 
review your medications, monitor adverse events, measure weight, blood pressure and 
heart rate, and draw a blood sample (1 teaspoon) to assess your kidney function. If at 
this visit your kidney function blood tests have increased by more than 30% since the 
beginning of the study, you will be asked to lower the dose of study medication to 80mg 
(telmisartan or placebo) and an unscheduled visit will be scheduled to repeat the kidney 
function blood tests (1 teaspoon). If the repeated blood test results remain abnormal, 
the study doctor will decide if it is unsafe for you to continue the study medication, even 
at the lower dose. If so, the study medication will be discontinued but you can remain 
enrolled in the dietary arm of the study. If the repeated blood tests are normal you will 
continue the study medication, but at the lower dose.  This visit should take between 1- 
2 hours. 
 
At the ninth visit you will come in with a completed weekly test food record. The study 
nurse will review compliance with study medication, review your medications, monitor 
adverse events, measure your weight, blood pressure and heart rate, and give you 
study medication. You will also meet with the nutrition counsellor to complete the 
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MedFICTS questionnaire, assess your compliance with the diet, be provided with 
dietary advice including any dietary adjustments or changes that may be required, and 
be given test foods. You will be given weekly test food records and a 3-day food diary 
for you to complete and return at the tenth visit.  This visit should take around 1-2 hours. 
 
At the tenth visit you will come in after an overnight (12hour) fast (no alcohol for 24 
hours) and bring in a completed 3-day food diary and the weekly test-food records. The 
study nurse will review compliance with study medication, review your medications, 
monitor adverse events, measure your weight, blood pressure, heart rate, and waist/hip 
circumference, and perform a bioelectrical impedance analysis. You will be asked to 
provide a random urine sample that will be stored until analysis (kidney function test). If 
you are a pre-menopausal woman, a pregnancy test will be performed on that urine 
sample. You will have the OGTT at this visit with blood samples drawn (approximately 5 
tablespoons) for analysis of blood sugar levels, insulin and biomarkers. The study nurse 
will give you study medication. You will also meet with the nutrition counsellor to 
complete the MedFICTS questionnaire, assess your compliance with the diet, be 
provided with dietary advice including any dietary adjustments or changes that may be 
required, and be given test foods. You will be given weekly test food records for you to 
complete and return at the eleventh visit.  This visit should take around 3 hours. 
 
At the eleventh visit you will come in with a completed weekly test-food record. The 
study nurse will review compliance with the study medication, review your medications, 
monitor adverse events, measure your weight, blood pressure and heart rate, and give 
you study medication. You will also meet with the nutrition counsellor to complete the 
MedFICTS questionnaire, assess your compliance with the diet, be provided with 
dietary advice including any dietary adjustments or changes that may be required, and 
be given test foods. You will be given weekly test food records for you to complete and 
return at the twelfth visit.  This visit should take around 1-2 hours. 
 
At the twelfth visit you will come in with a completed weekly test-food record. The 
study nurse will review compliance with the study medication, review your medications, 
monitor adverse events, measure your weight, blood pressure and heart rate, and give 
you study medication. You will also meet with the nutrition counsellor to complete the 
MedFICTS questionnaire, assess your compliance with the diet, be provided with 
dietary advice including any dietary adjustments or changes that may be required, and 
be given test foods. You will be given weekly test food records and a 3-day food diary 
for you to complete and return at the fourteenth visit. You will then be scheduled for the 
end of study tests (visit 13).  This visit should take 1-2 hours. 
 
The thirteenth visit includes a series of end of study tests that will be completed before 
you discontinue study medication and study diet. These tests will be scheduled over a 2 
week period and will not be completed on the same day. In order to minimize your 
number of visits some of these tests may be scheduled with Visit 12 and/or visit 14. Due 
to scheduling availability, you will not have these tests in any particular order. The end 
of study tests include: magnetic resonance spectroscopy (MRS), 
HOMA/OGTT/biomarkers/lipid profile (fasting), bioelectrical impedance analysis (BIA), 
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fat biopsy (fasting), muscle biopsy (4 hour fast), echocardiography, continuous 
subcutaneous glucose monitoring, and Actical physical activity monitor. With the OGTT 
you will have blood drawn (9 tablespoons) and your weight, blood pressure and heart 
rate will be measured. This visit will take a total of about 9-10 hours (not consecutive 
hours). 
 
The fourteenth visit you will bring in a completed 3-day food diary and weekly test-food 
records (given to you at visit 12). The study nurse will review compliance with the study 
medication, review your medications, monitor adverse events, measure your weight, 
blood pressure and heart rate, and you will have a physical examination. You will be 
asked to provide a random urine sample that will be stored until analysis (kidney 
function test). If you are a pre-menopausal woman, a pregnancy test will be performed 
on the urine sample. If you are on low-dose aspirin, an additional sample of your urine 
will be stored until analysis. You will be instructed to stop taking the study medication 
(all remaining medication will be collected). You will also meet with the nutrition 
counsellor to complete the MedFICTS questionnaire, review dietary compliance and 
weekly test-food records. This visit should take around 1-2 hours. 
 
The fifteenth visit you will be scheduled three days to one week following 
discontinuation of study medication. You will have a Doppler ultra sound of the brachial 
artery in the forearm (to assess your blood vessel functioning).  This visit should take 
around 1 hour. 
 
The sixteenth visit will be a follow-up telephone call 2 weeks after stopping study 
medication, to discuss with you any remaining issues regarding your participation in the 
study.  The study nurse will assess adverse events and schedule a clinic visit if 
necessary. 
 
WHAT TESTS WILL I HAVE AND WHAT ARE THE BENEFITS OR RISKS OF THESE 
TESTS? 
Blood Tests 
Blood will be drawn at Visits 1, 5, 8, 10 and 13 to test your blood count, blood sugar, 
blood fats, insulin and other hormones, markers of kidney and liver function, markers of 
inflammation, obesity and heart problems.  The amount of blood drawn at each visit will 
range between 5 cc (1 teaspoon) to about 135 cc (9 tablespoons). The total amount of 
blood taken over the course of the study will be around 400 cc, which is less than that 
taken at a normal blood donation and should have no negative effects. Your blood 
samples will be sent to and stored in the Research Laboratory at the Hamilton General 
Hospital (HRLMP Clinical Trials and Clinical Research) and in Dr. Sharma’s lab at 
McMaster University in line with approved procedures. Your blood samples will be used 
for the purpose of this study and will allow us to explore new risk factors for obesity as 
they emerge in the future.  
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Potential risks: There is a possibility of a small bruise at the site where the needle stick 
is administered. Some individuals may also experience a feeling of fainting on having 
their blood drawn.  Please inform the study nurse if you have previously experienced 
such a reaction.   
Potential benefits: These tests will provide information on your blood glucose and fat 
levels, which, if elevated, are important risk factors for heart disease and stroke.  These 
tests will also provide information on kidney and liver function.  Should any 
abnormalities be detected in these tests, they will be discussed with you by the study 
doctor who will discuss the importance and treatment options for these findings. 
 
Glucose Tolerance Test 
 
An oral glucose tolerance test will be performed at Visits 5, 10 and 13.  For this test we 
will insert an intravenous needle (a small, 2 inches long, plastic needle as used for 
infusions) into your vein for drawing blood samples.  After taking 3 timed blood samples 
(a total of 105 cc or 7 tablespoons), you will drink a bottle of sweet liquid containing 75 g 
of glucose (sugar) and have 10 cc (2 teaspoons) of blood drawn after 30, 60, and 120 
min. This test, commonly used for the diagnosis of impaired glucose tolerance and 
diabetes, will be used to determine your glucose and insulin responses to a glucose 
load. These variables will be used to calculate your sensitivity to insulin and the rate of 
insulin release from your pancreas. 
Potential Risks: Some individuals may feel nausea on drinking the sweet liquid.  There 
are no harmful effects. 
Potential benefits: This will provide information on your risk for diabetes and heart 
disease.  Should any abnormalities be detected, they will be discussed with you by the 
study doctor who will discuss the importance and treatment options for these findings. 
 
Magnetic Resonance Spectroscopy 
 
This test will be performed to examine your muscle, liver and visceral (internal organs) 
fat at Visit 5 and Visit 13. The Magnetic Resonance Spectroscopy (MRS) is a new 
method of scanning that examines structures in the body using magnetic fields and 
harmless low energy radio waves.  No x-rays are used.  The scanning process is totally 
painless and has no known harmful effects.  However some people may not be suitable 
for MRS scanning so you will be required to fill in a patient questionnaire before each 
procedure.  
 
The scan can take from 30 to 60 minutes.  During the scan you will be asked to lie on a 
special table, which moves into the tunnel of the machine.  You need to keep still during 
the examination and at times you will be asked to hold your breath.  The technician will 
talk to you through an intercom telling you what is happening, and when they are 
starting each set of new scans.  You will have verbal contact with the operator and the 
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use of a button that will allow you to alert the operator if you need to be taken out of the 
machine.  
 
At times the machine makes loud knocking noises, which is part of the normal working 
of this machine.  You can wear earplugs or listen to music played in the background to 
make this noise less obvious.  
 
This test will be performed at McMaster University Medical Center.  This test will be 
done in the evening hours or during a weekend.   
 
Potential Risks: The scanning process is totally painless and has no known harmful 
effects.  However, some people may find lying in the scanner difficult to tolerate, as the 
tunnel is quite narrow.  If this should occur, imaging will be stopped immediately, and 
you will be removed from the scanner.   
 
Potential Benefits: Currently, this test is mainly used for scientific investigations and the 
results of this test are unlikely to be of direct benefit to you.  However, if the scanning 
does show an undiagnosed condition you will be informed and adequate therapy 
recommended. 
 
Fat Biopsy (mini liposuction) 
 
From all participants of this study, a total two fat biopsies will be taken from the area 
around the navel (one at Visit 5 and one at Visit 13).  This procedure involves the 
removal of small pieces of fat tissue using a sterile hollow needle, a technique also 
referred to as mini liposuction.  A medical doctor will clean an area located a few inches 
around your navel and inject a small amount of local anaesthetic ("freezing") into and 
under the skin.  He/she will then make a small incision (~4-5 mm) in the skin in order to 
create an opening through which to put the biopsy needle into the fat tissue located 
under your skin.  There is a small amount of bleeding from the incision, but this is 
minimal.  The doctor will then loosen and collect small pieces of fat through the biopsy 
needle. This procedure will be repeated several times to ensure that enough fat is 
collected (~2-5 grams; about 1-2 teaspoons).  During the time that the samples are 
being taken (~2-3 minutes), you may feel the pressure of the needle and on some 
occasions this may be moderately painful.  However, the discomfort passes very 
quickly.  This test will be performed at the Hamilton General Hospital.  The total time for 
each biopsy is around 20-30 minutes.  
 
Following the biopsies, the incisions will be closed with a sterile strip (paper tape) and 
covered with a sterile dressing.  In order to allow the incisions to heal properly and 
minimize any risk of infection, you should avoid prolonged submersion in water for 2-3 
days.  Daily showers are acceptable, but baths, swimming, saunas, etc. should be 
avoided for at least 4 days following the biopsy procedure. 
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Potential Risks. The biopsy technique is routinely used in physiological research, and 
complications are rare provided that proper precautions are taken.  However, there may 
be some internal bleeding at the site of the biopsy, which can result in bruising and 
temporary discoloration of the skin.  On occasion, a small lump may form under the site 
of the incision, but this normally disappears within 2-3 months or within a few days to a 
week if massaged.  As with any incision, there is also a slight risk of infection, however 
this risk is virtually eliminated through proper cleansing of the area and daily changing 
of wound coverings.  If the incision does not heal within a few days or you are in any 
way concerned about inflammation or infection, please contact us immediately.   
 
Dr. Sharma, a medical doctor who is trained in this procedure, will perform this biopsy.  
In past experience with similar subjects, almost all subjects experienced bruising and 
discoloration of the skin at the site of the biopsy (which lasted about 1-2 weeks); 
approximately 1 in 400 have experienced a local skin infection; 1 in 20 have 
experienced a small lump at the site of the biopsy (in all cases this disappeared within 
about 1-2 weeks using local massage); and 1 in 400 have experienced a temporary loss 
of sensation in the skin at the site of incision (an area of numbness about the size of a 
Loonie which lasted up to 4 months).  There is also an extremely remote chance (1 in 
1,000,000) that you will be allergic to the local anaesthetic. 
 
Potential Benefits: This test is currently only used for scientific investigations and the 
results of this test are unlikely to be of direct benefit to you.  However, this test can help 
us better understand the effects of telmisartan and the low-glycemic diet on fat tissue 
biology.  
 
Muscle Biopsy 
 
From some participants of this study, a total of two muscle biopsies will be taken from 
the outer thigh (one at Visit 5 and one at Visit 13).  This procedure involves the removal 
of a small piece of muscle tissue using a sterile hollow needle.  A medical doctor will 
clean an area over your quadriceps muscle (Vastus Lateralis) and inject a small amount 
of local anaesthetic ("freezing") into and under the skin.  He/she will then make a small 
incision (~4-5 mm) in the skin in order to create an opening through which to put the 
biopsy needle into your thigh.  There is a small amount of bleeding from the incision, but 
this is minimal.  The doctor will then quickly cut off a very small piece of muscle (~250 
mg; about the size of the eraser on the end of a pencil) and remove the needle from 
your leg.  A small sample of fat tissue will also be collected from this site at the same 
time.  During the time that the sample is being taken (~5 sec), you may feel the 
sensation of deep pressure in your thigh and on some occasions this is moderately 
painful.  However, the discomfort very quickly passes and you will be quite capable of 
performing exercise and daily activities.  
 
Following the biopsies, the incisions will be closed with sterile suture (stitch), and 
wrapped with a tensor bandage.  You should refrain from excessive muscle use for the 
remainder of the day.  Once the anaesthetic wears off, your leg may feel tight and often 
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there is the sensation of a deep bruise or "Charlie Horse".  Analgesics (pain killers) such 
as Tylenol ® or Ibuprofen (such as Advil ® or 
 Motrin ®) are acceptable if you experience significant pain associated with the biopsy.  
It is also beneficial to periodically apply an ice pack to the biopsy site the following day, 
as this will help to reduce any swelling and any residual soreness. The following day 
your leg may feel uncomfortable when going downstairs.  The tightness in the muscle 
usually disappears within 2 days and subjects routinely begin exercising at normal 
capacity within a day. In order to allow the incision to heal properly and minimize any 
risk of infection, you should avoid prolonged submersion in water for 2-3 days.  Daily 
showers are acceptable, but baths, swimming, saunas, etc. should be avoided for at 
least 4 days following the biopsy procedure. 
 
This test will be performed at McMaster University Medical Center.  The total time for 
each biopsy is around 30-60 minutes.  
 
Potential Risks.  The biopsy technique is routinely used in research, and complications 
are rare provided that proper precautions are taken.  However, there is a risk of internal 
bleeding at the site of the biopsy, which can result in bruising and temporary 
discoloration of the skin.  On occasion, a small lump may form under the site of the 
incision, but this normally disappears within 2-3 months or within a few days to a week if 
massaged.  As with any incision, there is also a slight risk of infection, however this risk 
is virtually eliminated through proper cleansing of the area and daily changing of wound 
coverings.  If the incision does not heal within a few days or you are in any way 
concerned about inflammation or infection, please contact us immediately.   
 
This biopsy will be performed by Dr. Tarnopolsky, who has performed over 10,000 of 
these in patients and healthy people ranging in age from 1 week to 90 years.  In past 
experience with healthy young subjects, approximately 1 in 2,000 have experienced a 
local skin infection; 1 in 500 have experienced a small lump at the site of the biopsy (in 
all cases this disappeared within ~1-2 weeks using local massage); 1 in 1,500 have 
experienced a temporary loss of sensation in the skin at the site of incision (an area of 
numbness about the size of a Loonie which lasted up to 4 months), and 1 in 100 have 
experienced bruising around the site of incision which lasted for ~4-5 days.  While there 
is also a theoretical risk of damage to a small motor nerve (that is used to allow your 
muscle to move) branch of the outer leg muscle, this has never been seen in over 
10,000 biopsies performed by Dr. Tarnopolsky. The risk of damaging a small motor 
nerve branch is impossible to truly estimate, but in the extremely unlikely chance that it 
did occur, only about 20% of the lower part of one of four large muscles that moves the 
knee would be affected (hence, it would not impact on function in daily activities) and 
even this small area of muscle would likely recover in 6 – 9 months.  There is also an 
extremely remote chance (1 in 1,000,000) that you will be allergic to the local 
anaesthetic. 
 
Potential Benefits:  This test is currently only used for scientific investigations and the 
results of this test are unlikely to be of direct benefit to you.  However, this test can help 
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us better understand the effects of telmisartan and the low-glycemic diet on muscle 
tissue biology. 
 
You will not be eligible for muscle or fat biopsies if you are taking certain medications 
such as anti-coagulants (blood thinners), e.g. warfarin, or antiplatelet medication 
(medication to prevent clumping of certain cells in you blood), e.g. Plavix®.  You will be 
asked about these types of medications at the beginning of the study and before the 
biopsies are scheduled. 
 
Continuous Glucose Monitoring 
A 3-day blood sugar (glucose) record will be obtained at Visits 5 and 13.  For this test a 
small plastic needle will be inserted under the skin and taped securely.  You will feel a 
small prick when the needle is inserted (most patients find it virtually painless). The 
needle will then be hooked to a monitor, the size of a mobile phone, which could easily 
be worn on your belt or placed in your pocket. The monitor will record blood sugars 
every 5 minutes. You will not feel this.   
In order to set the monitor you will need to do finger prick glucose testing 4 times a day 
using a glucose tester that we will provide.  These measurements will then be entered 
into the monitor. 
You can continue all normal activities except water immersion sports like swimming, 
sitting in a hot tub or bathing in a bathtub. 
Potential Risks: Besides the mild discomfort that you may experience when the needle 
is placed under the skin or when you do the finger-prick blood sugar measurements, 
there is really no other risk to you.  Although infection at the insertion site may occur, 
this is usually not a concern. 
Potential Benefits: The 3 day continuous glucose measurements will help us gauge how 
well you are responding to the diet or medication. This test will also provide more 
accurate measurements of how your blood sugars vary with activity and meals.  If any 
abnormalities are discovered, the study doctor will discuss these with you. 
Activity Monitoring 
 
In order to monitor your physical activity, you will be asked to wear an electronic activity 
monitor (Actical™).  This monitor is about the size of a matchbox and is worn around 
your waist on a belt for 72 hours at the same time as the continuous glucose-monitoring 
device at visits 5 and 13. 
Potential Risks: none. 
Potential Benefits: This device will let us calculate the amount of calories consumed by 
physical activity during the measurement period.  
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Heart Ultrasound 
 
An ultrasound study of your heart will be performed between visits 4 and 6.  
Measurements will be taken at rest by a trained ultrasound technician.  This test uses 
high frequency waves to create a picture of the heart. The test is painless and will take 
around 60 minutes. 
Potential Risks: none. 
Potential Benefits: This test will provide information on the structure and function of your 
heart.  Should we discover any abnormality that may be important to your health; you 
will be informed and advised to take the appropriate steps for further diagnostics or 
treatment.  
 
Ultrasound of the Blood Vessels of the Arm 
 
In this test, we will measure the diameter of your artery that supplies blood to your arm.  
This will be done with ultrasound. Measurements are taken at rest, after blocking the 
circulation in your upper arm with a blood pressure cuff for 5 minutes and after taking 
one tablet of nitro-glycerine (0.15mg or 0.3mg) under your tongue.  
 
Potential Risks: During this test, a blood pressure cuff will be inflated to high pressures 
for a continuous 5-minute period. At this time, the blood pressure cuff may cause mild 
discomfort or aching around your arm. You may feel increasing numbness or tingling 
(pins and needles) in your hand, which will rapidly stop when the cuff pressure is 
released. No harmful consequence is expected from this test. The ultrasound should not 
cause any discomfort. Nitro-glycerine may cause a brief headache or dizziness.  
 
Potential Benefits: This test is currently only used for scientific investigations and the 
results of this test are unlikely to be of direct benefit to you. However, this test can help 
us better understand the effects of telmisartan and the low-glycemic diet on blood 
vessel function. 
 
Body Composition Analysis (Bioelectrical impedance) 
 
This test will be performed at Visits 1, 5, 10 and 13.  This test examines the water and 
fat content of your body by passing weak electrical current through your body via 
electrodes attached to your hands and feet.  This test is totally painless, has no known 
harmful effects and takes less than 10 minutes.   
 
Electrocardiogram (ECG) 
An ECG will be performed at Visit 1 or 2.  This test measures the electrical activity in the 
heart through 12 leads connected to your chest and limbs to an electrocardiograph.  It is 
a non-invasive and safe procedure taking less than 15 minutes.  
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WHAT WILL HAPPEN WITH MY BLOOD, URINE, AND TISSUE SAMPLES? 
 
All samples will be used for the purpose of this study.  All samples will be stored under 
appropriate conditions either at the Research Laboratory at the Hamilton General 
Hospital (HRLMP Clinical Trials and Clinical Research) or in the research laboratory of 
Dr. Sharma.  They may also be shared with colleagues at other laboratories for 
measurements relevant to the study.  All samples will be stored and analyzed in a 
manner that will not allow direct identification of you (the participant).  Only Dr. Sharma 
will maintain a list linking the samples to an individual participant.  
 
Because these tests will be performed for research purposes only and will allow us to 
explore new risk factors for obesity as they emerge in the future, these tests will not be 
useful for the diagnosis or management of any medical condition.  Therefore you will not 
be provided with the results of these tests.  
 
Any samples remaining after the completion of the above measurements will be stored 
for a maximum duration of 10 years, after which they will be adequately discarded or 
destroyed.  During this time the samples can also be used for the measurements of new 
tests that may arise and be deemed relevant for this project.  
 
The samples will be used for research and such use may result in inventions or 
discoveries that create new products or diagnostic or therapeutic agents.  In some 
instances, these inventions and discoveries may be of potential commercial value and 
may be patented and licensed by the researchers/sponsor. You will not receive any 
money or other benefits derived from any commercial or other products that may be 
developed from use of the samples. 
 
WHAT ARE THE POSSIBLE RISKS AND DISCOMFORTS? 
 
This study will study the effects of telmisartan in people with metabolic syndrome.  
Telmisartan (MiCARDIS ®) is a commonly used drug for the control of high blood 
pressure.  The major side effects of telmisartan are headache, dizziness, fatigue 
(tiredness), back pain, diarrhea, and upper respiratory tract infections and sinusitis.  In 
rare cases, a potentially life threatening condition called angioedema may occur.  The 
symptoms of angioedema may include swelling of the face, lips, tongue and throat.  If 
you have any of these symptoms at any time during the study, immediately discontinue 
study medications and contact your physician or study doctor.  As the dose of 
telmisartan used in this study is higher than the dose approved for the treatment of high 
blood pressure, the side effects may be more common.  This study will also test the 
effect of a “low-glycemic” or a “low-fat” diet.  This requires your cooperation and may be 
considered inconvenient.  There is a reasonable likelihood (1 in 50) that changes to 
your diet may result in indigestion, constipation, bloating, or other symptoms.  In such 
cases, you should report these problems to the nutrition counsellor, who will 
recommend appropriate adjustments to your diet.  
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The potential risks and discomforts of the various tests have been described above.  
When blood samples and biopsies are taken, you may have some discomfort and/or 
develop some bruising or very rarely, a minor infection.  You may also have some 
nausea during the oral glucose tolerance tests.  You will be asked about side effects of 
the diet and treatment at each visit.   
 
Because the safety of telmisartan for an unborn fetus or newborn is unknown, you 
cannot participate in this study if you intend to become pregnant, are pregnant or are 
breastfeeding.  If you are a woman who is able to have children, you must agree not to 
become pregnant while you are in this study.  You will need to use an acceptable 
method of birth control to avoid pregnancy. Acceptable methods of birth control for this 
study include: intra-uterine device (IUD), oral, implantable/injectable contraceptives, or 
epidermal patch.  Using barrier methods such as condoms, vaginal diaphragm, 
spermicidal jelly or sponge is not acceptable.  If you become pregnant despite these 
precautions OR if your method of birth control is discontinued or changes, you agree to 
immediately notify the study team. 
 
If you choose to take part in this study, you will be told about any new information, 
which might affect your willingness to continue to participate in this research.  
 
 
HOW MANY PEOPLE WILL BE IN THIS STUDY?  
 
There will be at least 100 people with the metabolic syndrome taking part in this study. 
 
WHAT ARE THE POSSIBLE BENEFITS FOR ME AND/OR FOR SOCIETY? 
 
The information obtained from participating in this study may show that telmisartan 
and/or a low-glycemic diet are effective in the reduction of muscle fat and improve 
insulin sensitivity and other health problems related to the metabolic syndrome.  
Observations made in this study may also help us better understand some of the 
biological abnormalities related to this syndrome.  No other benefit of participation can 
be guaranteed.  
 
You will receive some counselling regarding healthy lifestyles and will receive all of your 
study medication and some foods free of charge.  You will also receive information 
regarding your body composition, blood pressure, blood glucose and lipid values and 
heart function during the course of the study.   
 
IF I DO NOT WANT TO TAKE PART IN THE STUDY, ARE THERE OTHER 
CHOICES? 
 
It is important for you to know that you can choose not to take part in the study.  There 
are other choices such as improving your diet and increasing your level of exercise or 
taking other medications, for the treatment of the metabolic syndrome.  Your study 
doctor will discuss these with you. 
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Choosing not to participate in this study will in no way affect your care or treatment. 
 
WHAT INFORMATION WILL BE KEPT CONFIDENTIAL? 
 
The study staff will contact your family doctor regarding your selection and participation 
in this study.  This is important for your safety and well being. 
 
Personal records relating to this study will be kept confidential at all times except where 
required by law.  Only the study doctor will keep a record of your name, address, phone 
number, health card number and family doctor’s name.  On documents, your initials and 
assigned participant number will identify you. 
 
Information obtained during this study, including your medical records, will be available 
to the sponsor of this study, the Hamilton Health Sciences/McMaster University 
research ethics board that reviewed the ethical aspects of this study, and the 
government regulatory agencies (such as Health Canada) to check the accuracy and 
completeness of the information.  This is to ensure that the study has been conducted 
according to GCP (Good Clinical Practice) quality standards.  However, no records, 
which identify you by name or initials, will be allowed to leave the hospital.  By signing 
this consent form, you or your legally acceptable representative authorizes such access.  
It is important to note that this original signed consent form and the data, which follows, 
may be included in your health record.   
 
The results of this study may be published in a professional journal or presented at 
scientific meetings or to government regulatory authorities; however, your identity will 
NOT be disclosed in those journals or presentations. 
 
Blood, urine and tissue samples will be identified only by your participant number.  The 
individual results of any analyses, except for the screening and safety tests (blood 
sugar, blood lipids, blood count, kidney and liver function), body composition and blood 
pressure will not be made known to you or to any other party and will only be used to 
identify differences between treatment groups in the study.   
 
Your study records will be stored for the period of time required by applicable law.  Until 
those records and samples are destroyed, you have the right to request that the 
samples and data collected be destroyed.  Confirmation that the samples have been 
discarded will be made to you in writing. 
 
 
CAN PARTICIPATION IN THE STUDY END EARLY? 
 
If you volunteer to be in this study, you may withdraw at any time and this will in no way 
affect the quality of care you receive.  You may also refuse to answer any questions you 
do not want to answer and still remain in the study.  The investigator may withdraw you 
from this study if circumstances arise which warrant doing so.   
WILL I BE PAID TO PARTICIPATE IN THIS STUDY? 
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A small amount of compensation, will be offered to those patients who qualify for and 
undergo the muscle and fat biopsies ($50.00/ biopsy), otherwise, no compensation will 
be paid for your participation.  However, we will reimburse you for parking and meals 
during your visits. 
 
WILL THERE BE ANY COSTS? 
 
Participation in this study will be at no cost to you.  The medication, study foods and 
clinic visits will be provided free of charge.  Your participation in this research project will 
not involve any additional costs to you or your health care insurer. 
 
WHAT HAPPENS IF I HAVE A RESEARCH-RELATED INJURY? 
 
Side effects or harm are possible in any research despite high standards of care, and 
could occur through no fault of your own or the investigators.  Known side effects have 
been described in this consent form, however unforeseeable harm may also occur.  If 
you are injured as a direct result of taking part in this study, you should immediately 
contact the study doctor.  Reasonable and necessary medical expenses will be made 
available to you by the sponsor (Boehringer Ingelheim), provided such expenses are not 
covered by your medical or hospital insurance and are in no way attributable to the 
negligence or misconduct of any agent or employee of McMaster University or Hamilton 
Health Sciences.  Financial compensation for such things as lost wages, disability or 
discomfort due to this type of injury is not routinely available.  However, if you sign this 
consent form it does not mean that you waive any legal rights you may have under the 
law, nor does it mean that you are releasing the investigator(s), institution(s) and/or 
sponsor(s) from their legal and professional responsibilities.  
 
IF I HAVE ANY QUESTIONS OR PROBLEMS, WHOM CAN I CALL? 
 
If you have any questions about the study now or later, please phone Sue Damjanovic 
(TRIM Coordinator) at 905-527-4322 ext. 44710, or if you think you have a research-
related injury, please phone Dr. A. Sharma at 905-527-4322 ext 46806 or the Research 
Nurse at 905-521-5030 (pager). 
 
If you have any questions regarding your rights as a research participant, you may 
contact: Hamilton Health Sciences Patient Relations Specialist at 905-521-2100, ext. 
75240. 
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CONSENT STATEMENT 
 
 
SIGNATURE OF RESEARCH PARTICIPANT/LEGALLY-AUTHORIZED 
REPRESENTATIVE 
 
I have read the preceding information thoroughly.  I have had the opportunity to ask 
questions, and all of my questions have been answered to my satisfaction.  I agree to 
participate in this study.  I understand that I will receive a signed copy of this form.   
 
 
 ______________________________________ 
        Printed Name of Participant 
  
 
______________________________________ __________________ 
 Signature of Participant                                              Date / Time  
 
 
 
 
 
 
Consent form administered and explained in person by: 
 
_____________________________________ 
 Name and title 
 
 
_____________________________________  _____________________ 
 Signature                Date / Time 
 
 
 
 
 
SIGNATURE OF INVESTIGATOR: 
 
In my judgement, the participant is voluntarily and knowingly giving informed consent 
and possesses the legal capacity to give informed consent to participate in this research 
study.  
 
 
______________________________________  _______________ 
Signature of Investigator       Date 
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APPENDIX 8.2 
 
NUTRITION SOURCE DOCUMENT: 
 
ESTIMATED ENERGY REQUIREMENTS 
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Nutrition Source Document: Estimated Energy Requirements 
 
Date: ______/______/________          Completed by: ________________________ 
              day       month         year  
Participant initials:  ___________ Participant ID number:  ___________ (4 digits)    
 
1.) Weight (from Visit 1 source document)  _______ kg 
 
2.) Height (from Visit 1 source document)   _______ cm 
 
3.) Age (from Visit 1 source document)       _______  years 
 
4.) What are the participant’s daily Estimated Energy Requirements?______kcal 
 
   EER (kcal) = ( number based on age and gender x body wt in kg) + 300kcal 
     
      = ( ___________  x  __________kg ) + 300kcal 
   
      = ____________________ (Rounded to nearest 100kcal)  
 
5.) Number of daily test food servings to be consumed during randomization: ________ 
 
 
Table 1 - Calculation for daily EER      Table 2 – Daily Test Food Requirements for Randomization 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EER # Of Daily Test  Food Servings* 
 
EER 
# Of Daily Test  
Food Servings* 
1500 6 3100 12 
1600 6 3200 12 
1700 6.5 3300 12.5 
1800 7 3400 13 
1900 7 3500 13.5 
2000 7.5 3600 14 
2100 8 3700 14 
2200 8.5 3800 14.5 
2300 9 3900 15 
2400 9 4000 15 
2500 9.5 4100 15.5 
2600 10 4200 16 
2700 10.5 4300 16.5 
2800 10.5 4400 17 
2900 11 4500 17 
3000 11.5   
 Column 1 Column 2 
Age Males Females 
0 – 5 103.4 102.7 
6 – 9 78.5 72.5 
10 – 14 61.3 53.3 
15 – 19 50.8 36.7 
20 – 24 45.7 35.7 
25 – 29 39.6 33.8 
30 – 34 38.2 31.6 
35 – 39 34.3 29.4 
40 – 44 33.0 27.3 
45 – 49 32.3 27.9  
50 – 54 31.7 26.7 
55 – 59 29.9 26.1 
60 – 64 30.3 27.3 
65 – 69 28.3 26.3 
70 + 26.2 25.8 
Calculation for Energy Expenditure Requirements 
(EER) based on a diet of 55% of total energy 
derived from carbohydrates (CHO) with 40% of 
available CHO provided from the test foods. 
Total kcal/day x 0.55 = kcal from CHO 
kcal of CHO divided by 4 kcal/g = total g CHO 
total g CHO x 0.40 = grams CHO 
grams CHO divided by 15 grams of CHO per test 
food serving  = # test food servings  
# test food servings are rounded to the nearest 0.5 
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APPENDIX 8.3 
 
FACTS ON FAT INFORMATION SHEET 
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        It is important to include fat in our daily diet but a diet that is too high in fat, especially bad fats, 
        can lead to health problems.  There is a lot to learn about fat and its role in health.   
 
 
 
 
 
WHAT IS FAT? 
Fat is one of the three main components of 
food; the others are protein and 
carbohydrate. Fat has 9 Calories per gram 
compared to protein and carbohydrate at      
4 Calories per gram.  Individuals who eat a 
high fat diet regularly may be eating too 
many Calories and gain weight. 
 
 
UNSATURATED FAT 
If you are going to ingest fat, then these are 
the types of fats that you should have 
because they are “good fats”. Unsaturated 
fats are usually listed on product labels as 
monounsaturated or polyunsaturated fats.  
Any type of fat that is liquid at room 
temperature is an unsaturated fat.  Some 
unsaturated fats must be supplied by the diet 
because our body cannot make them.  These 
important good fats are the omega-3 fats.  
They can be found in liquid oils, nuts and 
seeds, soybeans, flaxseed, fish and omega-3 
products such as eggs.  The omega-3 fats 
may help reduce your risk for developing 
heart disease. 
 
 
 
SATURATED FAT 
These are the BAD fats. Saturated fats are 
found in meats, whole milk dairy products, 
coconut and palm oil, chocolate, processed 
foods, and fast foods. Saturated fat can  
increase  risk for heart disease, so it is 
important that you keep your saturated fats 
to less than    10 % of your daily diet. By 
reducing the total amount of fat in your diet, 
you will usually decrease the saturated fats 
as well. The important thing to remember is 
that saturated fats are the bad fats.  
 
 
 
HYDROGENATION 
Beware of hydrogenated fats because they 
are bad fats. Hydrogenation is a process that 
changes the good polyunsaturated fat to a 
bad saturated fat or “trans fat”.  Trans fats 
are found in margarines, bakery products, 
snack foods, and fast foods.  Foods that list 
hydrogenation or partially hydrogenated oils 
in the first 3 ingredients usually contain 
trans fats and saturated (bad) fats. Trans fats 
are linked to heart disease and should be 
avoided. 
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The recommended daily fat intake should be less than 30% of your total caloric intake.  Here are 
some suggestions to help reduce the total amount of fat in your daily diet. 
 
 
 
 
Choose foods from all 4 food groups in  
Canada’s Food Guide to Healthy Eating. 
 
 
 
 
 
 
 
 
 
 
 
 
 
Try to avoid 
the bad fats 
   Food Sources 
Saturated 
whole milk, butter, 
poultry skin, fatty 
cuts of meat, 
coconut oil and 
palm oil, creamy 
salad dressings 
“Trans fats” 
shortening, 
hydrogenated 
margarine, crackers, 
cookies, cakes, pies, 
chips and other 
snack foods, 
processed foods 
Have more of 
the good fats 
Food Sources 
 
Polyunsaturated 
and 
monounsaturated 
Any liquid 
vegetable oil, fish, 
flax seed and flax 
oil, nuts and seeds, 
oil salad dressings  
Food Group # of 
Servings 
Food Ideas 
(one serving) 
Milk 
Products 
2-4 
(for 
adults) 
1 cup low fat 
milk or non-fat 
yogurt 
Vegetables 
and Fruits 5-10 
½ cup of 
vegetables,  
1 fruit 
Grain 
Products 5-12 
1 slice of bread,  
½ cup of pasta 
Meat and 
Alternatives 2-3 
1/3 cup tofu,  
½ cup beans, 
 3 ½ oz of meat, 
fish or poultry 
Ways to reduce the fat in your diet: 
 Drink skim or 1% milk 
 Use less or try reduced-fat sauces, 
gravies, mayonnaise, cheeses and 
sour cream 
 Use non-hydrogenated margarine 
rather than butter or regular 
margarine 
 Cut extra fat off meat and remove 
skin and visible fat from poultry 
 Broil, bake, boil or barbeque rather 
than frying foods 
 Try salsa, mustard, chutneys, or 
spices to flavour foods rather than 
butter or margarine 
 Have lettuce salads with oil or low-
fat dressing instead of potato and 
macaroni salads  
 Limit snack foods, baked goods, and 
deep-fried foods 
 
 
HEALTHY FAST FOOD CHOICES 
 
Wendys: small chili, milk, salad with 
low fat dressing, (omit the fries) 
 
Tim Hortons: juice, soup (water 
based), low fat muffin, coffee with 
milk  
 
McDonalds: choose from the healthy 
choice menu, juice, milk (omit the 
fries) 
 
Subway: choose from the 7 grams of 
fat or less menu, water, juice, milk, 
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APPENDIX 8.4 
 
MEDFICTS DIETARY ASSESSMENT QUESTIONNAIRE 
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APPENDIX 8.5 
 
3-DAY FOOD DIARIES 
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3 DAY FOOD DIARY: PARTICIPANT INSTRUCTIONS 
 
 Participant initials: ____________ Participant ID#: ____________     
  
• Please maintain your usual eating habits.  
• Complete the food record the week before your next appointment. 
• Use a new diet record form for each day. It may be helpful for dietary input if the 
participant attaches labels from the products eaten to the 3-day food diary. The 
labels can be attached to page 2 of each day. 
•  Write down everything you eat and drink for 2 weekdays and 1 weekend day 
(whenever possible).  Try and record the food and beverage items immediately 
after you have consumed them. Remember to include the time at which the food 
was eaten. 
• Use measuring cups, tablespoons, teaspoons to measure or a scale to weigh out 
the quantities of food.  The more accurate the better!!  
• Describe the food in as much detail as possible. Specify item, brand, and 
amount.  
- ½ cup Delmonte fruit cocktail canned in light syrup 
- 2 tsp Becel regular margarine 
- 45 g (1 large slice) of Dempsters 7 grain bread 
• Write down the percent fat in milk products (i.e. %MF, or %BF).  
- 8 oz 1% milk 
- 175 g 1% Astro fruit bottom peach yogurt 
• Include items added to food and drinks.  
- i.e. sugar, cream, ketchup, dressings, sauces, toppings, spreads, etc. 
• Include on your food record the fat used when preparing foods. 
 - i.e. Butter, canola oil, etc.  
• Write down the name of the restaurant if you are eating out.  
• Describe the method of cooking. 
 - Steaming, broiling, pan-fried, deep-fried.  
   
   Examples 
 
 Correct      Incorrect 
 1 medium bagel     1 ham and cheese sandwich 
 1 teaspoon regular Becel Margarine 
 2 ounces of lean ham 
 1-ounce medium cheddar cheese (33% MF) 
 1 tsp mustard 
 1 lettuce leaf (Romaine lettuce) 
 
 Correct      Incorrect 
 1 ½ cup cooked white rice (Uncle Ben’s) rice with chicken and stir-fried vegetables 
 2 cups stir fried vegetables 
  ½ zucchini 
  ¼ red pepper 
  3 mushrooms 
  ½ cup cooked broccoli 
 2-ounce boneless, skinless chicken breast 
 1 tsp cornstarch 
 1 Tbsp soy sauce 
 1 Tbsp teriyaki sauce 
 1 Tbsp canola oil 
188 
 
3-DAY FOOD DIARY   Dispensed Visit # ___ Returned Visit #____ 
 
        Participant initials: ____________        Participant ID#: ____________     
   
Day 1            Date: ______/______/________         Is this a usual day?   ____no  ____yes 
                               day       month         year  
 
Amount 
of Food 
Description of Foods and Beverages 
(please, enter one item per line) Time of Day 
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3-DAY FOOD DIARY   Dispensed Visit # ___ Returned Visit #____ 
  
Participant initials: ____________        Participant ID#: ____________    
  
Day 2            Date: ______/______/________         Is this a usual day?   ____no  ____yes 
                               day       month         year  
 
Amount 
of Food 
Description of Foods and Beverages 
(please, enter one item per line) Time of Day 
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3-DAY FOOD DIARY   Dispensed Visit # ___ Returned Visit #____ 
 
     Participant initials: ____________        Participant ID#: ____________  
    
Day 3           Date: ______/______/________         Is this a usual day?   ____no  ____yes 
                               day       month         year  
 
Amount 
of Food 
Description of Foods and Beverages 
(please, enter one item per line) Time of Day 
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APPENDIX 8.6 
 
BAECKE PHYSICAL ACTIVITY QUESTIONNAIRE 
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APPENDIX 8.7 
 
LOW GLYCEMIC INDEX AND HIGH GLYCEMIC INDEX WEEKLY  
 
TEST FOOD DIARIES 
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Weekly Test Food Diary 
Low GI diet 
 
 
 
Initials: ________________      ID#:  __________________________       
 
 
 
 
Dispensed Visit #:  ______________ Returned Visit #: _______________ 
 
 
 
 
Start Date: _____________________ Finish Date: __________________ 
 
 
 
Please have ____________ servings of the test foods every day. 
 
= _______________ for ____________ days 
 
 
 
 
Compliance %  = # of test foods consumed _________________ 
          
divided by # of test foods required __________ X 100  =  _____________ 
 
 
 
 
 
•    Record the intake of the test foods as soon as possible after consumption. 
 
•    Ensure that at least two servings are with the first meal of the day. 
 
• Measure all of the foods as precisely as possible (use measuring cups and 
measuring spoons provided) 
 
•    Indicate the number of servings of each test food consumed.  
      (one “x” will equal one serving for each food) 
 
      Each measurement is one serving unless otherwise specified. 
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        ID#:  _______________________       Initials: _______________________         
        Week #:   ________          Week starting:  __________/__________/__________ 
                  Day         Month         Year 
Low Glycemic Index Diet 
 G  di  
       Serving Total 
Bran Buds with Psyllium 
(1/3 cup)                               
Raisin Bran  (dry) 
(1\2 cup)         
Oatmeal (non-instant) 
(1\2 cup cooked, 1/3 cup dry)          
Red River Cereal 
(1/2 cup cooked, 1/6 cup dry) 
  
        
Pumpernickel bread Dimpflmeier  
1 slice =  1 ½ servings         
Pumpernickel bread Holtzheuser 
1 slice = 1 ½ servings         
Linseed bread Dimpflmeier 
1 slice = 1 ½ servings         
100% Rye bread Vollkornbrot  
1 slice = 1 ½ servings         
Barley  (¼ cup dry or ½ cup cooked 
= 2 servings)         
Pasta (al dente) (3/4 cup cooked or 
1/3 cup dry = 2 servings)         
Parboiled Rice 
(1/3 cup cooked)          
Bulgar 
(1/2 cup cooked)         
Beans: canned, kidney, navy, white, 
cooked (1/2 cup)         
Beans, canned Brown, baked, plain 
(1/2 cup)         
Beans, Chickpeas, canned  
(3/4 cup = 2 servings)         
Lentils: red, brown, green,  
(1/2 cup cooked)         
PC Instant Black Bean Soup  
(dry) (½ portion or 34g)         
PC Instant Vegetable Barley soup 
(dry) ( ½ portion or 23g)         
PC Instant Lentil Soup 
(dry) (1/2 portion or 33g) 
 
        
Habitant Split Pea Soup, canned  
(2/3 cup)         
SERVING TOTAL         
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Weekly Test Food Diary 
Control diet 
 
 
 
Initials: _______________________    ID#:  ________________________     
  
 
 
Dispensed Visit #:  ______________ Returned Visit #: ___________ 
 
 
Start Date: _____________________ Finish Date: _______________ 
 
 
 
 
Please have __________ servings of the test foods every day. 
 
= _______________ for ____________ days 
 
 
 
 
Compliance %  = # of test foods consumed _________________ 
          
divided by # of test foods required __________ X 100  =  _____________ 
 
 
 
 
•    Record the intake of the test foods as soon as possible after 
consumption. 
 
•    Ensure that at least two servings are with the first meal of the day. 
 
• Measure all of the foods as precisely as possible (use measuring cups 
and measuring spoons provided) 
 
•    Indicate the number of servings of food consumed.  (put an “x” for each 
serving of food in the appropriate box) 
 
 
Each measurement is one serving unless otherwise specified. 
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     Initials: ___________________________          ID#:  _________________     
  
     Week #:   __________  Week of:  __________/__________/__________ 
                     Day       Month        Year 
Control Diet (High 
Glycemic Index Diet) 
 
       Serving Total 
President’s Choice 
Cornflakes  (2/3 cup)                                
Crispex Cereal 
(2/3 cup)         
Corn Bran Cereal 
(2/3 cup)         
Cheerios cereal 
General Mills (2/3 cup)         
Shredded Wheat 
(1 large or ½ cup)         
Cream Of Wheat 
(1/2 cup cooked)         
Melba Toast 
(4 each)         
White Bread 
(1 slice)         
Whole Wheat Bread 
60% (1 slice)         
Whole Wheat Bread 
100% (1 slice)         
Light Rye Bread 
(1 slice)         
Soda Crackers 
(7 each)         
Graham Crackers    
(3 each)         
Stoned Wheat Thins 
(3 each)         
White Polished Rice  
Cooked (1/3 cup)         
Brown Rice 
Cooked (1/3 cup)         
Instant Potatoes 
Cooked (1/2 cup)          
Home-made mashed 
potatoes, cooked 
(1/2 cup) 
        
Idaho Baked Potato 
(½ medium or ½ cup)         
Instant Potato and Leek Soup  
(1/2 package or 17 g)         
SERVING  
TOTAL         
 
 
 
 
